

## Discovery of a Chemical Probe Bisamide (CCT251236): An Orally Bioavailable Efficacious Pirin Ligand from a Heat Shock Transcription Factor 1 (HSF1) Phenotypic Screen

Matthew D. Cheeseman, Nicola E. A. Chessum, Carl S Rye, A Elisa Pasqua, Michael J Tucker, Birgit Wilding, Lindsay E Evans, Susan Lepri, Meirion Richards, Swee Y. Sharp, Salyha Ali, Martin G. Rowlands, Lisa O'Fee, Asadh Miah, Angela Hayes, Alan T. Henley, Marissa Powers, Robert te Poele, Emmanuel De Billy, Loredana Pellegrino, Florence I Raynaud, Rosemary Burke, Rob L.M. van Montfort, Suzanne A. Eccles, Paul Workman, and Keith Jones

*J. Med. Chem.*, **Just Accepted Manuscript** • DOI: 10.1021/acs.jmedchem.6b01055 • Publication Date (Web): 23 Nov 2016

Downloaded from <http://pubs.acs.org> on November 28, 2016

### Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

	Therapeutics Unit Eccles, Suzanne; The Institute of Cancer Research, Workman, Paul; Institute of Cancer Research, Cancer Research UK Centre for Cancer Therapeutics Jones, Keith; Institute for Cancer Research, CRUK Cancer Therapeutics Unit

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# Discovery of a Chemical Probe Bisamide (CCT251236): An Orally Bioavailable Efficacious Pirin Ligand from a Heat Shock Transcription Factor 1 (HSF1) Phenotypic Screen

*Matthew D. Cheeseman,<sup>1</sup> Nicola E. A. Chessum,<sup>1</sup> Carl S. Rye,<sup>1</sup> A. Elisa Pasqua,<sup>1</sup> Michael J. Tucker,<sup>1</sup> Birgit Wilding,<sup>1</sup> Lindsay E. Evans,<sup>1</sup> Susan Lepri,<sup>1</sup> Meirion Richards,<sup>1</sup> Swee Y. Sharp,<sup>1</sup> Salyha Ali,<sup>1,2</sup> Martin Rowlands,<sup>1</sup> Lisa O'Fee,<sup>1</sup> Asadh Miah,<sup>1</sup> Angela Hayes,<sup>1</sup> Alan T. Henley,<sup>1</sup> Marissa Powers,<sup>1</sup> Robert te Poele,<sup>1</sup> Emmanuel De Billy,<sup>1</sup> Loredana Pellegrino,<sup>1</sup> Florence Raynaud,<sup>1</sup> Rosemary Burke,<sup>1</sup> Rob L. M. van Montfort,<sup>1,2</sup> Suzanne A. Eccles,<sup>1</sup> Paul Workman,<sup>1,\*</sup> Keith Jones<sup>1,\*</sup>*

<sup>1</sup> Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SW7 3RP, United Kingdom.

<sup>2</sup> Division of Structural Biology at The Institute of Cancer Research, London SW7 3RP, United Kingdom.

Key Words. HSF1, Proteomics, Pirin, Phenotypic, Bisamide.

ABSTRACT

1  
2  
3 Phenotypic screens, which focus on measuring and quantifying discrete cellular changes rather  
4 than measuring affinity for individual recombinant proteins, have recently attracted renewed  
5 interest as an efficient strategy for drug discovery. In this paper, we describe the discovery of a  
6 new chemical probe, bisamide (CCT251236), identified using an unbiased phenotypic screen to  
7 detect inhibitors of the HSF1 stress pathway. The chemical probe is orally bioavailable and  
8 displays efficacy in a human ovarian carcinoma xenograft model. By developing cell-based SAR  
9 and using chemical proteomics, we identified pirin as a high affinity molecular target, which was  
10 confirmed by SPR and crystallography.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

## 24 INTRODUCTION

25  
26 Despite the recent extraordinary progress seen in cancer therapy using molecularly-targeted  
27 drugs, the disease commonly remains stubbornly resistant to effective long term treatment. Even  
28 when excellent responses to drugs are initially observed, resistance is almost inevitable and  
29 patients are then left with few treatment options<sup>1</sup> as the discovery of targeted therapies in  
30 oncology has focused on relatively few protein families.<sup>2</sup> To break this cycle and expand the  
31 treatment options for cancer patients, new approaches are needed to discover novel druggable  
32 protein targets.<sup>3</sup>  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 In phenotypic screens, small molecules undergo high-throughput screening against intact cells,  
44 rather than recombinant proteins, and discrete phenotypic changes in the cell are measured and  
45 quantified.<sup>4</sup> Interest in phenotypic screens has increased significantly in recent years, due to their  
46 potential to effectively discover new drugs.<sup>5</sup> Phenotypic screens have several advantages over  
47 screens using recombinant proteins. Hits from a phenotypic screen will, by definition, be cell  
48 permeable and have cellular activity, potentially reducing optimization cycles and timelines.  
49 Also, because the screening approach is unbiased, established knowledge of the biology of  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 molecular targets is not required. Finally, polypharmacology is often observed with small  
4  
5 molecules and structurally related protein families; this can be crucial for efficacy and is  
6  
7 perfectly compatible with a phenotypic screening approach.<sup>6</sup>  
8  
9

10 In contrast, progressing hits from a phenotypic screen can generate a number of unique  
11  
12 challenges. Discovering pharmacodynamic (PD) biomarkers in vivo for use in animals can be  
13  
14 difficult when developing hits from phenotypic screens, as the pathways commonly need to be  
15  
16 activated with an external stimulus.<sup>7</sup> Cell-based screens are typically more expensive and time-  
17  
18 consuming, so may require a greater commitment prior to the screening campaign.<sup>8</sup> Furthermore,  
19  
20 molecular target identification, deconvolution and validation are crucial steps if new chemical  
21  
22 probes<sup>9</sup> and drugs are to be discovered. These are often a bottle-neck in phenotypic screening.<sup>10</sup>  
23  
24 Even with successful target deconvolution, the target discovered may not be of interest; for  
25  
26 example, the target may already be drugged or be a known anti-target. Finally,  
27  
28 polypharmacology may be a serious impediment to compound progression, because the  
29  
30 interaction with multiple structurally related protein targets may prove impossible to  
31  
32 deconvolute.<sup>11</sup> These challenges alter the balance between prioritizing druglike properties of  
33  
34 compounds and an efficient target identification strategy.<sup>12</sup>  
35  
36  
37  
38  
39


40 To execute a successful phenotypic screening campaign, it is critical to select an appropriate  
41  
42 phenotype for small molecule intervention. Heat-shock factor protein 1 (HSF1) is a transcription  
43  
44 factor and the master regulator of the ancient, canonical heat-shock response.<sup>13</sup> A large body of  
45  
46 work has verified the importance of HSF1 to tumorigenesis and cancer progression.<sup>14</sup> HSF1 has  
47  
48 been proposed to be activated by various elements of the cancer state, potentially reprogramming  
49  
50 the transcriptome in a way that is overlapping with, but distinct from, the heat-shock response.<sup>15</sup>  
51  
52 Also, a strong correlation has been reported between the expression of activated HSF1 in tumors  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 and adverse clinical outcomes.<sup>16</sup> This evidence indicates that the inhibition of HSF1-mediated  
4 transcription could be a viable strategy in cancer treatment.<sup>17</sup> Moreover, inhibiting the HSF1  
5 stress pathway would represent an attempt at targeting non-oncogene addiction and proteotoxic  
6 stress, which has been proposed to be advantageous.<sup>18</sup> However, HSF1 is a ligandless  
7 transcription factor so is unlikely to be amenable to standard drug discovery strategies and direct  
8 inhibition with small molecules. Therefore, we proposed that an inhibitor of HSF1-mediated  
9 transcription, which antagonized the HSF1 pathway but without necessarily binding directly to  
10 HSF1, could be discovered and developed via a cell-based phenotypic screen.

## 21 RESULTS

22  
23  
24 **HSF1 Phenotypic Assay.** To observe HSF1-mediated transcription in an in vitro setting, the  
25 HSF1 pathway is activated by a validated heat-shock protein 90 (HSP90) inhibitor,<sup>19</sup> or another  
26 form of external stress,<sup>20</sup> which initiates the heat-shock response. Commonly, the output of the  
27 heat-shock response is quantified by measuring the induction of heat-shock 70 KDa protein 1  
28 (HSP72) expression, the stress-inducible HSP70 isoform.<sup>19</sup> HSF1 pathway inhibitors are then  
29 defined by their ability to block the induction of HSP72. Several HSF1-mediated HSP72  
30 induction inhibitors have been discovered via this method with different proposed molecular  
31 mechanisms of action (Figure 1).<sup>21,28</sup>


32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Figure 1.** Inhibitors of HSF1-mediated HSP72 induction

With the aim of discovering novel hit-matter that inhibits HSF1-mediated transcription, we previously carried out a cell-based high-throughput phenotypic screen in U2OS human osteosarcoma cells of ~200,000 compounds, including ~35,000 compounds from a kinase-focused library.<sup>22</sup> The screen quantified the inhibition of HSP72 induction using the Arrayscan assay<sup>28</sup> following treatment with the HSP90 inhibitor tanespimycin (17-AAG).<sup>23</sup>

**The Bisamide Series.** Using this screen, we identified a potent hit from the kinase-focused deck, bisamide **1** (CCT245232) (Figure 2).<sup>24</sup> Following re-synthesis, the screening hit was confirmed and displayed a  $pIC_{50}=8.55\pm 0.09$  ( $IC_{50}=2.8$  nM,  $n=49$ )<sup>25</sup> in our HSP72 cell-based enzyme-linked immunosorbent assay (ELISA) in U2OS cells. The HSP72 cell-based ELISA assay is an alternative assay format to the Arrayscan assay for quantifying the induced expression of HSP72 and was used as our primary phenotypic pathway assay throughout the study.<sup>26</sup> The  $IC_{50}$  was defined as the concentration that inhibited the signal to 50% of the 17-AAG (250 nM) induced HSP72 expression, relative to the control 17-AAG alone (see supporting information for details). The clear structural feature defining this chemotype was the *N,N'*-4-methyl-1,3-phenylenediamide core (Figure 2).



**Figure 2.** HSF1 pathway inhibitor, bisamide **1**

We had previously demonstrated that pan cyclin-dependent kinase (CDK) inhibitors, and potent CDK9 inhibitors in particular which act as transcription antagonists<sup>27</sup>, can inhibit HSF1-mediated HSP72 induction phenotype; therefore, we initially suspected a similar mechanism for this chemotype.<sup>28</sup> However, upon biochemical screening of bisamide **1** against CDK2 and CDK9, no inhibition was observed (<10 % inhibition at 1  $\mu$ M, see supporting information). Therefore, we hypothesized that bisamide **1** was acting through a different mechanism of action and consequently was submitted for further characterization.

**Hit Characterization – Kinase Activity.** HSF1 is regulated by multiple post-translational phosphorylations,<sup>29</sup> so we hypothesized that kinase inhibition other than CDK2 and CDK9 was causing the observed HSF1-mediated HSP72 induction inhibition. Therefore, bisamide **1** was screened against a broad kinase set using the KINOMEScan biochemical screening platform, a binding assay which gave single-point percentage inhibition values at 1  $\mu$ M (DiscoverX, <http://www.discoverx.com>).<sup>30</sup> Analysis of this data set for 442 kinases revealed that bisamide **1** inhibited only 9 kinases >50% and 4 kinases >90% (see supporting information for details). To validate the kinase hits, orthogonal functional assays were carried out on the 4 kinases that displayed >90% inhibition. Of these, KIT, PDGFRA and PDGFRB failed to confirm in their respective functional assays, all returning  $pIC_{50}<5$  ( $IC_{50}>10000$  nM). Bisamide **1** did display modest activity against BRAF, returning a  $pIC_{50}=6.38$  ( $IC_{50}=420$  nM,  $n=1$ ).<sup>31</sup> Although it seemed



1  
2  
3 unlikely that the modest biochemical BRAF activity would translate into cellular activity, seven  
4 commercially available<sup>32</sup> potent BRAF inhibitors of differing chemotypes were tested in our  
5 cellular HSF1-mediated HSP72 induction inhibition assay for comparison and none displayed  
6 pIC<sub>50</sub>>5 (IC<sub>50</sub><10000 nM).<sup>33</sup> This indicated that BRAF inhibition was not an important  
7 contributor to the observed HSF1 transcription inhibition phenotype (see supporting  
8 information).


9  
10  
11  
12  
13  
14  
15  
16  
17 **Hit Characterization – Cellular.** To establish whether bisamide **1** displays cellular activity  
18 without activation of the heat-shock response using the HSP90 inhibitor 17-AAG, the growth  
19 inhibitory effects were assayed in the U2OS cell line using the CellTiter-Blue (CTB) assay  
20 (Promega). Following four days of treatment, bisamide **1** displayed a highly potent  
21 pGI<sub>50</sub>=7.74±0.08 (GI<sub>50</sub>=18 nM, n=13), when compared to vehicle. To assess the broader single  
22 agent cellular activity of **1**, the compound was assayed for growth inhibition against a large,  
23 genetically-diverse panel of human cancer cell lines (Genomics of Drug Sensitivity in Cancer,  
24 www.cancerrxgene.org).<sup>34</sup> Of the 635 cell lines assayed, 628 (99%) displayed a pGI<sub>50</sub>>6  
25 (GI<sub>50</sub><1000 nM), 455 (72%) a pGI<sub>50</sub>>7 (GI<sub>50</sub><100 nM) and 18 (2.8%) a pGI<sub>50</sub>>8 (GI<sub>50</sub><10 nM),  
26 with no clear selectivity against any specific tissue type (see supporting information for details).  
27 These results suggested that bisamide **1** had wide-ranging anti-cancer activity and that activation  
28 of the HSF1 pathway with an HSP90 inhibitor was not required for **1** to inhibit cancer cell  
29 growth.

30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48 **Cell-Based SAR.** Given the complexity of factors underlying cell-based structure activity  
49 relationships (SAR), we focused on matched pair changes to establish which features were  
50 crucial for the cellular activity of the bisamide chemotype. There were two primary aims to our  
51 medicinal chemistry strategy. Firstly, because our biochemical kinase screening had failed to  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 reveal any potential kinase targets, a broader target identification strategy would need to be  
4 developed. Secondly, although bisamide **1** had excellent cellular potency, the compound had  
5 poor aqueous solubility (kinetic solubility  $<2 \mu\text{M}$ ), which would need to be addressed to validate  
6 HSF1 pathway inhibition as an anti-cancer strategy in an in vivo human tumor xenograft model.  
7 Both goals required us to improve our understanding of the cellular SAR, particularly to identify  
8 a vector-to-solvent through which either a chemical probe linker or a solubilizing group could be  
9 attached, without disrupting the ability of the compound to bind to the primary pharmacological  
10 target or targets.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

23 To develop the cell-based SAR, we switched to the human ovarian carcinoma cell line SK-  
24 OV-3, which was relatively sensitive to growth inhibition and is commonly used in translational  
25 drug discovery both in vitro<sup>35</sup> and in vivo.<sup>36</sup> When the activity of bisamide **1** in the SK-OV-3 cell  
26 line was assayed, it gave a  $\text{pIC}_{50}=7.17\pm 0.07$  ( $\text{IC}_{50}=68 \text{ nM}$ ,  $n=4$ ) using the HSP72 cell-based  
27 ELISA assay induced with 250 nM 17-AAG. Bisamide **1** also inhibited the proliferation of SK-  
28 OV-3 cells in the CTB assay with a  $\text{pGI}_{50}=8.08\pm 0.12$  ( $\text{GI}_{50}=8.4 \text{ nM}$ ,  $n=12$ ).  
29  
30  
31  
32  
33  
34  
35  
36

### 37 **Scheme 1.** Synthesis of the benzodioxane bisamide replacements



*Reagents and conditions: (i) Oxalyl chloride, DMF, DCM; then, pyridine, DCM. (ii) Fe,  $\text{NH}_4\text{Cl}$ ,  $\text{EtOH}/\text{H}_2\text{O}$ . (iii)  $\text{RPhCO}_2\text{H}$ , HATU, DIPEA, DMF.*

We first focused the exploration on the benzodioxane motif (Scheme 1). The left-hand ring system analogues (Table 1, Entries 1-6) were synthesized via a three-step procedure from the commercially available 2-methyl-5-nitroaniline **2**. Following amide bond formation, through the reaction of 2-methyl-5-nitroaniline **2** with 2-methylquinoline-6-carboxylic acid **3**, and subsequent reduction of the nitro-group using iron, the second amide bond was generated using the corresponding carboxylic acid in a HATU-mediated coupling to afford the various benzodioxane analogues in good to moderate yields.

**Table 1.** Bisamide analogues

Entry	Compd	Structures		SK-OV-3 pIC <sub>50</sub> ±SEM (IC <sub>50</sub> , n) <sup>a,b</sup>	SK-OV-3 pGI <sub>50</sub> ±SEM (GI <sub>50</sub> , n) <sup>a,c</sup>	Pirin SPR pK <sub>D</sub> ±SEM (K <sub>D</sub> , n) <sup>a,d</sup>
1	<b>1</b>			7.17±0.07 (68 nM, n=4)	8.08±0.12 (8.3 nM, n=12)	7.42±0.03 (38 nM, n=3)
2	<b>6</b>			<5.00 (>10000 nM, n=2)	<6.00 (>1000 nM, n=2)	ND
3	<b>7</b>			<5.00 (>10000 nM, n=2)	<6.00 (>1000 nM, n=2)	<6.00 (>1000 nM, n=3)
4	<b>8</b>			6.35±0.07 (450 nM, n=3)	7.26±0.09 (55 nM, n=3)	7.57±0.01 (27 nM, n=3)
5	<b>9</b>			5.59±0.09 (2600 nM, n=4)	6.37±0.12 (430 nM, n=5)	7.74±0.03 (18 nM, n=3)
6	<b>10</b>			<5.00 (>10000 nM, n=2)	<6.00 (>1000 nM, n=2)	7.57±0.03 (27 nM, n=3)
7	<b>11</b>			<5.00 (>10000 nM, n=2)	<6.00 (>1000 nM, n=2)	ND
8	<b>12</b>			<5.00 (>10000 nM, n=2)	<6.00 (>1000 nM, n=2)	ND
9	<b>13</b>			<5.00 (>10000 nM, n=2)	<6.00 (>1000 nM, n=2)	<6.00 (>1000 nM, n=3)
10	<b>14</b>			<5.00 (>10000 nM, n=2)	<6.00 (>1000 nM, n=2)	ND
11	<b>15</b>			7.92±0.25 (12 nM, n=5)	8.60±0.11 (8.6 nM, n=4)	ND
12	<b>16</b>			7.29±0.23 (51 nM, n=6)	8.29±0.05 (5.1 nM, n=3)	ND
13	<b>17</b>			6.65±0.09 (220 nM, n=6)	8.05±0.08 (8.9 nM, n=7)	7.42±0.00 (38 nM, n=3)

<sup>a</sup>All results are quoted as the geometric mean $\pm$ SEM.  $pIC_{50}/pGI_{50}/pK_D = -\log IC_{50}/GI_{50}/K_D$  (M). The number of repeats, *n*, are described in parentheses. ND=Not determined. <sup>b</sup>Cell-based ELISA assay for inhibition of HSP72 induction; SK-OV-3 cells were pretreated with compound at the relevant concentration for 1 hour before the addition of 250 nM 17-AAG. HSP72 levels were then quantified after 18 hours. <sup>c</sup>Growth inhibition was measured after 96 hours of treatment and compared to vehicle control. <sup>d</sup> $pK_D$  values were measured through analysis of the sensorgram at equilibrium where possible. Values were then fitted to a one-site specific binding model using Graphpad Prism Version 6.

Changing the 5-substituted dioxane isomer **1** (Table 1, entry 1) to the 6-substituted dioxane isomer **6** (Table 1, entry 2) resulted in a complete loss of cellular activity ( $pIC_{50} < 5$ ), indicating that the isomer of the benzodioxane was crucial. The acyclic dimethoxy analogue **7** (Table 1, entry 3) also displayed a complete loss of cellular activity. Next, we investigated the role of the two oxygen atoms of the dioxane ring. Removing the *para*-oxygen of the dioxane to give the *meta*-chroman **8** (Table 1, entry 4) resulted in a modest 5-fold decrease in cellular HSF1-mediated HSP72 induction inhibition and a 7-fold decrease in growth inhibition compared to **1**; while the *para*-chroman isomer **9** (Table 1, entry 5) displayed a further 6-fold decrease in HSF1-mediated HSP72 induction inhibition and an 8-fold decrease in growth inhibition compared to **8**, which represents a 37- and 51-fold decrease in cellular activity respectively compared to the original hit, bisamide **1**. Surprisingly, isochroman **10** (Table 1, entry 6) displayed no measurable cellular activity. From these results, it was clear that the benzodioxane moiety was crucial for the cellular activity of the bisamide series. Because the SAR surrounding the benzodioxane was steep and complex, we decided that this region was unlikely to be solvent exposed, so would be incompatible with linker and solubilizing group attachment.


Secondly, we investigated the role of the central ring and amide moieties in the cellular activity of the bisamide chemotype. We hypothesized that the amide groups could play an important role in hydrogen bonding with a potential target and in controlling the overall shape of the ligand, while substitution at the central ring could lead to the discovery solvent-exposed vectors. The

1  
2  
3 synthesis of these analogues (Table 1, Entries 7-10) was similar to that described in Scheme 1.  
4  
5 Substitution at both the 6-position (Table 1, entry 7) and the 4-position (Table 1, entry 8) of the  
6  
7 central benzene ring resulted in a complete loss of cellular activity, suggesting that neither of  
8  
9 these vectors represented a viable route to solvent. Owing to the potential for the toluene methyl  
10  
11 group to affect the conformation of the right-hand amide, we decided to leave this group  
12  
13 unchanged. *N*-Methyl substitution of the left-hand amide (Table 1, entry 9) and an attempted  
14  
15 sulfonamide bioisosteric replacement (Table 1, entry 10) also resulted in a complete loss of  
16  
17 cellular activity. Again, owing to the steep SAR in this region of the chemotype, it was clearly  
18  
19 incompatible with linker and solubilizing group attachment.  
20  
21  
22  
23

24  
25 Finally, we examined the role of the 2-methylquinoline ring in the cellular activity of the  
26  
27 bisamide series. All analogues (Table 1, Entries 11-13) were synthesized via a method similar to  
28  
29 that described in Scheme 1. Firstly, we removed the 2-methyl group, which is both lipophilic and  
30  
31 has the potential to be a weak hydrogen bond donor, to give quinoline **15** (Table 1, entry 11).  
32  
33 Removal of this group resulted in no significant change in the cellular activity when compared to  
34  
35 **1** (Table 1, entry 1). Next we moved the quinoline nitrogen from the 1- to the 3-position, to give  
36  
37 isoquinoline **16** (Table 1, entry 12). Again, no significant change in cellular activity was  
38  
39 observed when compared to bisamide **1**. Finally, we partially reduced the quinoline ring to give  
40  
41 tetrahydroquinoline **17** (Table 1, entry 13). By changing to tetrahydroquinoline **17**, the nitrogen  
42  
43 atom now acts as a hydrogen bond donor rather than an acceptor. Despite this reversal in  
44  
45 anticipated binding properties, only a 3.5-fold decrease in HSF1-mediated HSP72 induction  
46  
47 inhibition and no significant change in antiproliferative activity was observed when compared to  
48  
49 bisamide **1**. The broad SAR of the quinoline region of the molecule suggested that this moiety is  
50  
51 solvent exposed, so could therefore be exploited for solubilizing group and linker attachment.  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Exploiting Vectors-to-Solvent – Solubilizing Group Optimization.** Owing to the  
4  
5 complexities of the cellular SAR, attaching a solubilizing group to the solvent-exposed region of  
6  
7 the ligand was considered a more expeditious strategy to generate an in vivo chemical probe  
8  
9 suitable for use in animal models, rather than attempting to optimize the intrinsic solubility of the  
10  
11 bisamide series without insight from structural information. To address this objective, we  
12  
13 adopted an iterative strategy to exploit the rapid synthesis of analogues that would exhibit  
14  
15 improved physicochemical properties and demonstrate the appropriate mouse pharmacokinetic  
16  
17 (PK) parameters for in vivo study (Scheme 2).  
18  
19  
20  
21

22 **Scheme 2.** Synthesis of solubilizing group analogues  
23  
24




46 *Reagents and conditions: (i) Oxalyl chloride, DMF, 1,4-benzodioxane-6-carboxylic acid DCM;*  
47 *then, 4-methyl-3-nitroaniline, pyridine, DCM, RT; then Pd/C (10%), H<sub>2</sub> (1 atm), EtOH. (ii) NaH,*  
48 *RCH<sub>2</sub>OH, THF, 0 °C to reflux. (iii) n-BuLi, CO<sub>2</sub>(s), THF, -78 °C. (iv) HATU, DIPEA, DMF, RT.*  
49  
50

51 The optimal route to the synthesis of these analogues would be to introduce the solubilizing  
52  
53 group via nucleophilic aromatic substitution on the quinoline as the final step; however, this  
54  
55 failed due to consistently low yields. Therefore, the solubilizing group was introduced at the start  
56  
57 of the synthesis. Formation of the precursor carboxylic acid **19** was achieved via lithium halogen  
58  
59  
60

exchange of the corresponding arylbromide **20**. The resulting bisamides were then assayed for cellular activity and in vitro PK parameters (Table 2).

**Table 2.** Optimization of the bisamide solubilizing group



Entry	Compd	Sol. Group	SK-OV-3 pGI <sub>50</sub> ±SEM (GI <sub>50</sub> , n) <sup>a</sup>	MLM Cl <sub>int</sub> (μL/min/mg) <sup>b</sup>	KS (μM) <sup>c</sup>	LogD <sub>7.4</sub> <sup>d</sup>	Calculated pK <sub>a</sub> (MoKa) <sup>e</sup>
1	<b>1</b>		8.08±0.12 (8.3 nM, n=12)	35	1	2.6	NA
2	<b>21</b>		8.37±0.06 (4.3 nM, n=3)	92	5	3.3	NA
3	<b>22</b>		8.94±0.10 (1.1 nM, n=4)	170	90	2.0	9.5
4	<b>23</b>		8.13±0.18 (7.4 nM, n=4)	76	7	2.9	7.7
5	<b>24</b>		8.87±0.09 (1.3 nM, n=8)	24	40	2.4	9.7
6	<b>25</b>		8.97±0.03 (1.1 nM, n=6)	57	30	2.5	8.8
7	<b>26</b>		8.65±0.10 (2.2 nM n=25)	23	70	2.1	8.9

<sup>a</sup>pGI<sub>50</sub>=-log GI<sub>50</sub> (M); geometric mean±SEM, n=number of biological repeats in parentheses. For the corresponding SK-OV-3 HSP72 cell-based ELISA data see the supporting information.

<sup>b</sup>Mouse liver microsome (MLM) assay was carried out at Cyprotex, arithmetic mean of n=2. In vitro Cl<sub>int</sub> is calculated from the half-life using standard procedures. Assumes the fraction unbound in the assay is 1.<sup>37</sup> <sup>c</sup>Kinetic Solubility (KS) measured via an in-house HPLC method from phosphate buffer at pH 7.4, all values quoted to 1 SF, the dynamic range of the assay is 1-100 μM, arithmetic mean of n=2. <sup>d</sup>Measured via an in-house HPLC method, arithmetic mean of n=2, all values quoted to 2 SF.<sup>38</sup> <sup>e</sup>MoKa version 2.5.2, all values quoted to 2 SF. See supporting information for details.

We first attached the oxygen-linked ether chain to give glycol **21** (Table 2, entry 2). No significant decrease in either HSF1-mediated HSP72 induction inhibition (see supporting information) or the antiproliferative activity was observed when compared to lead bisamide **1** (Table 2, entry 1). This suggested firstly, the oxygen linker had no detrimental effect on activity and secondly, that this region of the molecule was indeed solvent exposed. To carryout multi-

1  
2  
3 parameter optimization of the solubilizing group, we used four in vitro properties to assess each  
4  
5 compound's potential for in vivo mouse PK: microsomal stability, kinetic solubility at pH 7.4,  
6  
7 lipophilicity as measured by  $\text{LogD}_{7.4}$  and the predicted basicity of the solubilizing group. The  
8  
9 glycol **21** displayed an increase in lipophilicity compared to lead bisamide **1**; this increase was  
10  
11 reflected in the 2.4-fold decrease in microsomal stability with a modest increase in kinetic  
12  
13 solubility. However, glycol **21** remained a low solubility compound, which is inconsistent with  
14  
15 good oral bioavailability. From these data, we concluded that the compound would need to be  
16  
17 charged to deliver the correct balance of properties. To introduce a charged moiety, we first  
18  
19 focused on the dimethylamine group with a 3-carbon linker. Dimethylamine **22** (Table 2, entry 3)  
20  
21 displayed no significant change in cellular activity, despite this analogue now being  
22  
23 predominately charged at physiological pH, according to the calculated  $\text{pK}_a$ . Consistent with its  
24  
25 cationic character, dimethylamine **22** displayed a 1.4 log unit decrease in lipophilicity when  
26  
27 compared to **21**, which was accompanied by an 18-fold improvement in kinetic solubility.  
28  
29 Unfortunately, the decrease in lipophilicity was not reflected in an improvement in microsomal  
30  
31 stability. We hypothesized that this was due to oxidation of the *N*-methyl groups, so we moved to  
32  
33 cyclic amines to reduce the CYP450 mediated degradation. Morpholine **23** (Table 2, entry 4)  
34  
35 showed little improvement in microsomal stability or kinetic solubility when compared to **21**.  
36  
37 Analysis of the  $\text{LogD}_{7.4}$  and calculated  $\text{pK}_a$  for morpholine **23** suggested that the solubilizing  
38  
39 group was not sufficiently basic to balance the physicochemical properties of the compound.  
40  
41 Moving to piperidine **24** (Table 2, entry 5), we observed a better balance in physicochemical  
42  
43 properties, with the reduction in lipophilicity reflected in improvements in both microsomal  
44  
45 stability and kinetic solubility. However, piperidine **24** was predicted to be highly basic and we  
46  
47 were concerned that this would have a detrimental effect on permeability, and therefore on oral  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



bioavailability. To reduce the basicity of the solubilizing group without increasing lipophilicity, we reduced the linker length to give **25** (Table 2, entry 6), thereby exploiting the inductive effect of the oxygen. Despite the 0.9 log unit decrease in predicted basicity, the kinetic solubility and lipophilicity were unchanged. Unfortunately, **25** displayed a decrease in microsomal stability, so we reduced the ring size to give pyrrolidine **26** (CCT251236, Table 2, entry 7),<sup>24</sup> which displayed the desired balance of in vitro properties, while maintaining excellent cellular activity with a  $pIC_{50}=7.73\pm 0.07$  ( $IC_{50}=19$  nM,  $n=15$ , see Table S3 in the supporting information for details) for inhibition of HSF1-mediated HSP72 induction. The free  $GI_{50}$  in SK-OV-3 cells was then calculated from the free fraction in the cell assay, which gave a free  $GI_{50}=1.1$  nM.<sup>39</sup> Western blotting confirmed that pyrrolidine **26** blocked the HSF1-mediated induction of both HSP72 and HSP27 as representative heat shock proteins, following treatment with the HSP90 inhibitor 17-AAG. Also, qPCR analysis demonstrated that **26** inhibited the induction of HSP72 at the mRNA level, clearly blocking the induction of *HSPA1A* gene expression with a  $pIC_{50}=7.40$  ( $IC_{50}=40$  nM,  $n=1$ , see supporting information). Taking these results together, pyrrolidine **26** was selected for in vivo study.

**Mouse Pharmacokinetics (PK).** To assess the potential of bisamide **26** as an in vivo chemical tool to study HSF1-mediated transcriptional activity inhibition, the compound was dosed in BALB/c mice at 5 mg/Kg as an oral solution and iv bolus. Blood concentrations were then measured over a 24 hour period (Table 3).

**Table 3.** Mouse blood PK parameters for bisamide **26**

Mouse	Dose po/iv (mg/Kg)	$AUC_{0-24h}^{PO}$ (h*nM) <sup>a</sup>	Blood Cl (mL/min/Kg) <sub>a</sub>	$V_{ss}$ (L/Kg) <sup>a</sup>	Half- life (h)	%F	$f_{ub}^b$	$AUC_{u,0-24}^{PO}$ (h*nM) <sup>c</sup>	$Cl_u$ (mL/min/Kg) <sup>d</sup>	$V_{du}$ (L/Kg) <sup>e</sup>
BALB/c	5/5	5800 (8100-4200)	9.2 (12-7.3)	4.2 (6.3-2.8)	5.3	39	0.0083 <sup>c</sup>	48	1100	510
Athymic	20/0	1900 (2800-1400)	NA	NA	NA	NA	0.015 <sup>d</sup>	29	NA	NA


1  
2  
3 *All values are quoted to 2 SF. The 90% confidence intervals (CI) are in parentheses. NA=not*  
4 *applicable. <sup>a</sup>The geometric mean of n=3 individual mice. <sup>b</sup> $f_{ub}=f_{up}/B:P$ , <sup>c</sup> $f_{up}=0.010$  (0.011-*  
5 *0.0097),  $B:P@1 \mu M=1.2:1$  (1.4-1.0). <sup>d</sup> $f_{up}=0.025$  (0.030-0.020),  $B:P@1 \mu M=1.7:1$  (1.7-1.7).*  
6 *<sup>c</sup> $AUC_u=AUC*f_{ub}$ . <sup>d</sup> $Cl_u=Cl/f_{ub}$ . <sup>e</sup> $V_{du}=V_{ss}/f_{ub}$ .*  
7  
8

9 Analysis of the mouse PK data revealed that bisamide **26** possessed low total blood clearance  
10 (10% hepatic blood flow)<sup>40</sup> and moderate oral bioavailability, with a half-life sufficient to allow  
11 once-a-day dosing. In vitro assessment of the plasma protein binding and the blood to plasma  
12 ratio revealed that **26** was highly bound to plasma proteins (~99%); therefore, the unbound  
13 clearance was high, with a low free exposure from the 5 mg/Kg oral dose, equivalent to free  $C_{av}^{0-}$   
14  $^{24h}=2.0$  nM.<sup>41,42</sup> The high unbound volume of distribution indicates that **26** readily binds to  
15 tissues, consistent with the basicity of the compound.<sup>43</sup>  
16  
17  
18  
19  
20  
21  
22  
23  
24

25 **Bisamide 26 Displays Efficacy in a Human Ovarian Carcinoma Xenograft Model.** Despite  
26 the high unbound clearance of bisamide **26** in mouse, the good oral bioavailability, half-life and  
27 excellent in vitro cellular activity (free  $GI_{50}=1.1$  nM) encouraged us to test the potential efficacy  
28 of **26** in an in vivo human tumor xenograft model. Based on the free  $C_{av}^{0-24h}=2.0$  nM observed in  
29 non-tumor bearing immunocompetent BALB/c mice following the 5 mg/kg po qd dose, a 20  
30 mg/kg po qd dose in immunodeprived athymic mice was selected to cover ~10-times the in vitro  
31 free  $GI_{50}$  in SK-OV-3 cells.<sup>44</sup> To our surprise, following this 20 mg/kg po dose, the free exposure  
32 was actually a disappointing  $AUC_u^{0-24h}=29$  h\*nM, equivalent to free  $C_{av}^{0-24h}=1.2$  nM (Table 3,  
33 see supporting information for details). Despite the lower than expected free exposure of  
34 bisamide **26**, this dose still represented coverage of the in vitro free  $GI_{50}$  in SK-OV-3 cells and  
35 was well tolerated in a mouse multi-dose tolerability study;<sup>45</sup> therefore, the 20 mg/kg po qd dose  
36 was selected for further investigation.<sup>46</sup>  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52

53 SK-OV-3 cells were injected subcutaneously into athymic mice for tumor formation. Once  
54 tumors were established, the mice were randomized into treatment and control groups and were  
55  
56  
57  
58  
59  
60

1  
2  
3 dosed orally once-a-day with either vehicle or 20 mg/kg of bisamide **26**. Tumor volumes and  
4  
5 mouse body weights were measured throughout and tumor weights were measured at the end of  
6  
7 the study, while total tumor concentrations were measured 2 and 6 hours post final dose. (Figure  
8  
9  
10  
11 3 and supporting information).



36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
**Figure 3.** Efficacy of bisamide **26** against SK-OV-3 human ovarian carcinoma xenograft model  
Blue: vehicle control n=8, Red: **26** 20 mg/kg po qd n=8, (Vehicle=10% DMSO, 90% of a 25%  
(2-hydroxypropyl)- $\beta$ -cyclodextrin in 50 mM citrate buffer pH 5). Error bars: arithmetic  
mean $\pm$ SEM. Dosing breaks were carried out on days 5-12, 14, 16, 18, 20, 22, 24, 26, 29, 31


46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
The mice were dosed intermittently throughout the study with **26** to maintain their condition,  
as assessed through monitoring body weights (see supporting information). Clear therapeutic  
efficacy was observed with bisamide **26**, with a Tumor Growth Inhibition (%TGI)<sup>47</sup> of 70%  
based on final tumor volumes. The study was terminated after 33 days and comparison of the  
control and treated arms indicated a 64 % reduction in mean tumor weights (p=0.015)<sup>48</sup> with total

1  
2  
3 tumor concentrations of **26** as high as 940 nM, consistent with the compound's basicity and high  
4  
5 volume of distribution (see supporting information).  
6  
7

8 **Target Identification.** Following the successful efficacy study, the potential for bisamide **26**  
9  
10 as a chemical probe to study the effects of HSF1 transcription inhibition, both in vitro and in  
11  
12 vivo, were clear. However, the variety of HSF1 transcription inhibitors in the literature<sup>49</sup> suggests  
13  
14 there are multiple mechanisms through which this phenotype may be observed, each with  
15  
16 differing potential for drug discovery.  
17  
18

19  
20 To decipher the molecular mechanism of the bisamide series, we needed to discover their  
21  
22 protein targets. The potency of the bisamide **26** in cell-based assays suggests that only high  
23  
24 affinity efficacy and epistatic targets would be of interest.<sup>11</sup> Our biochemical kinase screening  
25  
26 had indicated that there were no high affinity kinase targets. We therefore expanded our  
27  
28 biochemical screening to include other protein families. Bisamide **26** was submitted to the Cerep  
29  
30 Diversity Screen (Cerep, <http://www.cerep.fr>) comprising 98 molecular targets, including  
31  
32 receptors and enzymes, measured at 10  $\mu$ M.<sup>50</sup> Analysis of these screening data revealed that  
33  
34 bisamide **26** displays a good selectivity profile. Only six targets (the receptors: adenosine A2A  
35  
36 and A3, histamine H2 and H3, muscarinic and the enzyme acetylcholine esterase) displayed >80  
37  
38 % inhibition and these generally represented the highly promiscuous receptor protein targets (see  
39  
40 supporting information for details). No hits displayed sufficient activity to clearly relate the  
41  
42 molecular target to the efficacious free concentrations achieved in vitro or in vivo.  
43  
44  
45  
46  
47

48 Because no clear protein families had been revealed from our biochemical screening, a  
49  
50 different approach was necessary. We decided to exploit a chemical proteomics strategy and  
51  
52 using our knowledge of the cellular SAR, we designed a protein pull-down chemical probe to  
53  
54 identify high affinity molecular targets from a human cancer cell lysate (Figure 4).  
55  
56  
57  
58  
59  
60




**Figure 4.** Tool compounds for target identification. All quoted cellular activities are in the SK-OV-3 cell line, the numbers of repeats are in parentheses

To carry out the chemical proteomics pull-down strategy, the bisamide warhead would need to be attached via a linker to a solid-phase bead, without disrupting binding to the molecular target or targets. The solubilizing group vector was the obvious choice for the linker attachment, but to test whether cellular activity was maintained, amide **27** was designed as a cell-permeable mimic of the solid-phase probe. Pleasingly, amide **27** maintained excellent cellular potency (SK-OV-3  $pGI_{50}=8.04\pm 0.06$ ,  $GI_{50}=9.1$  nM, n=4), so amine **29** was used for attachment to the bead via amide bond formation. In addition to bisamide **26**, tetrahydroquinoline **17** was selected as a second positive control due to its distinct structural difference. These two compounds would be used to displace specific molecular targets from the solid-phase probe. Also, to help distinguish false positives from the pull-down experiment, a physicochemically-matched negative control was designed. The dioxane isomer **6** (Table 1, entry 2) had previously been shown to lose all cellular activity. To physicochemically match the dioxane isomer **6** to bisamide **26**, the same ethoxy pyrrolidine solubilizing group was attached to give isomer **28**, which, as expected, displayed no measurable cellular activity.

With all four probe molecules in hand, the compounds were submitted to the stable isotope labeling by amino acids in cell culture (SILAC) mass-spectrometry based pull-down assay (Evotec, <https://www.evotec.com>) to identify and quantify molecular targets of the bisamide series from the lysate of SK-OV-3 cells. Every protein captured by the bead, whether specific or non-specific, is analyzed in this methodology by quantitative mass spectrometry. By using SILAC to quantify the relative amounts of protein captured from the lysate, this approach can, in principle, determine the apparent affinity of every stable protein in the lysate for the surface-bound bisamide probe, although particularly low abundance proteins may not be discovered via this method and proteins that are unstable to the lysis conditions would not be detected. Displacement of the captured proteins with the free active bisamides **26** and **17**, then allows for estimation of their apparent affinities for specific protein targets. Proteins that are apparently displaced from the bead-bound probe by the inactive isomer **28** are considered non-specific or irrelevant for the cellular activity and discarded. The putative protein targets can then be ranked based on their affinity for further investigation (Table 4, see supporting information for details).<sup>51</sup>

**Table 4.** Molecular targets from the pull-down assay using the bisamide probes in SK-OV-3 cell lysate



Protein	Protein EC <sub>50</sub> (μM) <sup>a</sup>	<b>26</b> AC <sub>50</sub> (μM) <sup>b</sup>	<b>26</b> K <sub>i</sub> <sup>app</sup> (μM) <sup>c</sup>	<b>17</b> AC <sub>50</sub> (μM) <sup>b</sup>	<b>17</b> K <sub>i</sub> <sup>app</sup> (μM) <sup>c</sup>	<b>28</b> AC <sub>50</sub> (μM) <sup>b</sup>
GSK3β	1.3	1.2	NA	10	NA <sup>d</sup>	NA <sup>a</sup>
Pirin	1.3	1.5	0.028	10	0.19	NA <sup>a</sup>

1  
2  
3 *A: SK-OV-3 cell lysate protein binding curves for immobilized 29. B: protein displacement*  
4 *curves for pyrrolidine 26. Curves are an average of two different mixing conditions.  $EC_{50}$  and*  
5  *$AC_{50}$  are determined from analysis of the curves without limits.  $^aEC_{50}$  is the apparent*  
6 *immobilized bisamide probe concentration at which 50% of the available protein is bound. The*  
7 *probe bisamide is assumed to be >10-fold molar excess over proteins in the lysate.  $^bAC_{50}$  is the*  
8 *apparent free bisamide concentration at which 50% of the protein is displaced from the*  
9 *immobilized bisamide probe. At least 2-fold enrichment of bound proteins when compared to the*  
10 *matrix.  $^cK_i^{app}$  values are estimated using the Cheng-Prusoff equation, apparent [29-*  
11 *immobilized]=67  $\mu M$ ,<sup>52</sup> assuming no mass transport limitation, interactions are purely*  
12 *competitive and all interactions are direct.  $^d$ Not Applicable (NA) –  $K_i^{app}$  cannot be calculated if*  
13 *the interaction with the probe is indirect.*  
14  
15  
16


17  
18 Analysis of these data from the quantified chemical proteomics pull-down experiment revealed  
19  
20 very few molecular targets of the bisamides, consistent with the selectivity observed with our  
21  
22 biochemical screening. After excluding highly promiscuous proteins commonly observed in pull-  
23  
24 down experiments,<sup>53</sup> three putative targets were identified. PDE6D displayed only weak apparent  
25  
26 affinity for the bead-bound probe and little selectivity between active (**26** and **17**) and inactive  
27  
28 (**28**) probes, so was not considered further. GSK3 $\beta$  displayed apparent high affinity for both  
29  
30 active analogues, with no apparent affinity for the inactive analogue. However, GSK3 $\beta$  had  
31  
32 previously been assayed in our biochemical kinase screening and both binding and functional  
33  
34 assays (see supporting information) had demonstrated that the bisamide series have no  
35  
36 measurable affinity for this kinase; we therefore concluded that GSK3 $\beta$  was potentially an  
37  
38 indirect target of the bisamide series. The final putative protein target was pirin. The binding  
39  
40 curve for pirin to the bead-bound bisamide probe was quite shallow; however, the displacement  
41  
42 curves for pirin, which were very similar to the displacement curves for GSK3 $\beta$  with both cell  
43  
44 active probe ligands, gave robust data with an apparent  $K_i=28$  nM for **26** and no affinity was  
45  
46 observed with the inactive control. Using this method on a SK-OV-3 cell lysate, pirin emerged as  
47  
48 the only remaining putative target of the bisamide series.<sup>54</sup>  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Pirin Validation.** Very little is known about pirin and few papers have been published  
4 discussing its possible function. Pirin was first identified in 1997 by Wendler et al. from a yeast  
5 two-hybrid screen to discover interactors of the transcription factor NFI/CTF1. Pirin was  
6 described as an iron-binding, metal-dependent protein, predominately localized within the  
7 nucleus, highly conserved across species and ubiquitously expressed across all tissue types.<sup>55</sup>  
8 Following this initial discovery, Scheidereit et al. reported that human pirin interacts with the  
9 proto-oncoprotein, BCL3, linking pirin with the NFκB pathway.<sup>56</sup> The role of pirin in the NFκB  
10 pathway was further demonstrated by Lui et al.; using SPR, they revealed the metal-dependent  
11 formation of a pirin/p65/DNA complex and hypothesized the role of human pirin to be a redox-  
12 sensing transcription factor regulator.<sup>57</sup> The redox activity of pirin has previously been discussed,  
13 as the expression level of pirin is proposed to be under the control of the transcription factor  
14 NRF2 through changes in cellular oxidative stress.<sup>58</sup> Wang et al. previously reported that human  
15 pirin interacts with the tumor suppressor protein EAF2/U19 and that exogenous overexpression  
16 of pirin increased colony formation in LNCaP human prostate cancer cells.<sup>59</sup> In the human  
17 melanoma cell line WM266.4, Alcalay et al. demonstrated that shRNA knockdown of pirin could  
18 induce a senescence phenotype and suppress colony formation.<sup>60</sup> Also in the WM266.4 cell-line,  
19 Osada et al. demonstrated that siRNA knockdown of pirin could suppress cell migration.<sup>61-62</sup>  
20 These results are consistent with the observation by Simizu et al. that siRNA knockdown of pirin  
21 suppressed migration of human adenocarcinoma HeLa cells and that pirin was important for  
22 epithelial-mesenchymal transition (EMT).<sup>63</sup> However, little evidence has emerged of an  
23 antiproliferative phenotype from genetic inhibition of pirin expression and our in-house data  
24 using siRNA in SK-OV-3 cells was consistent with this finding.<sup>64</sup> Nonetheless, because our  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



original screening paradigm was designed to discover inhibitors of transcription, the proposed role of pirin as a redox-sensitive transcription factor regulator was certainly intriguing.

To confirm pirin as a high affinity molecular target of the bisamide series, we needed to assess the affinity of the compounds and establish SAR in an orthogonal assay format. Pirin has no known catalytic function and no known endogenous ligand in mammalian cells, consequently we decided to focus on surface plasmon resonance (SPR) to measure the affinity of the bisamide series for pirin. Purified recombinant human pirin was attached to the SPR chip through a standard amide coupling. The affinity of the bisamide ligand was assessed by equilibrium analysis of the resulting sensorgram (Figure 5).



**Figure 5.** Representative SPR sensorgram and binding isotherm of bisamide **26** bound to recombinant pirin. The dotted-line represents the time-point the equilibrium response was measured. The binding isotherm was fitted to a one-site specific binding model using Graphpad Prism 6


The known pirin ligand TPh A<sup>61</sup> was used as a positive control and to protect the binding site during amine coupling to the SPR chip, but displayed only modest affinity in our hands ( $pK_D=5.77\pm0.04$ ,  $K_D=1700$  nM,  $n=4$ ).<sup>65</sup> The SPR sensorgram showed that bisamide **26** is indeed a tight-binding ligand of pirin. Equilibrium analysis revealed that bisamide **26** had a  $pK_D=7.36\pm0.01$  ( $K_D=44$  nM,  $n=3$ ). However, the ratio of theoretical  $R_{max}$  to measured  $R_{max}$  from

1  
2  
3 the binding isotherm was 0.40, indicating apparent substoichiometric binding. This could be due  
4  
5 to the coupling of pirin to the SPR chip impairing protein folding or because pirin is a metal-  
6  
7 dependent protein and the metal was leaching out into the running buffer; both effects could  
8  
9 negatively impact the apparent binding affinity and stoichiometry.  
10  
11

12 To establish the SAR surrounding pirin binding, several bisamide analogues were selected for  
13  
14 further study. We first focused on the two other analogues used in target identification. The cell  
15  
16 active analogue tetrahydroquinoline **17** (Table 1, entry 13) was also found to display tight-  
17  
18 binding affinity for pirin; in contrast, the negative control dioxane isomer **28** ( $pIC_{50} < 5.00$ ,  
19  
20  $IC_{50} > 10000$  nM,  $n=2$ ) displayed no measurable affinity. These data suggested that pirin SAR and  
21  
22 the cellular SAR were linked. Increasing the steric bulk of the solubilizing group, as exemplified  
23  
24 by piperidine **24** (Table 2, entry 4) again returned a high affinity pirin ligand ( $pK_D = 7.52 \pm 0.02$ ,  
25  
26  $K_D = 30$  nM,  $n=3$ ), consistent with the potent cellular activity. However, structural changes to the  
27  
28 benzodioxane amide motif proved more complex. The original hit, bisamide **1** (Table 1, entry 1),  
29  
30 was a tight-binding pirin ligand; whereas the cell inactive analogues, methylated amide **13** (Table  
31  
32 1, entry 9) and dimethoxy **7** (Table 1, entry 3), displayed no affinity for pirin. However, the two  
33  
34 chroman isomers **8** and **9** (Table 1, Entries 4 and 5) were tight-binding ligands for pirin but their  
35  
36 target affinity did not reflect their decrease in cellular activity when compared to bisamide **1**.  
37  
38 Finally, the isochroman analogue **10** (Table 1, entry 6) was still a high affinity ligand for pirin,  
39  
40 despite displaying no cellular activity (see Table S11 supporting information for details).  
41  
42  
43  
44  
45  
46  
47

48 Pirin is a member of the cupin super family of proteins which are so called because they all  
49  
50 possess a conserved  $\beta$ -barrel.<sup>66</sup> However, due to minimal sequence homology between members  
51  
52 of the cupin family, crystallography is often needed to identify them. The cupins display a huge  
53  
54  
55  
56  
57  
58  
59  
60

array of functionality, including oxidases and isomerases.<sup>67</sup> To better understand pirin SAR, we determined the crystal structure of efficacious bisamide **26** bound to pirin (Figure 6).



**Figure 6.** X-ray crystal structure of bisamide **26**. PDB 5JCT, Pymol image of pirin (light blue cartoon representation) in complex with bisamide **26** (cyan stick representation), 2 Fo-Fc map contoured at 1.0  $\sigma$  (blue mesh) and Pymol image of pirin (magenta, blue stick representation) in complex with bisamide **26** (cyan stick representation), distances shown are in Ångstroms, 2 Fo-Fc map contoured at 1.0  $\sigma$  (blue mesh). Crystals belonged to the space group P2<sub>1</sub>2<sub>1</sub>2<sub>1</sub> and diffracted to resolution of 1.73 Å


Pirin is a metal-binding bicupin characterized by the two  $\beta$ -barrels that are clearly visible in the crystal structure.<sup>68</sup> Pirin binds a single metal-ion in one of the  $\beta$ -barrels, which is where a deep, small molecule binding pocket is located. The metal-ion is clearly visible in the electron density, although it is unclear which metal-ion is actually bound. The metal-ion binding site is formed of three histidine residues (His56, His58 and His101), a glutamic acid (Glu103) and two water molecules, showing the metal-ion possesses octahedral coordination. Bisamide **26** forms no direct interactions with the metal-ion, instead a water-mediated interaction is created by the two amide functional groups, which form a hydrogen bonding pincer around this metal-

1  
2  
3 coordinated water molecule, revealing why the two amides are crucial for binding. The methyl-  
4  
5 distal amide also acts as a hydrogen-bond donor with an aspartic acid (Asp43) at the base of the  
6  
7 binding site, explaining why methylation of that group is not tolerated. The methylpyridine ring  
8  
9 of the quinoline substituent is clearly solvent exposed and the solubilizing group cannot be  
10  
11 resolved due to flexibility, consistent with the broad SAR at this position and the eventual  
12  
13 success of the pull-down probe. The SAR around the benzodioxane ring is less clear. From the  
14  
15 cellular SAR, the oxygen atoms of the dioxane are crucial for activity. The narrow binding site is  
16  
17 consistent with the cellularly-inactive dioxane isomer **28** and the cellularly-inactive dimethoxy  
18  
19 analogue **7** having low affinity for pirin (Table 1 and Table S11), as both these groups would  
20  
21 cause a steric clash. However, there are no clear interactions between the protein and the dioxane  
22  
23 ring oxygens, so it is unsurprising that changing the positions of the oxygen atoms has little  
24  
25 effect on pirin affinity, such that chromans **8**, **9** and isochroman **10** (Table 1, Entries 4-6) still  
26  
27 display high affinity for pirin, in contrast to their complex cellular SAR.  
28  
29  
30  
31  
32  
33

34 The apparent disconnect between the pirin affinity SAR and the antiproliferative cellular SAR,  
35  
36 led us to hypothesize that either simply binding to pirin was not enough to recapitulate the  
37  
38 cellular phenotype or that binding to a second molecular target was also crucial. For example, in  
39  
40 the study by Lui et al.<sup>57</sup> the formation of protein-protein interactions with pirin was under the  
41  
42 allosteric control of the redox-state of the iron bound in the protein. Ligands bound in the metal-  
43  
44 binding site are therefore likely to act in an allosteric manner to regulate the function of pirin. It  
45  
46 is commonly known that allosteric modulators display complex SAR, where small structural  
47  
48 changes can have little effect on protein affinity but can drastically alter the observed phenotype,  
49  
50 switching ligands between positive, negative and neutral allosteric modulation.<sup>69,70</sup> The  
51  
52 alternative hypothesis consistent with the observed complex cellular SAR was that a second high  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 affinity protein target was required to explain the antiproliferative activity of the bisamide **26** and  
4 was not detected in our target-ID campaign due to either low abundance or poor stability in the  
5 lysate. The dual targeting of proteins is often observed; for example, CDK4 and CDK6, where  
6  
7 simultaneous inhibition of both kinases is necessary to observe an antiproliferative phenotype,<sup>71</sup>  
8 owing to the similarity of their respective binding sites, small-molecule inhibitors inevitably  
9 inhibit both proteins.<sup>72</sup> RNAi knockdown of pirin by several groups has demonstrated very  
10 limited effects on cell proliferation and as pirin has no known enzymatic function, discovering  
11 and validating a cellular biomarker to investigate its role in the antiproliferative phenotype and in  
12 vivo efficacy is an ongoing challenge.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

24 One phenotype that has previously been associated with a small-molecule binding to pirin is  
25 cancer cell migration.<sup>61</sup> Miyazaki et al. demonstrated that their pirin ligand, TPh A, inhibited the  
26 migration of the melanoma cell line, WM266.4.<sup>61</sup> To investigate whether our tool compound,  
27 bisamide **26**, phenocopied this distinct pirin-ligand chemotype, we decided to investigate its anti-  
28 migratory activity using a scratch-wound assay. The scratch-wound assay is commonly used to  
29 assess the effects of small-molecules on cell migration.<sup>73</sup> Bisamide **26** demonstrated excellent  
30 antiproliferative activity against the WM266.4 cell line ( $pGI_{50}=7.92\pm 0.10$ ,  $GI_{50}=12$  nM,  $n=11$ ).  
31 To exclude the effect of inhibiting proliferation on migration in the scratch-wound assay, the  
32 cells were plated at high confluency and the time-frame of the assay was reduced to 30 h. The  
33 relative wound-density was then measured at various concentrations and time-points. The  
34 negative control isomer **28** displayed no measurable anti-migratory activity in stark contrast to  
35 the potent pirin ligand bisamide **26**, which was able to strongly inhibit the migration of  
36 WM266.4 cells at 100 nM (Figure 7).  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Figure 7.** The anti-migratory activity of chemical probe bisamide **26**. A: wound healing images of WM266.4 cells, after 30 h the wound has almost completely healed in the control in contrast to 100 nM **26**. B: quantification of the relative wound density reveals the maximum anti-migratory activity is achieved at 100 nM **26**.

## DISCUSSION

Bisamide **26** displays excellent and wide-ranging in vitro cellular potency, inhibiting both HSF1-mediated transcriptional activity (defined by the inhibition of the induced expression of the heat-shock proteins HSP72 and HSP27 and *HSPA1A* mRNA) and cancer cell proliferation. Also, **26** has good mouse PK, and demonstrated its anticancer effects in vivo at low free exposures with clear tumor growth inhibition at tolerable doses. Kinase screening and broader proteome screening, in addition to the chemical proteomics using SILAC quantified pull-down with rigorous controls and follow-up testing, indicate that pirin was the sole specific protein target that could be identified to date. SPR analysis of the binding of the bisamide series to pirin confirms that these compounds are high affinity ligands, with most aspects of the pirin SAR being consistent with the cellular SAR. However, there was an apparent disconnect surrounding the dioxane group of the chemotype. This requires further investigation to determine whether pirin is crucial for the in vitro antiproliferative activity and in vivo efficacy via an allosteric

1  
2  
3 modulation mechanism or whether binding to a second high affinity protein target is needed to  
4  
5 fully account for the observed phenotype. Because the SILAC quantified pulldown assay can  
6  
7 only identify protein targets that are stable to cell lysis, additional in-cell target-ID methods are  
8  
9 currently under investigation to probe for a potential second target. Nevertheless, the tool  
10  
11 compound, bisamide **26**, demonstrated the previously proposed anticancer phenotype of pirin  
12  
13 ligands, by inhibiting the migration of WM266.4 melanoma cells in vitro. The role of pirin in the  
14  
15 bisamide phenotype and the cellular effects of modulating the HSF1 pathway with bisamide **26**  
16  
17 are currently also under investigation and will be reported subsequently.  
18  
19  
20  
21

## 22 CONCLUSIONS

23  
24 Using a high-throughput screen to identify inhibitors of the HSF1-mediated stress pathway, we  
25  
26 have discovered an extremely potent inhibitor of human cancer cell proliferation in vitro from  
27  
28 the bisamide chemotype. By exploring the SAR from the cellular assays, we designed a chemical  
29  
30 probe, bisamide **26**, which is highly potent and displays an appropriate mouse pharmacokinetic  
31  
32 profile to significantly inhibit growth in a human ovarian carcinoma xenograft model. The  
33  
34 chemical probe **26** was also used to design a chemical proteomic pull-down experiment, which  
35  
36 identified the putative transcription factor regulator, pirin as a protein target. The high affinity of  
37  
38 chemical probe **26** for pirin was confirmed by SPR. Comparison of the biophysical with the  
39  
40 cellular data indicated that active molecules bind pirin, but that the cellular SAR is more  
41  
42 complex, although **26** did display a potent inhibitory effect on the migration of human melanoma  
43  
44 cells, consistent with the putative pirin cancer phenotype. Despite this, we propose that bisamide  
45  
46  
47  
48  
49  
50 **26**, combination with the physicochemically matched negative control dioxane isomer **28**, are  
51  
52 promising chemical probes to investigate the role of HSF1 pathway inhibition and pirin binding  
53  
54 in vitro and in vivo.  
55  
56  
57  
58  
59  
60

## EXPERIMENTAL SECTION

*Experimental Procedures (Chemistry)*

All final compounds were screened through our in-house computational PAINS filter and gave no structural alerts as potential assay interference compounds.<sup>74</sup> Unless otherwise stated, reactions were conducted in oven dried glassware under an atmosphere of nitrogen or argon using anhydrous solvents. All commercially obtained reagents and solvents were used as received. Thin layer chromatography (TLC) was performed on pre-coated aluminum sheets of silica (60 F254 nm, Merck) and visualized using short-wave UV light. Flash column chromatography was carried out on Merck silica gel 60 (partial size 40-65  $\mu\text{m}$ ). Column chromatography was also performed on a Biotage SP1 purification system using Biotage Flash silica cartridges (SNAP KP-Sil). Ion exchange chromatography was performed using acidic Isolute Flash SCX-II columns. Semi-preparative HPLC was performed on an Agilent 6120 system, flow 20 mL/min, eluents 0.1 % acetic acid in water and 0.1 % acetic acid in methanol, gradient of 10 % to 100 % organic phase.  $^1\text{H}$ -NMR spectra were recorded on Bruker AMX500 (500 MHz) spectrometers using an internal deuterium lock. Chemical shifts are quoted in parts per million (ppm) using the following internal references:  $\text{CDCl}_3$  ( $\delta\text{H}$  7.26), MeOD ( $\delta\text{H}$  3.31) and  $\text{DMSO-d}_6$  ( $\delta\text{H}$  2.50). Signal multiplicities are recorded as singlet (s), doublet (d), triplet (t), quartet (q) and multiplet (m), doublet of doublets (dd), doublet of doublet of doublets (ddd), broad (br) or obscured (obs). Coupling constants,  $J$ , are measured to the nearest 0.1 Hz.  $^{13}\text{C}$ -NMR spectra were recorded on Bruker AMX500 spectrometers at 126 MHz using an internal deuterium lock. Chemical shifts are quoted to 0.01 ppm, unless greater accuracy was required, using the following internal references:  $\text{CDCl}_3$  ( $\delta\text{C}$  77.0), MeOD ( $\delta\text{C}$  49.0) and  $\text{DMSO-d}_6$  ( $\delta\text{C}$  39.5). High resolution mass spectra were recorded on an Agilent 1200 series HPLC and diode array detector coupled to a 6210 time of flight mass spectrometer with dual multimode APCI/ESI



1  
2  
3 source or on a Waters Acquity UPLC and diode array detector coupled to a Waters G2 QToF  
4 mass spectrometer fitted with a multimode ESI/APCI source. Analytical separation was carried  
5 out according to the methods listed below. The mobile phase was a mixture of methanol (solvent  
6 A) and water (solvent B), both containing formic acid at 0.1 %, UV detection was at 254 nm.  
7  
8 Method I: Agilent 1200 series HPLC, Merck Purospher STAR (RP-18e, 30x4 mm) column using  
9 a flow rate of 1.5 mL/min in a 4 minute gradient elution. Gradient elution was as follows: 10:90  
10 (A/B) to 90:10 (A/B) over 2.5 min, 90:10 (A/B) for 1 min, and then reversion back to 10:90  
11 (A/B) over 0.3 min, finally 10:90 (A/B) for 0.2 min. Method II: Agilent 1200 series HPLC,  
12 Merck Chromolith Flash column (RP-18e, 25 x 2 mm) at 30 °C using a flow rate of 0.75 mL/min  
13 in a 4 minute gradient elution. Gradient elution was as follows: 5:95 (A/B) to 100:0 (A/B) over  
14 2.5 min, 100:0 (A/B) for 1 min, and then reversion back to 5:95 (A/B) over 0.1 min, finally 5:95  
15 (A/B) for 0.4 min. Method III: Waters Acquity UPLC, Phenomenex Kinetex XB-C18 column  
16 (30 x 2.1 mm, 1.7u, 100A) at 30 °C using flow rate of 0.3 mL/min in a 4 minute gradient elution.  
17 Gradient elution was as follows: 10:90 (A/B) to 90:10 (A/B) over 3 min, 90:10 (A/B) for 0.5  
18 min, and then reversion back to 10:90 (A/B) over 0.3 min, finally 10:90 (A/B) for 0.2 min;  
19 Method IV: Waters Acquity UPLC, Phenomenex Kinetex C18 column (30 x 2.1 mm, 2.6u,  
20 100A), flow rate and gradient elution according to Method III. The following reference masses  
21 were used for HRMS analysis: Agilent 1200 series: caffeine  $[M + H]^+$  195.087652;  
22 hexakis(1*H*,1*H*,3*H*-tetrafluoropentoxy)phosphazene  $[M + H]^+$  922.009798 and hexakis(2,2-  
23 difluoroethoxy)phosphazene  $[M + H]^+$  622.02896 or reserpine  $[M + H]^+$  609.280657; Waters  
24 Acquity UPLC: Leucine Enkephalin fragment ion  $[M + H]^+$  397.1876. All compounds were >95  
25 % purity by LCMS analysis unless otherwise stated.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54

#### 55 56 57 **General synthetic procedures:** 58 59 60

1  
2  
3     **Method A:** Oxalyl chloride (1.2-1.7 eq.) was added dropwise to a solution of the carboxylic  
4 acid (1.0-1.5 eq.) and DMF in anhydrous dichloromethane. The reaction mixture was stirred at  
5 room temperature for three to four hours, and then concentrated. The remaining residue was re-  
6 dissolved in dichloromethane and concentrated again. Then, the aniline (1.0 eq.) was added to  
7 the remaining residue and the combined solids were dissolved in anhydrous pyridine or a mixture  
8 of anhydrous pyridine and dichloromethane. The resulting reaction mixture was stirred at room  
9 temperature overnight.

10  
11     **Method B:** 1-[Bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid  
12 hexafluorophosphate (HATU, 1.2-1.3 eq.) was added to a solution of the carboxylic acid (1.0-1.2  
13 eq.) and *N,N*-diisopropylethylamine (2.0-5.0 eq.) in anhydrous DMF. The reaction mixture was  
14 stirred for 10 min, before the aniline (1.0 eq.) was added. The reaction mixture was stirred at  
15 room temperature overnight. The reaction mixture was then diluted with water. The resulting  
16 precipitate was isolated by filtration and washed with water.

17  
18     **Method C:** The (3-nitrophenyl)amide (1.0 eq.), iron powder (9-11 eq.), and ammonium  
19 chloride (9-11 eq.) in ethanol/ water (4/1) were added to a round bottom flask and heated to  
20 reflux overnight. Then, the reaction mixture was filtered over a short pad of Celite<sup>®</sup> or silica gel.  
21 The filtrate was reduced *in vacuo* until dryness. The remaining residue was re-suspended in  
22 dichloromethane and washed with sat. NaHCO<sub>3</sub> (aq.), water and brine. The organic layer was  
23 dried over sodium sulfate or magnesium sulfate and reduced *in vacuo* until dryness to afford the  
24 corresponding (3-aminophenyl)amide.

25  
26     **Method D:** Palladium (10 % on activated carbon, 42-68 mg/1 mmol) was added to a  
27 suspension of the nitro compound in a 1:1 mixture of ethanol/ethyl acetate and stirred under H<sub>2</sub>  
28 (1 atm.) at 28 °C overnight. The reaction mixture was then filtered through Celite<sup>®</sup> and the  
29  
30  
31  
32  
33

1  
2  
3 Celite<sup>®</sup> pad washed with further ethyl acetate. The filtrate was concentrated *in vacuo* to afford  
4  
5  
6 the corresponding aniline.  
7

8 **Method E:** NaH (60 % in mineral oil, 1.1-2.2 eq.) was added to a solution of the alcohol (1.2-  
9  
10 2.8 eq.) in anhydrous THF at 0 °C. The reaction was allowed to stir at 0 °C for 10 min, then at  
11  
12 room temperature for 30 min. 6-Bromo-2-chloroquinoline was added and the resulting  
13  
14 suspension heated to reflux for 1-16 h. The reaction was allowed to cool to room temperature,  
15  
16 then diluted with water/sat. NaHCO<sub>3</sub> (aq.) and extracted with dichloromethane (3x). The organic  
17  
18 layers were combined, washed with water, dried over magnesium sulfate and concentrated *in*  
19  
20  
21  
22 *vacuo* to afford the crude product.  
23

24 **Method F:** *n*-BuLi (1.2-2.2 eq., 2.5 M in hexanes, freshly titrated before use using standard  
25  
26 procedures) was added dropwise to a solution of the aryl bromide in anhydrous THF at -78 °C  
27  
28 under nitrogen. The reaction was stirred at -78 °C for 40 min, before solid CO<sub>2</sub> was added. After  
29  
30 stirring for 5 min, the reaction was allowed to warm to room temperature. The reaction was  
31  
32 quenched with water and concentrated under reduced pressure to remove the THF. The aqueous  
33  
34 layer was washed with ethyl acetate, acidified to pH 3 by the addition of 2M HCl (aq.) and  
35  
36 concentrated *in vacuo* to afford the crude product.  
37  
38  
39

#### 40 41 **Preparation of compounds in Table 1:** 42

##### 43 2-Methyl-*N*-(2-methyl-5-nitrophenyl)quinoline-6-carboxamide **4**

44  
45 2-Methylquinoline-6-carboxylic acid **3** (3.69 g, 19.72 mmol), oxalyl chloride (1.8 mL, 20.15  
46  
47 mmol) and DMF (310 μL, 4.00 mmol) in anhydrous dichloromethane (35 mL) were reacted  
48  
49 according to method A. 2-Methyl-5-nitroaniline **2** (3.0 g, 19.72 mmol) and the acid chloride were  
50  
51 then reacted in anhydrous pyridine (35 mL). The reaction mixture was reduced *in vacuo* until  
52  
53 dryness. The remaining residue was triturated with diethyl ether. The crude product was purified  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 by column chromatography (Biotage, gradient of 0-50 % ethanol in dichloromethane) to afford  
4 the product as a yellow amorphous solid (5.57 g, 88 %). IR (thin film):  $\nu_{\max}$  1661, 1527, 1342,  
5 1260  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (500 MHz,  $\text{DMSO-}d_6$ )  $\delta$  10.36 (s, 1H), 8.63 (d,  $J = 1.8$  Hz, 1H), 8.43 (d,  $J$   
6 = 8.4 Hz, 1H), 8.40 (d,  $J = 2.4$  Hz, 1H), 8.25 (dd,  $J = 8.7, 2.0$  Hz, 1H), 8.07 (d,  $J = 2.9$  Hz, 1H),  
7 8.05 (d,  $J = 3.0$  Hz, 1H), 7.60 (d,  $J = 8.5$  Hz, 1H), 7.54 (d,  $J = 8.4$  Hz, 1H), 2.71 (s, 3H), 2.44 (s,  
8 3H).  $^{13}\text{C}$  NMR (126 MHz,  $\text{DMSO-}d_6$ )  $\delta$  165.54, 161.05, 146.20, 144.90, 143.38, 142.15, 137.76,  
9 132.04, 130.08, 129.93, 129.31, 126.62, 126.09, 124.16, 121.00, 120.94, 23.98, 18.82. HRMS  
10 (ESI<sup>+</sup>): calcd for  $\text{C}_{18}\text{H}_{15}\text{NaN}_3\text{O}_3$  ( $\text{M} + \text{Na}$ )<sup>+</sup>, 344.1006; found 344.0999.

21  
22 *N*-(5-amino-2-methylphenyl)-2-methylquinoline-6-carboxamide **5**

23  
24 2-Methyl-*N*-(2-methyl-5-nitrophenyl)quinoline-6-carboxamide **4** (4.0 g, 12.45 mmol), iron  
25 powder (6.95 g, 124.0 mmol) and ammonium chloride (2.12 g, 124.0 mmol) in ethanol (50 mL)  
26 and water (12.5 mL) were reacted according to method C to afford the product as a light yellow  
27 amorphous solid (1.95 g, 54 %). IR (thin film):  $\nu_{\max}$  3340, 3252, 1645, 1582, 1487, 1278  $\text{cm}^{-1}$ .  $^1\text{H}$   
28 NMR (500 MHz,  $\text{DMSO-}d_6$ )  $\delta$  9.86 (s, 1H), 8.61 – 8.51 (m, 1H), 8.38 (d,  $J = 8.4$  Hz, 1H), 8.21  
29 (dd,  $J = 8.8, 1.7$  Hz, 1H), 8.00 (d,  $J = 8.8$  Hz, 1H), 7.51 (d,  $J = 8.4$  Hz, 1H), 6.91 (d,  $J = 8.1$  Hz,  
30 1H), 6.65 (d,  $J = 2.0$  Hz, 1H), 6.42 (dd,  $J = 8.1, 2.2$  Hz, 1H), 4.94 (s, 2H), 2.70 (s, 3H), 2.09 (s,  
31 3H).  $^{13}\text{C}$  NMR (126 MHz,  $\text{DMSO-}d_6$ )  $\delta$  165.18, 161.09, 148.86, 147.31, 137.58, 137.01, 132.25,  
32 130.87, 128.72, 128.49, 128.38, 125.84, 123.38, 120.72, 112.75, 112.61, 25.49, 17.50. HRMS  
33 (ESI<sup>+</sup>): calcd for  $\text{C}_{18}\text{H}_{18}\text{N}_3\text{O}$  ( $\text{M} + \text{H}$ )<sup>+</sup>, 292.1444; found 292.1446.

34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48 *N*-(5-(2,3-Dihydrobenzo[*b*][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-methylquinoline-  
49 6-carboxamide **1**.

50  
51  
52 2-Methyl-6-quinolinecarboxylic acid (600 mg, 3.21 mmol), HATU (1.46 g, 3.85 mmol), and  
53 *N*-(5-amino-2-methylphenyl)-2-methylquinoline-6-carboxamide **5** (910 mg, 3.21 mmol) were  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 reacted in *N,N*-diisopropylethylamine (1.12 mL, 6.41 mmol) and anhydrous DMF (25 mL)  
4  
5 according to method B to afford the product as an off-white amorphous solid (1.38 g, 95 %). IR  
6  
7 (solid):  $\nu_{\max}$  2922, 1645, 1582, 1496, 1284, 1258, 1063  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (500 MHz,  $\text{DMSO-}d_6$ )  $\delta$   
8  
9 10.14 (s, 1H), 10.08 (s, 1H), 8.61 (s, 1H), 8.41 (br d,  $J = 7.3$  Hz, 1H), 8.24 (d,  $J = 8.7$  Hz, 1H),  
10  
11 8.03 (d,  $J = 8.8$  Hz, 1H), 7.87 (d,  $J = 2.1$  Hz, 1H), 7.64 – 7.56 (m, 2H), 7.54 (d,  $J = 2.1$  Hz, 1H),  
12  
13 7.51 (dd,  $J = 8.4, 2.2$  Hz, 1H), 7.24 (d,  $J = 8.5$  Hz, 1H), 6.98 (d,  $J = 8.4$  Hz, 1H), 4.35 – 4.26 (m,  
14  
15 4H), 2.71 (s, 3H), 2.24 (s, 3H).  $^{13}\text{C}$  NMR (126 MHz,  $\text{DMSO-}d_6$ )  $\delta$  165.44, 164.82, 161.21,  
16  
17 148.93, 146.80, 143.39, 137.77, 137.62, 136.74, 131.97, 130.59, 129.23, 128.81, 128.64, 128.38,  
18  
19 128.14, 125.86, 123.44, 121.66, 119.07, 118.63, 117.30, 117.12, 64.86, 64.48, 25.51, 17.94.  
20  
21 HRMS (ESI<sup>+</sup>): calcd for  $\text{C}_{27}\text{H}_{24}\text{N}_3\text{O}_4$  (M + H)<sup>+</sup>, 454.1761; found 454.1733.  
22  
23  
24  
25  
26

27 *N*-(5-(2,3-Dihydrobenzo[*b*][1,4]dioxine-5-carboxamido)-2-methylphenyl)-2-methylquinoline-  
28  
29 6-carboxamide **6**.  
30

31  
32 2,3-Dihydrobenzo[*b*][1,4]dioxine-5-carboxylic acid (46 mg, 0.26 mmol), HATU (127 mg, 0.34  
33  
34 mmol) and *N*-(5-amino-2-methylphenyl)-2-methylquinoline-6-carboxamide **5** (75 mg, 0.26  
35  
36 mmol) in *N,N*-diisopropylethylamine (0.14 mL, 0.82 mmol) and anhydrous DMF (2.5 mL) were  
37  
38 reacted according to method B to afford the product as a white amorphous solid (95 mg, 81 %).  
39  
40 IR (solid):  $\nu_{\max}$  3370, 3256, 1644, 1598, 1532, 1450 1091, 743  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (500 MHz,  
41  
42  $\text{DMSO-}d_6$ )  $\delta$  10.16 (s, 1H), 10.09 (s, 1H), 8.61 (s, 1H), 8.41 (d,  $J = 8.4$  Hz, 1H), 8.27 – 8.21 (m,  
43  
44 2H), 8.03 (d,  $J = 8.7$  Hz, 1H), 7.82 (br s, 1H), 7.58 – 7.52 (m, 2H), 7.25 (d,  $J = 8.3$  Hz, 1H), 7.18  
45  
46 – 7.11 (m, 2H), 7.02 – 6.98 (m, 1H), 6.92 (t,  $J = 7.8$  Hz, 1H), 4.40 – 4.27 (m, 4H), 2.71 (s, 3H),  
47  
48 2.24 (s, 3H).  $^{13}\text{C}$  NMR (126 MHz,  $\text{DMSO-}d_6$ )  $\delta$  165.43, 164.26, 161.23, 148.94, 144.11, 141.65,  
49  
50 137.62, 137.52, 136.89, 131.90, 130.74, 129.44, 128.81, 128.67, 128.38, 126.14, 125.85, 123.45,  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 121.73, 121.17, 119.51, 118.44, 118.00, 64.93, 64.21, 25.51, 17.97. HRMS (ESI<sup>+</sup>): calcd for  
4  
5 C<sub>27</sub>H<sub>24</sub>N<sub>3</sub>O<sub>4</sub> (M + H)<sup>+</sup>, 454.1761; found 454.1760.  
6  
7

8 *N*-(5-(3,4-Dimethoxybenzamido)-2-methylphenyl)-2-methylquinoline-6-carboxamide **7**.

9  
10 3,4-Dimethoxybenzoic acid (34 mg, 0.189 mmol), HATU (82 mg, 0.215 mmol), and *N*-(5-  
11 amino-2-methylphenyl)-2-methylquinoline-6-carboxamide **5** (50 mg, 0.172 mmol) in *N,N*-  
12 diisopropylethylamine (0.075 mL, 0.429 mmol) and anhydrous DMF (1.2 mL) were reacted  
13 according to method B. The crude product was purified by flash column chromatography (1-5 %  
14 methanol in dichloromethane) to afford compound **7** as a white amorphous solid (52 mg, 67 %).  
15 IR (thin film):  $\nu_{\max}$  1648, 1601, 1508, 1418, 1268, 1225 cm<sup>-1</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>)  $\delta$   
16 10.13 (s, 1H), 10.09 (s, 1H), 8.61 (d, *J* = 2.0 Hz, 1H), 8.41 (d, *J* = 8.4 Hz, 1H), 8.24 (dd, *J* = 8.8,  
17 2.0 Hz, 1H), 8.03 (d, *J* = 8.8 Hz, 1H), 7.85 (d, *J* = 2.2 Hz, 1H), 7.62 (td, *J* = 8.8, 2.2 Hz, 2H),  
18 7.55 (d, *J* = 2.1 Hz, 1H), 7.53 (d, *J* = 8.4 Hz, 1H), 7.26 (d, *J* = 8.5 Hz, 1H), 7.08 (d, *J* = 8.5 Hz,  
19 1H), 3.85 (s, 3H), 3.84 (s, 3H), 2.71 (s, 3H), 2.26 (s, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-*d*<sub>6</sub>)  $\delta$   
20 165.01, 164.74, 160.76, 151.58, 148.48, 148.26, 137.32, 137.16, 136.27, 131.51, 130.15, 128.75,  
21 128.37, 128.16, 127.91, 126.92, 125.40, 122.98, 121.03, 118.76, 118.32, 110.98, 110.91, 55.67,  
22 55.62, 25.04, 17.46. HRMS (ESI<sup>+</sup>): calcd for C<sub>27</sub>H<sub>26</sub>N<sub>3</sub>O (M + H)<sup>+</sup>, 456.19178; found  
23 456.19189.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 *N*-(5-(Chroman-7-carboxamido)-2-methylphenyl)-2-methylquinoline-6-carboxamide **8**.

44  
45 2-Methyl-6-quinolinecarboxylic acid (75 mg, 0.42 mmol), HATU (182 mg, 0.48 mmol) and *N*-  
46 (5-amino-2-methylphenyl)-2-methylquinoline-6-carboxamide **5** (111 mg, 0.38 mmol) in *N,N*-  
47 diisopropylethylamine (0.20 mL, 1.15 mmol) and anhydrous DMF (3.5 mL) were reacted  
48 according to method B. The crude product was purified by column chromatography (Biotage,  
49 gradient of 0-10 % methanol in dichloromethane) to afford an off-white amorphous solid. This  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 material was triturated with diethyl ether to afford the product as a white amorphous solid (51  
4 mg, 30 %). IR (thin film):  $\nu_{\max}$  2957, 1651, 1599, 1527, 1499, 1310, 1283  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (500  
5 MHz,  $\text{DMSO-}d_6$ )  $\delta$  10.14 (s, 1H), 10.13 (s, 1H), 8.61 (d,  $J = 1.8$  Hz, 1H), 8.41 (d,  $J = 8.4$  Hz,  
6 1H), 8.24 (dd,  $J = 8.8, 1.9$  Hz, 1H), 8.03 (d,  $J = 8.8$  Hz, 1H), 7.89 (d,  $J = 2.0$  Hz, 1H), 7.60 (dd,  
7  $J = 8.3, 2.1$  Hz, 1H), 7.53 (d,  $J = 8.4$  Hz, 1H), 7.43 (dd,  $J = 7.9, 1.7$  Hz, 1H), 7.36 (d,  $J = 1.6$   
8 Hz, 1H), 7.25 (d,  $J = 8.4$  Hz, 1H), 7.19 (d,  $J = 7.9$  Hz, 1H), 4.23 – 4.14 (m, 2H), 2.80 (t,  $J = 6.4$   
9 Hz, 2H), 2.71 (s, 3H), 2.25 (s, 3H), 1.94 (p,  $J = 6.3$  Hz, 2H).  $^{13}\text{C}$  NMR (126 MHz,  $\text{DMSO-}d_6$ )  $\delta$   
10 165.44, 165.31, 161.21, 154.79, 148.93, 137.70, 137.63, 136.73, 134.25, 131.96, 130.61, 130.29,  
11 129.32, 128.81, 128.64, 128.38, 126.70, 125.86, 123.44, 119.61, 119.08, 118.64, 115.94, 66.57,  
12 25.51, 24.73, 22.00, 17.95. HRMS ( $\text{ESI}^+$ ): calcd for  $\text{C}_{28}\text{H}_{26}\text{N}_3\text{O}_3$  ( $\text{M} + \text{H}$ ) $^+$ , 452.1969; found  
13 452.1956.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

29 *N*-(5-(Chroman-6-carboxamido)-2-methylphenyl)-2-methylquinoline-6-carboxamide **9**.

30  
31  
32 Chroman-6-carboxylic acid (40 mg, 0.227 mmol), HATU (98 mg, 0.257 mmol), and *N*-(5-  
33 amino-2-methylphenyl)-2-methylquinoline-6-carboxamide **5** (60 mg, 0.206 mmol) in *N,N*-  
34 diisopropylethylamine (0.088 mL, 0.505 mmol) and anhydrous DMF (1.5 mL) were reacted  
35 according to method B. The crude product was purified by flash column chromatography (1-3.5  
36 % methanol in dichloromethane) to afford the product as a white amorphous solid (62 mg, 62  
37 %). IR (thin film):  $\nu_{\max}$  1647, 1600, 1528, 1495, 1318, 1256  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (500 MHz,  $\text{DMSO-}$   
38  $d_6$ )  $\delta$  10.13 (s, 1H), 10.04 (s, 1H), 8.61 (d,  $J = 2.0$  Hz, 1H), 8.41 (d,  $J = 8.4$  Hz, 1H), 8.24 (dd,  $J$   
39 = 8.7, 2.0 Hz, 1H), 8.03 (d,  $J = 8.7$  Hz, 1H), 7.87 (d,  $J = 2.2$  Hz, 1H), 7.75 (d,  $J = 2.3$  Hz, 1H),  
40 7.72 (dd,  $J = 8.5, 2.3$  Hz, 1H), 7.59 (dd,  $J = 8.3, 2.2$  Hz, 1H), 7.53 (d,  $J = 8.4$  Hz, 1H), 7.24 (d,  $J$   
41 = 8.6 Hz, 1H), 6.84 (d,  $J = 8.5$  Hz, 1H), 4.23 – 4.17 (m, 2H), 2.82 (t,  $J = 6.4$  Hz, 2H), 2.71 (s,  
42 3H), 2.24 (s, 3H), 2.00 – 1.91 (m, 2H).  $^{13}\text{C}$  NMR (126 MHz,  $\text{DMSO-}d_6$ )  $\delta$  164.98, 164.86,  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 160.75, 157.36, 148.47, 137.46, 137.16, 136.25, 131.51, 130.12, 129.78, 128.63, 128.36, 128.17,  
4  
5 127.91, 127.00, 126.26, 125.40, 122.98, 122.03, 118.54, 118.11, 116.07, 66.36, 25.05, 24.26,  
6  
7 21.54, 17.47. HRMS (ESI<sup>+</sup>): calcd for C<sub>28</sub>H<sub>26</sub>N<sub>3</sub>O (M + H)<sup>+</sup>, 452.19687; found 452.19758.  
8  
9

10 *N*-(5-(Isochroman-7-carboxamido)-2-methylphenyl)-2-methylquinoline-6-carboxamide **10**.

11  
12 7-Bromoisochroman (152 mg, 0.71 mmol), Herrmann's palladacycle (33.4 mg, 0.04 mmol)  
13 and tri-*tert*-butylphosphonium tetrafluoroborate (41 mg, 0.14 mmol) were combined with 2-  
14 (trimethylsilyl)ethanol (7.0 mL) in a microwave vial. Molybdenum hexacarbonyl (377 mg, 1.427  
15 mmol) was then added, followed by DBU (1.0M in THF, 2.57 mL, 2.57 mmol) and the vial  
16 promptly sealed. The reaction mixture was heated to 130 °C for 1 h in a microwave. After this  
17 time further 2-(trimethylsilyl)ethanol (3.0 mL) was added and the reaction heated to 130 °C for 1  
18 h under microwave irradiation. The reaction mixture was concentrated under high vacuum. The  
19 resulting residue was purified by column chromatography (Biotage, gradient of 0-100 % ethyl  
20 acetate in cyclohexane) to afford 2-(trimethylsilyl)ethyl isochroman-7-carboxylate compound as  
21 a yellow oil (108 mg, 54 %). This oil was only 80 % pure but was used directly in the next step.<sup>75</sup>  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

36 To a stirring solution of 2-(trimethylsilyl)ethyl isochroman-7-carboxylate (105 mg, 0.302  
37 mmol) in THF (3 mL) at room temperature under argon was dropwise added TBAF 1.0 M in  
38 THF (0.45 mL, 0.45 mmol). The reaction was allowed to stir at room temperature for 2 h. The  
39 reaction mixture was then diluted with water (25 mL) and the THF removed *in vacuo*. The  
40 aqueous layer was washed with dichloromethane (15 mL). TLC/LCMS showed that there was  
41 product in both the aqueous and organic layers. Therefore the organic layer was extracted with a  
42 portion of 1M NaOH (15 mL), followed by water (15 mL). The combined aqueous layers were  
43 acidified (to ~pH 2) using 1M HCl (aq.) and extracted with dichloromethane (3 x 15 mL). The  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 combined organic layer was concentrated *in vacuo* to afford isochroman-7-carboxylic acid as a  
4 colorless amorphous solid. This material was used in the next step without further purification.  
5  
6

7  
8 2-Methyl-6-quinolinecarboxylic acid **3** (89 mg, 0.28 mmol), HATU (130 mg, 0.34 mmol) and  
9  
10 *N*-(3-amino-4-methylphenyl)-2,3-dihydrobenzo[*b*][1,4]dioxine-6-carboxamide **5** (54 mg, 0.30  
11 mmol) in *N,N*-diisopropylethylamine (0.14 mL, 0.82 mmol) and anhydrous DMF (2.5 mL) were  
12 reacted according to method B. The crude product was purified by column chromatography  
13 (Biotage, gradient of 0-5 % methanol in dichloromethane) to afford a pale yellow amorphous  
14 solid (78 mg, 63 %). IR (thin film):  $\nu_{\max}$  2965, 1650, 1600, 1528, 1499, 1285  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (500  
15 MHz, DMSO-*d*<sub>6</sub>)  $\delta$  10.19 (s, 1H), 10.14 (s, 1H), 8.61 (d, *J* = 2.0 Hz, 1H), 8.41 (d, *J* = 8.4 Hz,  
16 1H), 8.24 (dd, *J* = 8.8, 2.0 Hz, 1H), 8.03 (d, *J* = 8.8 Hz, 1H), 7.88 (d, *J* = 2.1 Hz, 1H), 7.78 (dd,  
17 *J* = 8.0, 1.8 Hz, 1H), 7.67 – 7.65 (m, 1H), 7.60 (dd, *J* = 8.3, 2.2 Hz, 1H), 7.53 (d, *J* = 8.4 Hz,  
18 1H), 7.29 (d, *J* = 8.0 Hz, 1H), 7.26 (d, *J* = 8.6 Hz, 1H), 4.76 (s, 2H), 3.91 (t, *J* = 5.7 Hz, 2H),  
19 2.86 (t, *J* = 5.7 Hz, 2H), 2.71 (s, 3H), 2.25 (s, 3H).  $^{13}\text{C}$  NMR (126 MHz, DMSO-*d*<sub>6</sub>)  $\delta$  165.58,  
20 165.46, 161.22, 148.91, 137.70, 137.66, 137.49, 136.76, 135.49, 132.87, 131.96, 130.65, 129.34,  
21 129.26, 128.80, 128.65, 128.40, 125.96, 125.86, 124.37, 123.46, 119.05, 118.63, 67.49, 64.82,  
22 28.24, 25.50, 17.95. HRMS (ESI<sup>+</sup>): calcd for C<sub>28</sub>H<sub>26</sub>N<sub>3</sub>O<sub>3</sub> (M + H)<sup>+</sup>, 452.1969; found 452.1964.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

40  
41 *N*-(3-(2,3-Dihydrobenzo[*b*][1,4]dioxine-6-carboxamido)-2,6-dimethylphenyl)-2-  
42 methylquinoline-6-carboxamide **11**.  
43  
44

45  
46 2,6-Dimethylaniline (4.07 mL, 32.7 mmol) and sulfuric acid (30 mL) were added to a round  
47 bottom flask. The solution was cooled on an ice bath and nitric acid (2.6 mL, 43.1 mmol, 69 %)  
48 was added dropwise to the stirred solution. The resulting reaction mixture was warmed to room  
49 temperature and stirred for further 30 min at room temperature. The reaction mixture was then  
50 poured onto cold water and neutralized by addition of amorphous solid sodium hydroxide. 2,6-  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 dimethyl-3-nitroaniline was isolated by filtration and washed with copious amounts of water.  
4  
5 The crude product was purified by column chromatography (Biotage, gradient of 0- 40 % ethyl  
6 acetate in cyclohexane) to afford the product as a brown amorphous solid (1.82 g, 33 %). IR  
7  
8 (solid):  $\nu_{\max}$  3421, 3349, 2919, 1634, 1513, 1460, 1348  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$   
9  
10 6.99 (d,  $J = 8.1$  Hz, 1H), 6.93 (d,  $J = 8.1$  Hz, 1H), 5.21 (s, 2H), 2.15 (s, 3H), 2.14 (s, 3H).  $^{13}\text{C}$   
11  
12 NMR (126 MHz, DMSO- $d_6$ )  $\delta$  150.03, 146.44, 127.90, 126.09, 113.71, 111.03, 18.71, 13.41.  
13  
14 HRMS (ESI $^+$ ): calcd for  $\text{C}_8\text{H}_{11}\text{N}_2\text{O}_2$  (M + H) $^+$ , 167.0815; found 167.0831.  
15  
16  
17  
18  
19

20 2-Methylquinoline-6-carboxylic acid **3** (1.27 g, 6.77 mmol), oxalyl chloride (750  $\mu\text{L}$ , 8.40  
21 mmol) and DMF (110  $\mu\text{L}$ , 1.42 mmol) in anhydrous dichloromethane (15 mL) were reacted  
22 according to method A. The resulting acid chloride and 2,6-dimethyl-3-nitroaniline (1.5 g, 3.01  
23 mmol) were then reacted in anhydrous pyridine (20 mL). The reaction mixture was concentrated  
24 *in vacuo*. The remaining residue was re-dissolved in dichloromethane and washed with sat.  
25  $\text{NaHCO}_3$  (aq.), water, and brine. The organic layer was dried over sodium sulfate and reduced *in*  
26 *vacuo* until dryness to afford *N*-(2,6-dimethyl-3-nitrophenyl)-2-methylquinoline-6-carboxamide  
27 as a dark red to brown amorphous solid (1.69 g). The crude product was used in the next  
28 synthetic step without further purification.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 *N*-(2,6-Dimethyl-3-nitrophenyl)-2-methylquinoline-6-carboxamide (1.50 g, 4.47 mmol), iron  
42 powder (2.50 g, 44.7 mmol), and ammonium chloride (762 mg, 44.7 mmol) in ethanol (40 mL)  
43 and water (10 mL) were reacted according to method C. The crude product was purified by  
44 column chromatography (Biotage, gradient 0-30 % ethanol in dichloromethane) to afford the  
45 product as a brown amorphous solid (1.14 g, 84 %). IR (solid):  $\nu_{\max}$  3232, 2916, 1649, 1621,  
46 1487, 1281  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  9.84 (s, 1H), 8.60 (d,  $J = 1.9$  Hz, 1H), 8.39  
47  
48 (d,  $J = 8.4$  Hz, 1H), 8.25 (dd,  $J = 8.8, 2.0$  Hz, 1H), 8.01 (d,  $J = 8.7$  Hz, 1H), 7.51 (d,  $J = 8.4$  Hz,  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 1H), 6.82 (d,  $J = 8.1$  Hz, 1H), 6.56 (d,  $J = 8.1$  Hz, 1H), 4.72 (s, 2H), 2.70 (s, 3H), 2.07 (s, 3H),  
4  
5 1.95 (s, 3H).  $^{13}\text{C}$  NMR (126 MHz,  $\text{DMSO-}d_6$ )  $\delta$  165.08, 161.05, 148.86, 145.57, 137.57, 135.64,  
6  
7 132.08, 128.77, 128.40, 128.27, 127.51, 125.89, 123.38, 123.09, 120.01, 113.46, 25.49, 18.15,  
8  
9 12.84. HRMS (ESI<sup>+</sup>): calcd for  $\text{C}_{19}\text{H}_{20}\text{N}_3\text{O}$  (M + H)<sup>+</sup>, 306.1606; found 306.1597.

10  
11  
12 2,3-Dihydrobenzo[*b*][1,4]dioxine-6-carboxylic acid (415 mg, 2.30 mmol), oxalyl chloride (350  
13  
14  $\mu\text{L}$ , 3.92 mmol) and DMF (50  $\mu\text{L}$ , 646 mmol) in anhydrous dichloromethane (10 mL) were  
15  
16 reacted according to method A. *N*-(3-Amino-2,6-dimethylphenyl)-2-methylquinoline-6-  
17  
18 carboxamide (703 mg, 2.30 mmol) and the acid chloride were then reacted in anhydrous  
19  
20 pyridine. The reaction mixture was diluted with diethyl ether. The product precipitated from the  
21  
22 solution, was isolated by filtration and washed with water and diethyl ether. The crude product  
23  
24 was purified by column chromatography (Biotage, gradient of 0-10 % ethanol in  
25  
26 dichloromethane) to afford compound **11** as a beige amorphous solid (237.4 mg, 22 %). IR (thin  
27  
28 film):  $\nu_{\text{max}}$  1649, 1584, 1487, 1290, 1067  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (500 MHz,  $\text{DMSO-}d_6$ )  $\delta$  10.08 (s, 1H),  
29  
30 9.80 (s, 1H), 8.63 (s, 1H), 8.41 (d,  $J = 8.4$  Hz, 1H), 8.27 (d,  $J = 10.8$  Hz, 1H), 8.04 (d,  $J = 8.8$   
31  
32 Hz, 1H), 7.55 (d,  $J = 2.0$  Hz, 1H), 7.54 – 7.53 (m, 1H), 7.53 – 7.50 (m, 1H), 7.18 (m, 2H), 6.98  
33  
34 (d,  $J = 8.4$  Hz, 1H), 4.32 – 4.29 (m, 4H), 2.71 (s, 3H), 2.24 (s, 3H), 2.10 (s, 3H).  $^{13}\text{C}$  NMR (126  
35  
36 MHz,  $\text{DMSO-}d_6$ )  $\delta$  165.22, 164.92, 161.17, 148.93, 146.73, 143.41, 137.60, 136.13, 135.30,  
37  
38 133.96, 132.95, 131.78, 128.86, 128.55, 128.27, 127.84, 127.38, 126.24, 125.90, 123.44, 121.61,  
39  
40 117.31, 117.12, 64.85, 64.47, 25.51, 18.59, 13.94. HRMS (ESI<sup>+</sup>): calcd for  $\text{C}_{28}\text{H}_{26}\text{N}_3\text{O}_4$  (M +  
41  
42 H)<sup>+</sup>, 468.1923; found 428.1932.

43  
44  
45  
46  
47  
48  
49  
50  
51  
52 *N*-(5-(2,3-Dihydrobenzo[*b*][1,4]dioxine-6-carboxamido)-2,4-dimethylphenyl)-2-  
53  
54 methylquinoline-6-carboxamide **12**.

1  
2  
3 2,3-Dihydrobenzo[*b*][1,4]dioxine-6-carboxylic acid (542 mg, 3.01 mmol), oxalyl chloride (325  
4 μL, 4.71 mmol) and DMF (50 μL, 0.646 mmol) in anhydrous dichloromethane (10 mL) were  
5  
6 reacted according to method A. 2,4-Dimethyl-5-nitroaniline (500 mg, 3.01 mmol) and the acid  
7  
8 chloride were then reacted in anhydrous pyridine (15 mL). The reaction mixture was  
9  
10 concentrated *in vacuo*. The remaining residue was triturated with diethyl ether and dried *in vacuo*  
11  
12 to give *N*-(2,4-dimethyl-5-nitrophenyl)-2,3-dihydrobenzo[*b*][1,4]dioxine-6-carboxamide as a  
13  
14 brown amorphous solid (1.11 g), which was used in the next synthetic step without further  
15  
16 purification.  
17  
18  
19  
20  
21

22 *N*-(2,4-Dimethyl-5-nitrophenyl)-2,3-dihydrobenzo[*b*][1,4]dioxine-6-carboxamide (988 mg,  
23 2.08 mmol), ammonium chloride (394 mg, 23.1 mmol) and iron powder (1.29 g, 23.1 mmol) in  
24 ethanol (10 mL) and water (2.5 mL) were reacted according to method C to afford *N*-(5-amino-  
25 2,4-dimethylphenyl)-2,3-dihydrobenz[*b*][1,4]dioxine-6-carboxamide as a brown amorphous solid  
26  
27 (353 mg, 57 % over two steps). IR (solid):  $\nu_{\max}$  3352, 3265, 2918, 1634, 1613, 1489, 1288  $\text{cm}^{-1}$ .  
28  
29  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  9.43 (s, 1H), 7.49 (d,  $J = 2.0$  Hz, 1H), 7.47 (dd,  $J = 8.3, 2.1$   
30 Hz, 1H), 6.95 (d,  $J = 8.3$  Hz, 1H), 6.77 (s, 1H), 6.58 (s, 1H), 4.65 (s, 2H), 4.40 – 4.10 (m, 4H),  
31 2.02 (s, 3H), 2.00 (s, 3H).  $^{13}\text{C}$  NMR (126 MHz, DMSO- $d_6$ )  $\delta$  164.53, 146.53, 144.85, 143.36,  
32 134.81, 131.82, 128.22, 121.45, 121.11, 119.64, 117.23, 117.00, 113.13, 64.81, 64.46, 17.41,  
33 17.29. HRMS (ESI $^+$ ): calcd for  $\text{C}_{17}\text{H}_{19}\text{N}_2\text{O}_3$  ( $\text{M} + \text{H}$ ) $^+$ , 299.1396; found 299.1555.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

46 2-Methylquinoline-6-carboxylic acid **3** (188 mg, 1.00 mmol), oxalyl chloride (80 μL, 0.896  
47 mmol) and DMF (20 μL, 0.258 mmol) in anhydrous dichloromethane (5 mL) were reacted  
48 according to method A. The resulting acid chloride and *N*-(5-amino-2,4-dimethylphenyl)-2,3-  
49 dihydrobenz[*b*][1,4]dioxine-6-carboxamide (201 mg, 0.674 mmol) were then reacted in  
50  
51 anhydrous pyridine (10 mL). The reaction mixture was then diluted with dichloromethane and  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 washed with sat. NaHCO<sub>3</sub> (aq.), water and brine. The organic layer was dried over sodium  
4 sulfate and reduced *in vacuo* until dryness. The crude product was purified by column  
5 chromatography (Biotage, gradient of 0-5 % ethanol in dichloromethane). The product was  
6 further purified by semi-preparative HPLC, according to the method specified in the general  
7 procedures, to afford a beige amorphous solid (30.4 mg, 9.7 %). IR (solid):  $\nu_{\max}$  1664, 1620,  
8 1531, 1497, 1291 cm<sup>-1</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>)  $\delta$  10.09 (s, 1H), 9.71 (s, 1H), 8.59 (s,  
9 1H), 8.40 (d, *J* = 8.4 Hz, 1H), 8.29 – 8.16 (m, 1H), 8.02 (d, *J* = 8.8 Hz, 1H), 7.64 – 7.43 (m, 3H),  
10 7.35 (s, 1H), 7.17 (s, 1H), 6.98 (d, *J* = 8.3 Hz, 1H), 4.39 – 4.15 (m, 4H), 2.70 (s, 3H), 2.25 (s,  
11 3H), 2.20 (s, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-*d*<sub>6</sub>)  $\delta$  165.48, 164.83, 161.18, 148.91, 146.74,  
12 143.41, 137.60, 134.65, 134.46, 132.25, 132.01, 131.85, 131.63, 128.77, 128.61, 128.40, 127.87,  
13 125.84, 125.00, 123.43, 121.60, 117.31, 117.11, 64.84, 64.48, 25.50, 17.97, 17.89. HRMS  
14 (ESI<sup>+</sup>): calcd for C<sub>28</sub>H<sub>26</sub>N<sub>3</sub>O<sub>4</sub> (M + H)<sup>+</sup>, 468.1923; found 468.1914.

15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32 2-Methyl-*N*-(2-methyl-5-(*N*-methyl-2,3-dihydrobenzo[*b*][1,4]dioxine-6-  
33 carboxamido)phenyl)quinolone-6-carboxamide **13**.

34  
35  
36  
37 4-Methyl-3-nitroaniline **2** (5.15 g, 33.8 mmol) was dissolved in DMF (20 mL) and  
38 iodomethane (1.8 mL, 28.9 mmol) was added. Then, sat. NaHCO<sub>3</sub> (aq.) (20 mL, 28.2 mmol) was  
39 added portionwise to the stirred reaction mixture. The resulting reaction mixture was stirred at  
40 room temperature overnight. The reaction mixture was partitioned between dichloromethane and  
41 water. The aqueous layer was extracted with dichloromethane. The combined organic layers  
42 were then washed with water and brine. The crude product was purified by column  
43 chromatography (Biotage, gradient of 0-20 % ethyl acetate in cyclohexane) to afford *N*,4-  
44 dimethyl-3-nitroaniline as a red amorphous solid (1.55 g, 33 % yield). IR (thin film):  $\nu_{\max}$  3401,  
45 2926, 1690, 1526, 1493, 1321, 1286 cm<sup>-1</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  7.18 (d, *J* = 2.6 Hz,  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 1H), 7.10 (d,  $J = 8.3$  Hz, 1H), 6.75 (dd,  $J = 8.3, 2.6$  Hz, 1H), 3.91 (s, 1H), 2.87 (s, 3H), 2.47 (s,  
4 3H).  $^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ )  $\delta$  149.77, 148.06, 133.16, 121.34, 117.63, 106.97, 30.65,  
5  
6 19.53. HRMS ( $\text{ESI}^+$ ): calcd for  $\text{C}_8\text{H}_{11}\text{N}_2\text{O}_2$  ( $\text{M} + \text{H}$ ) $^+$ , 167.0820; found 167.0825.  
7  
8

9  
10 2,3-Dihydrobenzo[*b*][1,4]dioxine-6-carboxylic acid (1.63 g, 9.03 mmol), oxalyl chloride (970  
11  $\mu\text{L}$ , 10.86 mmol) and DMF (140  $\mu\text{L}$ , 1.81 mmol) in anhydrous dichloromethane (15 mL) were  
12 reacted according to method A. The resulting acid chloride and *N*-4-Dimethyl-3-nitroaniline (1.5  
13 g, 9.03 mmol) were then reacted in anhydrous dichloromethane (15 mL) and pyridine (3.0 mL,  
14 34.0 mmol). The reaction mixture was diluted with dichloromethane and washed with sat.  $\text{NH}_4\text{Cl}$   
15 (aq.). The aqueous layer was extracted with dichloromethane. The combined organic layers were  
16 washed with sat.  $\text{NH}_4\text{Cl}$  (aq.), water, and brine. The organic layer was dried over sodium sulfate  
17 and reduced in vacuum until dryness to give *N*-Methyl-*N*-(4-methyl-3-nitrophenyl)-2,3-  
18 dihydrobenz[*b*][1,4]dioxine-6-carboxamide (2.51 g), which was used in the next synthetic step  
19 without further purification.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

33  
34 *N*-Methyl-*N*-(4-methyl-3-nitrophenyl)-2,3-dihydrobenz[*b*][1,4]dioxine-6-carboxamide (2.50 g,  
35 7.61 mmol), iron powder (4.56 g, 82.0 mmol) and ammonium chloride (1.36 g, 80 mmol) in  
36 ethanol (20 mL) and water (5 mL) were reacted according to method C. The crude product was  
37 re-suspended in water. The product was isolated by filtration and washed with water and diethyl  
38 ether. The product was isolated as a beige amorphous solid (1.18 g, 52 %). IR (solid):  $\nu_{\text{max}}$  3447,  
39 3354, 2934, 1600, 1579, 1509, 1426, 1282  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (500 MHz,  $\text{DMSO}-d_6$ )  $\delta$  6.85 – 6.82  
40 (m, 1H), 6.80 (d,  $J = 7.8$  Hz, 1H), 6.78 – 6.72 (m, 1H), 6.66 (d,  $J = 8.4$  Hz, 1H), 6.40 – 6.32 (m,  
41 1H), 6.23 – 6.13 (m, 1H), 4.92 (s, 2H), 4.18 (d,  $J = 8.0$  Hz, 4H), 3.23 (s, 3H), 1.97 (s, 3H).  $^{13}\text{C}$   
42 NMR (126 MHz,  $\text{DMSO}-d_6$ )  $\delta$  168.76, 147.70, 144.89, 144.04, 142.72, 130.83, 129.67, 122.40,  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 119.85, 118.09, 116.54, 114.85, 112.22, 64.58, 64.32, 38.98, 17.45. HRMS (ESI<sup>+</sup>): calcd for  
4 C<sub>17</sub>H<sub>19</sub>N<sub>2</sub>O<sub>3</sub> (M + H)<sup>+</sup>, 300.1474; found 299.1401.  
5  
6

7  
8 2-Methylquinoline-6-carboxylic acid **3** (345 mg, 1.84 mmol), oxalyl chloride (180 μL, 2.06  
9 mmol) and DMF (300 μL, 3.87 mmol) in anhydrous dichloromethane (10 mL) were reacted  
10 according to method A. The resulting acid chloride and *N*-(3-amino-4-methylphenyl)-*N*-methyl-  
11 2,3-dihydrobenzo[*b*][1,4]dioxine-6-carboxamide (500 mg, 1.68 mmol) were then reacted in  
12 anhydrous dichloromethane (13 mL) and pyridine (1.2 mL, 14.89 mmol). The reaction mixture  
13 was diluted with water. The product was isolated by filtration and washed with water and diethyl  
14 ether. The crude product was then purified with a cation exchange sorbent (Isolute SCX-II,  
15 washing first with methanol, and then with 10 % 2 M ammonia in methanol). The product was  
16 further purified by semi-preparative HPLC according to the method specified in the general  
17 procedures to afford a yellow amorphous solid (22.4 mg, 2.9 %). IR (solid):  $\nu_{\max}$  2927, 1624,  
18 1493, 1282 cm<sup>-1</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>)  $\delta$  10.09 (s, 1H), 8.59 (d, *J* = 1.8 Hz, 1H), 8.39  
19 (d, *J* = 8.4 Hz, 1H), 8.21 (dd, *J* = 8.8, 1.9 Hz, 1H), 8.02 (d, *J* = 8.8 Hz, 1H), 7.52 (d, *J* = 8.4 Hz,  
20 1H), 7.36 (d, *J* = 2.2 Hz, 1H), 7.18 (d, *J* = 8.2 Hz, 1H), 6.90 (dd, *J* = 8.1, 2.2 Hz, 1H), 6.87 (d, *J*  
21 = 2.0 Hz, 1H), 6.76 (d, *J* = 2.0 Hz, 1H), 6.68 (d, *J* = 8.4 Hz, 1H), 4.27 – 4.14 (m, 4H), 3.17 (s,  
22 3H), 2.70 (s, 3H), 2.23 (s, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-*d*<sub>6</sub>)  $\delta$  169.06, 161.29, 148.95,  
23 144.99, 143.28, 142.94, 137.62, 137.39, 131.93, 131.75, 131.25, 129.44, 128.80, 128.75, 128.39,  
24 125.81, 125.05, 124.52, 123.47, 122.42, 118.16, 116.71, 64.60, 64.33, 49.06, 38.94, 25.51, 18.04.  
25  
26 HRMS (ESI<sup>+</sup>): calcd for C<sub>28</sub>H<sub>26</sub>N<sub>3</sub>O<sub>4</sub> (M + H)<sup>+</sup>, 468.1923; found 468.1919.  
27  
28

29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51 *N*-(5-(2,3-Dihydrobenzo[*b*][1,4]dioxine-6-sulfonamido)-2-methylphenyl)-2-methylquinoline-  
52 6-carboxamide **14**  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 2-Methylquinoline-6-carboxylic acid (3.69 g, 19.72 mmol), oxalyl chloride (1.8 mL, 20.15  
4 mmol) and DMF (310  $\mu$ L, 4.00 mmol) were reacted in anhydrous dichloromethane (35 mL)  
5  
6 according to method A. The resulting acid chloride was reacted with 2-methyl-5-nitroaniline (3.0  
7  
8 g, 19.72 mmol) in anhydrous pyridine (35 mL). The reaction mixture was reduced *in vacuo* until  
9  
10 dryness. The remaining residue was triturated with diethyl ether and dried *in vacuo*. The crude  
11  
12 product was purified by column chromatography (Biotage, gradient of 0-50 % ethanol in  
13  
14 dichloromethane) to afford the product as a yellow amorphous solid (5.57 g, 88 %). IR (thin  
15  
16 film):  $\nu_{\max}$  1661, 1527, 1342, 1260  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (500 MHz,  $\text{DMSO-}d_6$ )  $\delta$  10.36 (s, 1H), 8.63  
17  
18 (d,  $J = 1.8$  Hz, 1H), 8.43 (d,  $J = 8.4$  Hz, 1H), 8.40 (d,  $J = 2.4$  Hz, 1H), 8.25 (dd,  $J = 8.7, 2.0$  Hz,  
19  
20 1H), 8.07 (d,  $J = 2.9$  Hz, 1H), 8.05 (d,  $J = 3.0$  Hz, 1H), 7.60 (d,  $J = 8.5$  Hz, 1H), 7.54 (d,  $J = 8.4$   
21  
22 Hz, 1H), 2.71 (s, 3H), 2.44 (s, 3H).  $^{13}\text{C}$  NMR (126 MHz,  $\text{DMSO-}d_6$ )  $\delta$  165.54, 161.05, 146.20,  
23  
24 144.90, 143.38, 142.15, 137.76, 132.04, 130.08, 129.93, 129.31, 126.62, 126.09, 124.16, 121.00,  
25  
26 120.94, 23.98, 18.82. HRMS ( $\text{ESI}^+$ ): calcd for  $\text{C}_{18}\text{H}_{15}\text{NaN}_3\text{O}_3$  ( $\text{M} + \text{Na}$ ) $^+$ , 344.1006; found  
27  
28 344.0999.  
29  
30  
31  
32  
33  
34  
35

36 2-Methyl-*N*-(2-methyl-5-nitrophenyl)quinoline-6-carboxamide (4.0 g, 12.45 mmol), iron  
37  
38 powder (6.95 g, 124.0 mmol), and ammonium chloride (2.12 g, 124.0 mmol) in ethanol (50 mL)  
39  
40 and water (12.5 mL) were reacted according to method C to afford *N*-(5-amino-2-methylphenyl)-  
41  
42 2-methylquinoline-6-carboxamide as a light yellow amorphous solid (1.95 g, 48 % over two  
43  
44 steps). IR (thin film):  $\nu_{\max}$  3340, 3252, 1645, 1582, 1487, 1278  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (500 MHz,  
45  
46  $\text{DMSO-}d_6$ )  $\delta$  9.86 (s, 1H), 8.61 – 8.51 (m, 1H), 8.38 (d,  $J = 8.4$  Hz, 1H), 8.21 (dd,  $J = 8.8, 1.7$   
47  
48 Hz, 1H), 8.00 (d,  $J = 8.8$  Hz, 1H), 7.51 (d,  $J = 8.4$  Hz, 1H), 6.91 (d,  $J = 8.1$  Hz, 1H), 6.65 (d,  $J =$   
49  
50 2.0 Hz, 1H), 6.42 (dd,  $J = 8.1, 2.2$  Hz, 1H), 4.94 (s, 2H), 2.70 (s, 3H), 2.09 (s, 3H).  $^{13}\text{C}$  NMR  
51  
52 (126 MHz,  $\text{DMSO-}d_6$ )  $\delta$  165.18, 161.09, 148.86, 147.31, 137.58, 137.01, 132.25, 130.87, 128.72,  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 128.49, 128.38, 125.84, 123.38, 120.72, 112.75, 112.61, 25.49, 17.50. HRMS (ESI<sup>+</sup>): calcd for  
4 C<sub>18</sub>H<sub>18</sub>N<sub>3</sub>O (M + H)<sup>+</sup>, 292.1444; found 292.1446.  
5  
6

7  
8 *N*-(5-Amino-2-methylphenyl)-2-methylquinoline-6-carboxamide (500 mg, 1.60 mmol) and  
9  
10 2,3-dihydrobenzo[*b*][1,4]dioxine-6-sulfonyl chloride (591 mg, 2.39 mmol) and anhydrous  
11  
12 pyridine (7 mL) were added to a round bottom flask. The resulting reaction mixture was stirred  
13  
14 at room temperature under argon overnight. The reaction mixture was diluted with diethyl ether.  
15  
16 The product was isolated by filtration and washed with water and diethyl ether. The crude  
17  
18 product was purified by column chromatography (Biotage, gradient of 0-10 % ethanol in  
19  
20 dichloromethane) to afford the product as a beige amorphous solid (90.7 mg, 12 %). IR (thin  
21  
22 film):  $\nu_{\max}$  1651, 1529, 1494, 1328, 1285, 1254, 1153 cm<sup>-1</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>)  $\delta$   
23  
24 10.14 (s, 1H), 10.06 (s, 1H), 8.57 (d, *J* = 1.9 Hz, 1H), 8.40 (d, *J* = 8.4 Hz, 1H), 8.20 (dd, *J* = 8.8,  
25  
26 2.0 Hz, 1H), 8.01 (d, *J* = 8.8 Hz, 1H), 7.52 (d, *J* = 8.4 Hz, 1H), 7.30 – 7.23 (m, 2H), 7.22 (d, *J* =  
27  
28 2.2 Hz, 1H), 7.14 (d, *J* = 8.4 Hz, 1H), 6.99 (d, *J* = 8.4 Hz, 1H), 6.94 (dd, *J* = 8.2, 2.2 Hz, 1H),  
29  
30 4.53 – 3.98 (m, 4H), 2.70 (s, 3H), 2.16 (s, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-*d*<sub>6</sub>)  $\delta$  165.30,  
31  
32 161.25, 147.61, 143.69, 137.73, 137.72, 137.30, 136.26, 132.43, 131.78, 131.30, 129.59, 128.75,  
33  
34 128.72, 128.41, 125.83, 123.47, 120.81, 118.35, 118.00, 117.84, 116.11, 64.80, 64.48, 25.46,  
35  
36 17.83. HRMS (ESI<sup>+</sup>): calcd for C<sub>26</sub>H<sub>24</sub>N<sub>3</sub>O<sub>5</sub>S (M + H)<sup>+</sup>, 490.1436; found 490.1436.  
37  
38  
39  
40  
41  
42

43  
44 *N*-(5-(2,3-Dihydrobenzo[*b*][1,4]dioxine-6-carboxamido)-2-methylphenyl)quinoline-6-  
45  
46 carboxamide **15**  
47

48  
49 6-Quinolinecarboxylic acid (0.064 g, 0.369 mmol), HATU (0.160 g, 0.422 mmol), and *N*-(3-  
50  
51 amino-4-methylphenyl)-2,3-dihydrobenzo[*b*][1,4]dioxine-6-carboxamide **18** (0.100 g, 0.352  
52  
53 mmol) in *N,N*-Diisopropylethylamine (0.123 mL, 0.703 mmol) and anhydrous DMF (2.5 mL)  
54  
55 were reacted according to method B to afford a white amorphous solid (141 mg, 91 %). IR (thin  
56  
57  
58  
59  
60

1  
2  
3 film):  $\nu_{\max}$  1649, 1599, 1528, 1504, 1318, 1290, 1260, 1066  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (500 MHz, DMSO-  
4  $d_6$ )  $\delta$  10.18 (s, 1H), 10.08 (s, 1H), 9.02 (dd,  $J = 4.2, 1.9$  Hz, 1H), 8.67 (d,  $J = 1.9$  Hz, 1H), 8.55  
5  
6 (dd,  $J = 8.5, 1.9$  Hz, 1H), 8.29 (dd,  $J = 8.8, 2.2$  Hz, 1H), 8.15 (d,  $J = 8.8$  Hz, 1H), 7.88 (d,  $J =$   
7  
8 2.1 Hz, 1H), 7.65 (dd,  $J = 9.6, 2.2$  Hz, 1H), 7.59 (dd,  $J = 8.5, 2.2$  Hz, 1H), 7.54 (d,  $J = 2.2$  Hz,  
9  
10 1H), 7.51 (dd,  $J = 8.5, 2.2$  Hz, 1H), 7.25 (d,  $J = 8.5$  Hz, 1H), 6.99 (d,  $J = 8.5$  Hz, 1H), 4.33 –  
11  
12 4.29 (m, 4H), 2.25 (s, 3H).  $^{13}\text{C}$  NMR (126 MHz, DMSO- $d_6$ )  $\delta$  165.38, 164.83, 152.68, 149.25,  
13  
14 146.82, 143.40, 137.80, 137.67, 136.67, 132.83, 130.63, 129.61, 129.24, 128.95, 128.47, 128.14,  
15  
16 127.61, 122.73, 121.67, 119.06, 118.68, 117.31, 117.13, 64.86, 64.49, 17.95. HRMS (ESI $^+$ ):  
17  
18 calcd for  $\text{C}_{26}\text{H}_{22}\text{N}_3\text{O}_4$  (M + H) $^+$ , 440.1605; found 440.1768.  
19  
20  
21  
22  
23

24 *N*-(5-(2,3-Dihydrobenzo[*b*][1,4]dioxine-6-carboxamido)-2-methylphenyl)isoquinoline-7-  
25  
26 carboxamide **16**  
27

28  
29 Isoquinoline-7-carboxylic acid (50 mg, 0.290 mmol), HATU (130 mg, 0.343 mmol) and *N*-(3-  
30  
31 amino-4-methylphenyl)-2,3-dihydrobenzo[*b*][1,4]dioxine-6-carboxamide **18** (75 mg, 0.264  
32  
33 mmol) in *N,N*-diisopropylethylamine (0.101 mL, 0.580 mmol) and anhydrous DMF (1.8 mL)  
34  
35 were reacted according to method B. The crude product was purified by trituration and brief  
36  
37 sonication in ethyl acetate, then isolated by filtration and washed with ethyl acetate to afford the  
38  
39 product as a white amorphous solid (52 mg, 45 %). IR (thin film):  $\nu_{\max}$  1641, 1599, 1531, 1504,  
40  
41 1319, 1295, 1243, 1065  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  10.23 (s, 1H), 10.08 (s, 1H),  
42  
43 9.48 (s, 1H), 8.81 (s, 1H), 8.62 (d,  $J = 5.7$  Hz, 1H), 8.30 (dd,  $J = 8.6, 1.7$  Hz, 1H), 8.12 (d,  $J =$   
44  
45 8.6 Hz, 1H), 7.94 (d,  $J = 5.7$  Hz, 1H), 7.89 (d,  $J = 2.1$  Hz, 1H), 7.59 (dd,  $J = 8.3, 2.2$  Hz, 1H),  
46  
47 7.54 (d,  $J = 2.1$  Hz, 1H), 7.51 (dd,  $J = 8.4, 2.2$  Hz, 1H), 7.25 (d,  $J = 8.6$  Hz, 1H), 6.98 (d,  $J = 8.4$   
48  
49 Hz, 1H), 4.32 – 4.29 (m, 4H), 2.25 (s, 3H).  $^{13}\text{C}$  NMR (126 MHz, DMSO- $d_6$ )  $\delta$  165.08, 164.82,  
50  
51 153.21, 146.81, 143.39, 143.20, 137.80, 137.37, 136.53, 134.19, 130.65, 130.19, 129.23, 128.72,  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 128.11, 127.81, 127.48, 121.65, 121.41, 119.02, 118.74, 117.30, 117.12, 64.85, 64.48, 17.93.

4  
5 HRMS (ESI<sup>+</sup>): calcd for C<sub>26</sub>H<sub>22</sub>N<sub>3</sub>O<sub>4</sub> (M + H)<sup>+</sup>, 440.1605; found 440.1604.

6  
7  
8 *N*-(5-(2,3-Dihydrobenzo[*b*][1,4]dioxine-6-carboxamido)-2-methylphenyl)-1,2,3,4-  
9  
10 tetrahydroquinoline-6-carboxamide **17**

11  
12 A suspension of *N*-(5-(2,3-dihydrobenzo[*b*][1,4]dioxine-6-carboxamido)-2-  
13  
14 methylphenyl)quinoline-6-carboxamide **15** (0.097 g, 0.22 mmol) and Pd/C (10 %, 0.025 g) in  
15  
16 methanol (8 mL), ethyl acetate (6 mL) and 10 drops glacial acetic acid was stirred under 1 atm  
17  
18 hydrogen at 40°C overnight, filtered through Celite<sup>®</sup> with ethyl acetate, and concentrated. The  
19  
20 residue was purified by flash column chromatography using a gradient of 10 to 22 % ethyl  
21  
22 acetate in dichloromethane to afford the title compound (72 mg, 74 %) as a white amorphous  
23  
24 solid. IR (solid):  $\nu_{\max}$  2924, 1634, 1604, 1579, 1504, 1291, 1248, 1065, 888 cm<sup>-1</sup>. <sup>1</sup>H NMR (500  
25  
26 MHz, DMSO-*d*<sub>6</sub>)  $\delta$  10.02 (s, 1H), 9.35 (s, 1H), 7.77 (d, *J* = 2.2 Hz, 1H), 7.57 – 7.52 (m, 4H),  
27  
28 7.50 (dd, *J* = 8.5, 2.2 Hz, 1H), 7.18 (d, *J* = 8.4 Hz, 1H), 6.98 (d, *J* = 8.4 Hz, 1H), 6.47 (d, *J* = 9.0  
29  
30 Hz, 1H), 6.35 (br s, 1H), 4.34 – 4.27 (m, 4H), 3.27 – 3.20 (m, 2H), 2.72 (t, *J* = 6.2 Hz, 2H), 2.17  
31  
32 (s, 3H), 1.85 – 1.76 (m, 2H). <sup>13</sup>C NMR (126 MHz, DMSO-*d*<sub>6</sub>)  $\delta$  165.65, 164.74, 148.79, 146.76,  
33  
34 143.38, 137.56, 137.50, 130.31, 129.43, 129.00, 128.21, 127.29, 121.64, 120.44, 119.09, 119.06,  
35  
36 117.93, 117.28, 117.11, 112.41, 64.85, 64.48, 41.05, 27.27, 21.50, 17.95. HRMS (ESI<sup>+</sup>): calcd  
37  
38 for C<sub>26</sub>H<sub>26</sub>N<sub>3</sub>O<sub>4</sub> (M + H)<sup>+</sup>, 444.1718; found 444.1812.

39  
40  
41  
42  
43  
44  
45  
46 *N*-(3-Amino-4-methylphenyl)-2,3-dihydrobenzo[*b*][1,4]dioxine-6-carboxamide **18**

47  
48 1,4-Benzodioxane-6-carboxylic acid (2.486 g, 13.80 mmol), oxalyl chloride (1.40 mL, 16.6  
49  
50 mmol) and DMF (0.027 mL, 0.34 mmol) in anhydrous dichloromethane (34 mL) were reacted  
51  
52 according to method A. The resulting acid chloride was dissolved in anhydrous dichloromethane  
53  
54 (12 mL) and added dropwise to a solution of 4-methyl-3-nitroaniline **2** (2.100 g, 13.80 mmol)

1  
2  
3 and pyridine (2.23 mL, 27.6 mmol) in anhydrous dichloromethane (35 mL). The reaction  
4  
5 mixture was stirred at room temperature for two hours, and then concentrated. The resulting  
6  
7 amorphous solid was suspended in methanol, diluted with water and then isolated by filtration  
8  
9 and washed with water to afford *N*-(4-methyl-3-nitrophenyl)-2,3-dihydrobenzo[*b*][1,4]dioxine-6-  
10  
11 carboxamide (4.24 g, 98 %) as a pale tan colored amorphous solid, which was used in the next  
12  
13 step without further purification.  
14  
15

16  
17 Palladium (10 % on activated carbon, 0.567 g) and *N*-(4-methyl-3-nitrophenyl)-2,3-  
18  
19 dihydrobenzo[*b*][1,4]dioxine-6-carboxamide (4.237 g, 13.48 mmol) in ethanol (90 mL) and ethyl  
20  
21 acetate (90 mL) were reacted according to method D to afford the desired product (3.803 g, 99  
22  
23 %) as a pale yellow amorphous solid. IR (thin film):  $\nu_{\max}$  1641, 1611, 1582, 1289, 1064  $\text{cm}^{-1}$ .  $^1\text{H}$   
24  
25 NMR (500 MHz,  $\text{DMSO-}d_6$ )  $\delta$  9.70 (s, 1H), 7.49 (d,  $J = 2.2$  Hz, 1H), 7.46 (dd,  $J = 8.3, 2.2$  Hz,  
26  
27 1H), 7.10 (d,  $J = 2.0$  Hz, 1H), 6.95 (d,  $J = 8.4$  Hz, 1H), 6.83 (d,  $J = 8.1$  Hz, 1H), 6.79 (dd,  $J =$   
28  
29 8.1, 2.0 Hz, 1H), 4.81 (s, 2H), 4.32 – 4.26 (m, 4H), 2.01 (s, 3H).  $^{13}\text{C}$  NMR (126 MHz,  $\text{DMSO-}$   
30  
31  $d_6$ )  $\delta$  164.48, 146.89, 146.54, 143.30, 138.09, 130.04, 128.60, 121.54, 117.18, 117.05, 109.26,  
32  
33 106.88, 64.82, 64.47, 17.46. (1 carbon missing) HRMS (ESI $^+$ ): calcd for  $\text{C}_{16}\text{H}_{17}\text{N}_2\text{O}_3$  ( $\text{M} + \text{H}$ ) $^+$ ,  
34  
35 285.1234; found 285.1233.  
36  
37  
38  
39  
40

#### 41 **Preparation of compounds in Table 2:**

42  
43 *N*-(5-(2,3-Dihydrobenzo[*b*][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(2-  
44  
45 methoxyethoxy)quinoline-6-carboxamide **21**  
46  
47

48 NaH (60 % in mineral oil, 0.198 g, 4.950 mmol) was added to 2-methoxyethanol (4.0 mL, 50.7  
49  
50 mmol) at 0 °C under inert atmosphere. The reaction mixture was stirred at 0 °C for 10 min then  
51  
52 at room temperature for 20 min, before 6-bromo-2-chloroquinoline (0.400 g, 1.649 mmol) was  
53  
54 added. This suspension was then gradually heated to 70 °C, the amorphous solid dissolved as  
55  
56  
57  
58  
59  
60

1  
2  
3 heated and the resulting solution was allowed to stir overnight. The reaction mixture was cooled  
4  
5 to room temperature, diluted with water and the resulting precipitate isolated by filtration. The  
6  
7 precipitate was washed with water and dried to afford 6-bromo-2-(2-methoxyethoxy)quinoline as  
8  
9 a dull pink amorphous solid (0.497 g), which was used in the next step without further  
10  
11 purification.  
12  
13

14  
15 *n*-BuLi (1.84 M in hexanes) (0.578 mL, 1.063 mmol) was added dropwise to a solution of 6-  
16  
17 bromo-2-(2-methoxyethoxy)quinoline (0.250 g, 0.886 mmol) in anhydrous THF (3.0 mL) at -  
18  
19 78°C and the resulting brown-yellow mixture was stirred at -78°C for 35 min. Solid CO<sub>2</sub> was  
20  
21 added and the resulting orange mixture was stirred at -78°C for 5 min, then it was allowed to  
22  
23 warm to room temperature and concentrated under reduced pressure. The residue was dissolved  
24  
25 in brine (5.0 mL) and washed with dichloromethane (1 x 5.0 mL). The aqueous phase was  
26  
27 acidified with 2 M HCl (aq.) to pH 3 and the resulting precipitate was isolated by filtration and  
28  
29 washed with water to afford 2-(2-methoxyethoxy)quinoline-6-carboxylic acid as a pale pink  
30  
31 amorphous solid (0.127 g), which was used in next step without further purification.  
32  
33  
34

35  
36 2-(2-Methoxyethoxy)quinoline-6-carboxylic acid (0.048 g, 0.193 mmol), HATU (0.084 g,  
37  
38 0.220 mmol), and *N*-(3-amino-4-methylphenyl)-2,3-dihydrobenzo[*b*][1,4]dioxine-6-  
39  
40 carboxamide **18** (0.050 g, 0.176 mmol) in *N,N*-diisopropylethylamine (0.068 mL, 0.387 mmol)  
41  
42 and anhydrous DMF (1.25 mL) were reacted according to method B to afford the product **21** as a  
43  
44 white amorphous solid (87 mg, 56 % over 3 steps). IR (thin film):  $\nu_{\max}$  2925, 1642, 1602, 1582,  
45  
46 1526, 1502, 1345, 1286, 1261, 816, 784 cm<sup>-1</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>)  $\delta$  10.07 (app. d, *J*  
47  
48 = 3.0 Hz, 2H), 8.57 (d, *J* = 2.0 Hz, 1H), 8.39 (d, *J* = 8.8 Hz, 1H), 8.22 (dd, *J* = 8.7, 2.0 Hz, 1H),  
49  
50 7.89 – 7.84 (m, 2H), 7.58 (dd, *J* = 8.3, 2.2 Hz, 1H), 7.54 (d, *J* = 2.1 Hz, 1H), 7.51 (dd, *J* = 8.4,  
51  
52 2.2 Hz, 1H), 7.24 (d, *J* = 8.6 Hz, 1H), 7.14 (d, *J* = 8.8 Hz, 1H), 6.98 (d, *J* = 8.4 Hz, 1H), 4.61 –  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 4.55 (m, 2H), 4.32– 4.29 (m, 4H), 3.77 – 3.72 (m, 2H), 3.33 (s, 3H), 2.24 (s, 3H). <sup>13</sup>C NMR (126  
4  
5 MHz, DMSO-*d*<sub>6</sub>) δ 165.39, 164.81, 163.13, 147.93, 146.80, 143.38, 140.80, 137.75, 136.78,  
6  
7 130.57, 129.22, 128.90, 128.58, 128.15, 127.21, 126.76, 124.52, 121.65, 119.07, 118.57, 117.29,  
8  
9 117.12, 114.39, 70.56, 65.40, 64.85, 64.48, 58.58, 17.94. HRMS (ESI<sup>+</sup>): calcd for C<sub>29</sub>H<sub>28</sub>N<sub>3</sub>O<sub>6</sub>  
10  
11 (M + H)<sup>+</sup>, 514.1973; found 514.1969.

12  
13  
14 *N*-(5-(2,3-Dihydrobenzo[*b*][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(3-  
15  
16 (dimethylamino)propoxy)quinoline-6-carboxamide **22**

17  
18  
19  
20 NaH (60 % in mineral oil, 0.109 g, 2.72 mmol), 4-(2-hydroxyethyl)morpholine (0.337 mL,  
21  
22 2.78 mmol), and 6-bromo-2-chloroquinoline (0.3 g, 1.237 mmol) in anhydrous THF (4 mL) were  
23  
24 reacted according to method E. The reaction mixture was heated for 1 h. The crude product was  
25  
26 purified by flash column chromatography (4-6 % methanol in dichloromethane) to afford 3-((6-  
27  
28 bromoquinolin-2-yl)oxy)-*N,N*-dimethylpropan-1-amine as a pale salmon colored oil (0.346 g),  
29  
30 which was used directly in the next step.

31  
32  
33  
34 *n*-BuLi (1.62 M in hexanes, 0.788 mL, 1.277 mmol) and 3-((6-bromoquinolin-2-yl)oxy)-*N,N*-  
35  
36 dimethylpropan-1-amine (0.329 g, 1.064 mmol) in anhydrous THF (3.5 mL) were reacted  
37  
38 according to method F to afford 2-(3-(dimethylamino)propoxy)quinoline-6-carboxylic acid as a  
39  
40 white amorphous solid (0.170 g), which was used in the next step without further purification.

41  
42  
43  
44 2-(3-(Dimethylamino)propoxy)quinoline-6-carboxylic acid (91 mg, 0.220 mmol), HATU (104  
45  
46 mg, 0.275 mmol) and *N*-(3-amino-4-methylphenyl)-2,3-dihydrobenzo[*b*][1,4]dioxine-6-  
47  
48 carboxamide **18** (50 mg, 0.176 mmol) in *N,N*-diisopropylethylamine (0.154 mL, 0.879 mmol)  
49  
50 and anhydrous DMF (1.5 mL) were reacted according to method B. The crude product was  
51  
52 purified by flash column chromatography (3.5-6.6 % 2 M NH<sub>3</sub>-methanol in dichloromethane) to  
53  
54 afford the product **22** as a light tan amorphous solid (0.078 g, 38 % over 3 steps). IR (thin film):  
55  
56  
57  
58  
59  
60

1  
2  
3  $\nu_{\max}$  2945, 1647, 1603, 1583, 1528, 1502, 1286, 1262  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (500 MHz,  $\text{DMSO-}d_6$ )  $\delta$   
4 10.07 (s, 2H), 8.56 (d,  $J = 2.0$  Hz, 1H), 8.37 (d,  $J = 8.8$  Hz, 1H), 8.22 (dd,  $J = 8.7, 2.0$  Hz, 1H),  
5 7.88-7.84 (m, 2H), 7.58 (dd,  $J = 8.3, 2.2$  Hz, 1H), 7.54 (d,  $J = 2.1$  Hz, 1H), 7.51 (dd,  $J = 8.4, 2.2$   
6 Hz, 1H), 7.24 (d,  $J = 8.5$  Hz, 1H), 7.10 (d,  $J = 8.8$  Hz, 1H), 6.98 (d,  $J = 8.4$  Hz, 1H), 4.47 (t,  $J =$   
7 6.7 Hz, 2H), 4.34 – 4.27 (m, 4H), 2.39 (t,  $J = 7.1$  Hz, 2H), 2.24 (s, 3H), 2.17 (s, 6H), 1.93 (p,  $J =$   
8 6.8 Hz, 2H).  $^{13}\text{C}$  NMR (126 MHz,  $\text{DMSO-}d_6$ )  $\delta$  164.94, 164.35, 162.88, 147.63, 146.34, 142.93,  
9 140.17, 137.29, 136.33, 130.10, 130.01, 128.76, 128.39, 128.12, 127.69, 126.73, 123.98, 121.19,  
10 118.62, 118.11, 116.84, 116.66, 113.98, 64.38, 64.02, 55.76, 45.21, 26.55, 17.48. HRMS (ESI<sup>+</sup>):  
11 calcd for  $\text{C}_{31}\text{H}_{33}\text{N}_4\text{O}_5$  ( $\text{M} + \text{H}$ )<sup>+</sup>, 541.2446; found 541.24423.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

24 *N*-(5-(2,3-Dihydrobenzo[*b*][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(3-  
25 morpholinopropoxy)quinoline-6-carboxamide **23**  
26  
27

28 4-(3-Hydroxypropyl)morpholine (0.171 mL, 1.24 mmol), NaH (60 % mineral oil, 0.047 g,  
29 1.19 mmol) and 6-bromo-2-chloroquinoline (0.250 g, 1.03 mmol) in anhydrous THF (3.50 mL)  
30 were reacted according to method E. The reaction mixture was heated for 16 h. Purification  
31 using flash column chromatography (1.5-3.5 % methanol in dichloromethane) gave 4-(3-((6-  
32 bromoquinolin-2-yl)oxy)propyl)morpholine (221 mg) as a white amorphous solid, which was  
33 used directly in the next step.  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 *n*-BuLi (1.56 M in hexanes, 0.460 mL, 0.717 mmol) and 4-(3-((6-bromoquinolin-2-  
44 yl)oxy)propyl)morpholine (0.210 g, 0.598 mmol) in anhydrous THF (2.00 mL) were reacted  
45 according to method F to afford 2-(3-morpholinopropoxy)quinoline-6-carboxylic acid (0.273 g)  
46 as a yellow amorphous solid, which was used in the next step without further purification.  
47  
48  
49  
50  
51  
52

53 2-(3-Morpholinopropoxy)quinoline-6-carboxylic acid hydrochloride (0.076 g, 0.188 mmol),  
54 HATU (0.089 g, 0.234 mmol) and *N*-(3-amino-4-methylphenyl)-2,3-  
55  
56  
57  
58  
59  
60

1  
2  
3 dihydrobenzo[*b*][1,4]dioxine-6-carboxamide **18** (0.040 g, 0.141 mmol) in *N,N*-  
4 diisopropylethylamine (0.139 mL, 0.797 mmol) and anhydrous DMF (1.35 mL) were reacted  
5 according to method B. The crude product was purified by flash column chromatography to  
6 afford compound **23** as a white amorphous solid (51.0 mg, 47 % over 3 steps). IR (film):  $\nu_{\max}$   
7 3189, 2934, 1636, 1504, 1293, 1066, 819  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (500 MHz, DMSO-*d*<sub>6</sub>)  $\delta$  10.07 (s, 2H),  
8 8.56 (d, *J* = 2.1 Hz, 1H), 8.37 (d, *J* = 8.9 Hz, 1H), 8.22 (dd, *J* = 8.7, 2.0 Hz, 1H), 7.88 – 7.83 (m,  
9 2H), 7.58 (dd, *J* = 8.4, 2.2 Hz, 1H), 7.54 (d, *J* = 2.2 Hz, 1H), 7.51 (dd, *J* = 8.5, 2.2 Hz, 1H), 7.24  
10 (d, *J* = 8.3 Hz, 1H), 7.10 (d, *J* = 8.8 Hz, 1H), 6.98 (d, *J* = 8.4 Hz, 1H), 4.49 (t, *J* = 6.6 Hz, 2H),  
11 4.34 – 4.27 (m, 4H), 3.59 (t, *J* = 4.7 Hz, 4H), 2.50-2.44 (m, 2H), 2.39 (br s, 4H), 2.24 (s, 3H),  
12 1.97 (p, *J* = 6.7 Hz, 2H).  $^{13}\text{C}$  NMR (126 MHz, DMSO-*d*<sub>6</sub>)  $\delta$  164.95, 164.36, 162.88, 147.62,  
13 146.35, 142.94, 140.21, 137.30, 136.34, 130.12, 130.03, 128.77, 128.42, 128.14, 127.70, 126.72,  
14 124.00, 121.21, 118.63, 118.12, 116.85, 116.67, 114.00, 66.20, 64.40, 64.33, 64.03, 54.93, 53.34,  
15 25.47, 17.49. (2 carbons missing) HRMS (ESI<sup>+</sup>): calcd for C<sub>33</sub>H<sub>35</sub>N<sub>4</sub>O<sub>6</sub> (M + H)<sup>+</sup>, 583.2551;  
16 found 583.2586.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

36 *N*-(5-(2,3-Dihydrobenzo[*b*][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(3-(piperidin-1-  
37 yl)propoxy)quinoline-6-carboxamide **24**  
38  
39

40 1-Piperidinepropanol (0.235 mL, 1.55 mmol), NaH (60 % in mineral oil, 0.059 g) and 6-  
41 bromo-2-chloroquinoline (0.300 g, 1.24 mmol) in anhydrous THF (4.00 mL) were reacted  
42 according to method E. The reaction was heated for 5 h. Purification using flash column  
43 chromatography (2.5-6 % methanol in dichloromethane) isolated 6-bromo-2-(3-(piperidin-1-  
44 yl)propoxy)quinoline (329 mg) as a yellow oil, which was used directly in the next step.  
45  
46  
47  
48  
49  
50  
51  
52

53 *n*-BuLi (1.56 M in hexanes, 0.732 mL, 1.14 mmol) and 6-bromo-2-(3-(piperidin-1-  
54 yl)propoxy)quinoline (0.319 g, 0.913 mmol) in anhydrous THF (3.10 mL) were reacted  
55  
56  
57  
58  
59  
60



1  
2  
3 according to method F to afford the crude product, which was used in the next step without  
4  
5 further purification.  
6  
7

8 2-(3-(Piperidin-1-yl)propoxy)quinoline-6-carboxylic acid hydrochloride (76 mg, 0.188 mmol),  
9  
10 HATU (89 mg, 0.234 mmol), and *N*-(3-amino-4-methylphenyl)-2,3-  
11  
12 dihydrobenzo[*b*][1,4]dioxine-6-carboxamide **18** (40 mg, 0.141 mmol) in *N,N*-  
13  
14 diisopropylethylamine (0.139 mL, 0.797 mmol) and anhydrous DMF (1.35 mL) were reacted  
15  
16 according to method B. The crude product was purified by flash column chromatography (3.5-15  
17  
18 % methanol in dichloromethane) to afford compound **24** as a white amorphous solid (53 mg, 49  
19  
20 % over 3 steps). IR (film):  $\nu_{\max}$  3257, 2928, 1601, 1526, 1284, 1064, 818  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (500  
21  
22 MHz,  $\text{DMSO-}d_6$ )  $\delta$  10.07 (s, 2H), 8.57 (d,  $J = 2.1$  Hz, 1H), 8.38 (d,  $J = 8.9$  Hz, 1H), 8.23 (dd,  $J$   
23  
24 = 8.8, 2.1 Hz, 1H), 7.89 – 7.83 (m, 2H), 7.58 (dd,  $J = 8.3, 2.1$  Hz, 1H), 7.54 (d,  $J = 2.1$  Hz, 1H),  
25  
26 7.51 (dd,  $J = 8.5, 2.2$  Hz, 1H), 7.24 (d,  $J = 8.4$  Hz, 1H), 7.10 (d,  $J = 8.8$  Hz, 1H), 6.98 (d,  $J = 8.4$   
27  
28 Hz, 1H), 4.49 (t,  $J = 6.5$  Hz, 2H), 4.34 – 4.26 (m, 4H), 2.70-2.30 (m, 6H), 2.24 (s, 3H), 2.02 (br  
29  
30 s, 2H), 1.56 (br s, 4H), 1.42 (br s, 2H).  $^{13}\text{C}$  NMR (126 MHz,  $\text{DMSO-}d_6$ )  $\delta$  164.94, 164.37,  
31  
32 162.80, 147.59, 146.35, 142.94, 140.25, 137.31, 136.33, 130.12, 130.06, 128.78, 128.44, 128.15,  
33  
34 127.69, 126.72, 124.03, 121.20, 118.64, 118.14, 116.85, 116.67, 113.96, 64.40, 64.21, 64.03,  
35  
36 54.82, 53.67, 24.99, 23.34, 17.48, (3 carbons missing). HRMS ( $\text{ESI}^+$ ): calcd for  $\text{C}_{34}\text{H}_{37}\text{N}_4\text{O}_5$  (M  
37  
38 + H) $^+$ , 581.2758; found 581.2759.  
39  
40  
41  
42  
43  
44

45  
46 *N*-(5-(2,3-Dihydrobenzo[*b*][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(2-(piperidin-1-  
47  
48 yl)ethoxy)quinoline-6-carboxamide **25**  
49

50 4-(2-Hydroxyethyl)piperidine (0.197 mL, 1.49 mmol), NaH (60 % in mineral oil, 0.057 g, 1.42  
51  
52 mmol) and 6-bromo-2-chloroquinoline (0.300 g, 1.24 mmol) in anhydrous THF (4 mL) were  
53  
54 reacted according to method E. The reaction mixture was heated for 5 h. Purification by flash  
55  
56  
57  
58  
59  
60

1  
2  
3 column chromatography (4-5 % methanol in dichloromethane) isolated 334 mg of a pale yellow  
4  
5 oil, which was used directly in the next step.  
6  
7

8 *n*-BuLi (2.28 M in hexanes, 0.437 mL, 0.996 mmol) and 6-bromo-2-(2-(piperidin-1-  
9  
10 yl)ethoxy)quinoline (0.204 g, 0.664 mmol) in anhydrous THF (2.20 mL) were reacted according  
11  
12 to method F (a precipitate formed after addition of *n*-BuLi therefore further THF (1.0 mL) was  
13  
14 added to facilitate stirring) to afford the crude product, which was used in the next step without  
15  
16 further purification.  
17  
18

19  
20 2-(2-(Piperidin-1-yl)ethoxy)quinoline-6-carboxylic acid hydrochloride (85 %, 93 mg, 0.234  
21  
22 mmol), HATU (111 mg, 0.293 mmol), and *N*-(3-amino-4-methylphenyl)-2,3-  
23  
24 dihydrobenzo[*b*][1,4]dioxine-6-carboxamide **18** (50 mg, 0.176 mmol) in *N,N*-  
25  
26 diisopropylethylamine (0.174 mL, 0.997 mmol) and anhydrous DMF (1.5 mL) were reacted  
27  
28 according to method B. The crude product was purified by flash column chromatography (3.5-10  
29  
30 % methanol in dichloromethane) to afford compound **25** as a white amorphous solid (75 mg, 75  
31  
32 %). IR (film):  $\nu_{\max}$  3230, 2932, 1636, 1504, 1291, 1040, 822  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (500 MHz, DMSO-  
33  
34  $d_6$ )  $\delta$  10.07 (s, 2H), 8.57 (d,  $J = 1.9$  Hz, 1H), 8.38 (d,  $J = 8.9$  Hz, 1H), 8.22 (dd,  $J = 8.7, 2.0$  Hz,  
35  
36 1H), 7.88 – 7.84 (m, 2H), 7.58 (dd,  $J = 8.3, 2.2$  Hz, 1H), 7.54 (d,  $J = 2.1$  Hz, 1H), 7.51 (dd,  $J =$   
37  
38 8.4, 2.2 Hz, 1H), 7.24 (d,  $J = 8.5$  Hz, 1H), 7.11 (d,  $J = 8.8$  Hz, 1H), 6.98 (d,  $J = 8.4$  Hz, 1H),  
39  
40 4.60 – 4.54 (m, 2H), 4.34 – 4.27 (m, 4H), 2.75 (br s, 2H), 2.61 – 2.36 (br s, 4H), 2.24 (s, 3H),  
41  
42 1.51 (br s, 4H), 1.39 (br s, 2H).  $^{13}\text{C}$  NMR (126 MHz, DMSO- $d_6$ )  $\delta$  165.39, 164.81, 163.15,  
43  
44 148.00, 146.80, 143.39, 140.71, 137.75, 136.79, 130.57, 130.52, 129.23, 128.88, 128.57, 128.15,  
45  
46 127.21, 124.48, 121.65, 119.08, 118.58, 117.30, 117.12, 114.47, 64.86, 64.48, 63.73, 57.50,  
47  
48 54.76, 25.95, 24.30, 17.94 (2 carbons missing). HRMS (ESI $^+$ ): calcd for  $\text{C}_{33}\text{H}_{35}\text{N}_4\text{O}_5$  (M + H) $^+$ ,  
49  
50 567.2602; found 567.2598.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

*N*-(5-(2,3-Dihydrobenzo[*b*][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-(2-(pyrrolidin-1-yl)ethoxy)quinoline-6-carboxamide **26**

NaH (60 % in mineral oil, 57 mg, 1.42 mmol), 4(2-hydroxyethyl)pyrrolidine (171 mg, 1.48 mmol) and bromo-2-chloroquinoline (300 mg, 1.24 mmol) were reacted according to method E. The reaction was heated for 4 h. Purification by flash column chromatography using a gradient of 2 to 5 % methanol in dichloromethane afforded a pale yellow oil (329 mg), which was used directly in the next step.

*n*-BuLi (1.62 M in hexanes, 0.76 mL, 1.23 mmol) and 6-bromo-2-(2-(pyrrolidin-1-yl)ethoxy)quinolone (38 mg, 0.990 mmol) in anhydrous THF (3.3 mL) were reacted according to method F to afford the crude product, which was used in the next step without further purification.

2-(2-(Pyrrolidin-1-yl)ethoxy)quinoline-6-carboxylic acid hydrochloride (89 mg, 0.23 mmol), HATU (111 mg, 0.29 mmol) and *N*-(3-amino-4-methylphenyl)-2,3-dihydrobenzo[*b*][1,4]dioxine-6-carboxamide (50 mg, 0.18 mmol) in *N,N*-diisopropylethylamine (0.17 mL, 1.0 mmol) and anhydrous DMF (1.5 mL) was reacted according to method B. The crude product was purified by flash column chromatography using a gradient of 5-12 % methanol in dichloromethane to afford the product **26** as a white amorphous solid (66 mg, 70 %). IR (solid):  $\nu_{\max}$  1637, 1601, 1581, 1289, 1065, 819  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (500 MHz,  $\text{DMSO-}d_6$ )  $\delta$  10.07 (s, 2H), 8.57 (d,  $J = 2.0$  Hz, 1H), 8.38 (d,  $J = 8.8$  Hz, 1H), 8.22 (dd,  $J = 8.7, 2.0$  Hz, 1H), 7.88 – 7.84 (m, 2H), 7.58 (dd,  $J = 8.3, 2.2$  Hz, 1H), 7.54 (d,  $J = 2.1$  Hz, 1H), 7.51 (dd,  $J = 8.5, 2.2$  Hz, 1H), 7.24 (d,  $J = 8.5$  Hz, 1H), 7.12 (d,  $J = 8.8$  Hz, 1H), 6.98 (d,  $J = 8.4$  Hz, 1H), 4.57 (t,  $J = 5.8$  Hz, 2H), 4.34 – 4.27 (m, 4H), 2.89 (br s, 2H), 2.58 (br s, 4H), 2.23 (s, 3H), 1.70 (br s, 4H).  $^{13}\text{C}$  NMR (126 MHz,  $\text{DMSO-}d_6$ )  $\delta$  165.39, 164.81, 163.15, 148.00, 146.80, 143.39, 140.72, 137.76, 136.79, 130.57,

1  
2  
3 130.52, 129.23, 128.88, 128.58, 128.15, 127.21, 124.49, 121.65, 119.08, 118.58, 117.30, 117.12,  
4  
5 114.48, 65.03, 64.86, 64.48, 54.58, 54.42, 40.32, 40.15, 23.61, 17.95. HRMS (ESI<sup>+</sup>): calcd for  
6  
7 C<sub>32</sub>H<sub>33</sub>N<sub>4</sub>O<sub>5</sub> (M + H)<sup>+</sup>, 553.2446; found 553.2467.  
8  
9

#### 10 **Preparation of compounds in Figure 4:**

11  
12 *N*-(4-Methyl-3-(6-(2-propionamidoethoxy)-2-naphthamido)phenyl)-2,3-  
13 dihydrobenzo[*b*][1,4]dioxine-6-carboxamide **27**  
14

15  
16 Propionyl chloride (2.5 μL, 0.029 mmol) was added to a solution of 2-(2-aminoethoxy)-*N*-(5-  
17 (2,3-dihydrobenzo[*b*][1,4]dioxine-6-carboxamido)-2-methylphenyl)quinoline-6-carboxamide **29**  
18 (0.013 g, 0.026 mmol) in anhydrous dichloromethane (0.75 mL) and DMF (0.15 mL). The  
19 reaction mixture was stirred at room temperature for 2.5 h, concentrated to remove  
20 dichloromethane, then diluted with water, extracted with dichloromethane (3x), dried over  
21 magnesium sulfate, filtered and concentrated. Heptane was added and concentrated (2x) to  
22 remove residual DMF. The crude material was purified by flash column chromatography using a  
23 gradient of 2-3.5 % methanol in dichloromethane to afford the title compound **27** (10 mg, 71 %)  
24 as a white amorphous solid. IR (thin film): ν<sub>max</sub> 2934, 1645, 1529, 1502, 1286, 1262, 1065 cm<sup>-1</sup>.  
25  
26 <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 10.08 (s, 1H), 10.07 (s, 1H), 8.57 (d, *J* = 2.0 Hz, 1H), 8.39 (d,  
27 *J* = 8.8 Hz, 1H), 8.23 (dd, *J* = 8.7, 2.1 Hz, 1H), 8.04 (br t, *J* = 5.5 Hz, 1H), 7.88 – 7.84 (m, 2H),  
28 7.58 (dd, *J* = 8.4, 2.2 Hz, 1H), 7.54 (d, *J* = 2.1 Hz, 1H), 7.51 (dd, *J* = 8.5, 2.2 Hz, 1H), 7.24 (d, *J*  
29 = 8.4 Hz, 1H), 7.11 (d, *J* = 8.8 Hz, 1H), 6.98 (d, *J* = 8.4 Hz, 1H), 4.47 (t, *J* = 5.7 Hz, 2H), 4.34 –  
30 4.27 (m, 4H), 3.51 (q, *J* = 5.7 Hz, 2H), 2.24 (s, 3H), 2.10 (q, *J* = 7.6 Hz, 2H), 0.99 (t, *J* = 7.6 Hz,  
31 3H). <sup>13</sup>C NMR (126 MHz, DMSO-*d*<sub>6</sub>) δ 173.66, 165.39, 164.81, 163.13, 147.95, 146.80, 143.39,  
32 140.76, 137.75, 136.79, 130.58, 129.23, 128.91, 128.59, 128.15, 127.21, 124.54, 121.66, 119.08,  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 118.59, 117.30, 117.12, 114.42, 65.03, 64.86, 64.49, 38.44, 28.86, 17.95, 10.36, (1 carbon  
4 missing). HRMS (ESI<sup>+</sup>): calcd for C<sub>31</sub>H<sub>31</sub>N<sub>4</sub>O<sub>6</sub> (M + H)<sup>+</sup>, 555.2238; found 555.2228.  
5  
6

7  
8 *N*-(5-(2,3-Dihydrobenzo[*b*][1,4]dioxine-5-carboxamido)-2-methylphenyl)-2-(2-(pyrrolidin-1-  
9 yl)ethoxy)quinoline-6-carboxamide **28**  
10

11  
12 2,3-Dihydrobenzo[*b*][1,4]dioxine-5-carboxylic acid (980 mg, 5.44 mmol), oxalyl chloride  
13 (0.552 mL, 6.53 mmol) and DMF (0.011 mL, 0.14 mmol) in anhydrous dichloromethane (14  
14 mL) were reacted according to method A. The resulting acid chloride was dissolved in  
15 anhydrous dichloromethane (9 mL) and added dropwise to a solution of 4-methyl-3-nitroaniline  
16 **2** (828 mg, 5.44 mmol) and pyridine (0.88 mL, 10.88 mmol) in anhydrous dichloromethane (15  
17 mL). A precipitate formed during the addition. The reaction mixture was stirred at room  
18 temperature overnight, and then concentrated. The resulting amorphous solid was suspended in  
19 methanol, diluted with water and then isolated by filtration and washed with water to afford the  
20 title compound as a pale brown amorphous solid (1.57 g, 92 %). <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>)  
21 δ 10.45 (s, 1H), 8.53 (d, *J* = 2.2 Hz, 1H), 7.88 (dd, *J* = 8.3, 2.2 Hz, 1H), 7.49 (d, *J* = 8.5 Hz,  
22 1H), 7.16 (dd, *J* = 7.6, 1.6 Hz, 1H), 7.04 (dd, *J* = 8.1, 1.6 Hz, 1H), 6.97 – 6.92 (m, 1H), 4.39 –  
23 4.36 (m, 2H), 4.34 – 4.30 (m, 2H), 2.50 (s, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-*d*<sub>6</sub>) δ 164.91,  
24 149.06, 144.14, 141.73, 138.33, 133.53, 127.95, 125.57, 124.69, 121.71, 121.25, 119.85, 115.23,  
25 64.96, 64.23, 19.68. HRMS (ESI<sup>+</sup>): calcd for C<sub>16</sub>H<sub>15</sub>N<sub>2</sub>O<sub>5</sub> (M + H)<sup>+</sup>, 315.0975; found 315.0976.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

45  
46 Palladium (10 % on activated carbon, 0.325 g) and *N*-(4-methyl-3-nitrophenyl)-2,3-  
47 dihydrobenzo[*b*][1,4]dioxine-5-carboxamide (1.50 g, 4.77 mmol) in ethanol (32 mL) and ethyl  
48 acetate (32 mL) were reacted according to method D to afford *N*-(3-amino-4-methylphenyl)-2,3-  
49 dihydrobenzo[*b*][1,4]dioxine-5-carboxamide (1.30 g, 96 %) as a white amorphous solid. <sup>1</sup>H  
50 NMR (500 MHz, CDCl<sub>3</sub>) δ 9.35 (s, 1H), 7.80 (dd, *J* = 7.8, 1.6 Hz, 1H), 7.34 (br s, 1H), 7.03 (dd,  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  $J = 8.0, 1.7$  Hz, 1H), 7.01 – 6.92 (m, 2H), 6.76 (dd,  $J = 8.0, 2.0$  Hz, 1H), 4.49 – 4.44 (m, 3H),  
4  
5 4.36 – 4.30 (m, 3H), 3.54 (br s, 2H).  $^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ )  $\delta$  162.58, 145.09, 143.61,  
6  
7 141.73, 137.17, 130.51, 124.23, 122.59, 121.51, 121.00, 118.39, 110.47, 107.22, 65.13, 63.59,  
8  
9 16.91. HRMS ( $\text{ESI}^+$ ): calcd for  $\text{C}_{16}\text{H}_{17}\text{N}_2\text{O}_3$  ( $\text{M} + \text{H}$ ) $^+$ , 286.1265; found 286.1263. RMS ( $\text{ESI}^+$ ):  
10  
11 calcd for  $\text{C}_{16}\text{H}_{17}\text{N}_2\text{NaO}_3$  ( $\text{M} + \text{Na}$ ) $^+$ , 307.1053; found 307.1048.  
12  
13  
14

15 2-(2-(Pyrrolidin-1-yl)ethoxy)quinoline-6-carboxylic acid hydrochloride (95 mg, 0.253 mmol),  
16  
17 HATU, (104 mg, 0.274 mmol), and *N*-(3-amino-4-methylphenyl)-2,3-  
18  
19 dihydrobenzo[*b*][1,4]dioxine-5-carboxamide (0.060 g, 0.211 mmol) in *N,N*-  
20  
21 diisopropylethylamine (0.147 mL, 0.844 mmol) and anhydrous DMF (2 mL) were reacted  
22  
23 according to method B. The crude product was purified by flash column chromatography using a  
24  
25 gradient of 5-10 % methanol in dichloromethane to afford the title compound **28** as a cream  
26  
27 amorphous solid (61 mg, 52 %). IR (thin film):  $\nu_{\text{max}}$  2926, 1651, 1619, 1601, 1527, 1470, 1282  
28  
29  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (500 MHz,  $\text{DMSO-}d_6$ )  $\delta$  10.10 (s, 1H), 10.09 (s, 1H), 8.57 (d,  $J = 2.0$  Hz, 1H),  
30  
31 8.38 (d,  $J = 8.8$  Hz, 1H), 8.23 (dd,  $J = 8.7, 2.0$  Hz, 1H), 7.86 (d,  $J = 8.7$  Hz, 1H), 7.81 (d,  $J = 2.1$   
32  
33 Hz, 1H), 7.53 (dd,  $J = 8.3, 2.1$  Hz, 1H), 7.24 (d,  $J = 8.4$  Hz, 1H), 7.15 (dd,  $J = 7.6, 1.6$  Hz, 1H),  
34  
35 7.12 (d,  $J = 8.8$  Hz, 1H), 7.01 (dd,  $J = 8.0, 1.7$  Hz, 1H), 6.92 (t,  $J = 7.8$  Hz, 1H), 4.57 (t,  $J = 5.8$   
36  
37 Hz, 2H), 4.40 – 4.35 (m, 2H), 4.30 (dt,  $J = 3.8, 2.3$  Hz, 2H), 2.91 (br s, 2H), 2.60 (br s, 4H), 2.23  
38  
39 (s, 3H), 1.71 (s, 4H).  $^{13}\text{C}$  NMR (126 MHz,  $\text{DMSO-}d_6$ )  $\delta$  165.38, 164.26, 163.15, 148.01, 144.11,  
40  
41 141.65, 140.73, 137.51, 136.95, 130.72, 130.45, 129.44, 128.90, 128.62, 127.20, 126.15, 124.49,  
42  
43 121.72, 121.17, 119.50, 118.45, 117.95, 114.48, 64.93, 64.21, 54.55, 54.42, 23.60, 17.98, (2  
44  
45 carbons missing). HRMS ( $\text{ESI}^+$ ): calcd for  $\text{C}_{32}\text{H}_{33}\text{N}_4\text{O}_5$  ( $\text{M} + \text{H}$ ) $^+$ , 553.2445; found 553.2424.  
46  
47  
48  
49  
50  
51

52 2-(2-Aminoethoxy)-*N*-(5-(2,3-dihydrobenzo[*b*][1,4]dioxine-6-carboxamido)-2-  
53  
54 methylphenyl)quinoline-6-carboxamide **29**  
55  
56  
57  
58  
59  
60

1  
2  
3 NaH (60 % in mineral oil, 0.112 g, 2.79 mmol), *tert*-butyl *N*-(2-hydroxyethyl)carbamate (0.43  
4 mL, 2.79 mmol) and 6-bromo-2-chloroquinoline (0.564 g, 2.33 mmol) in anhydrous THF (13  
5 mL) were reacted according to method E. The reaction was heated for 5 h. Purification by flash  
6 column chromatography using a gradient of 20-25 % diethyl ether in petroleum ether afforded  
7 *tert*-butyl (2-((6-bromoquinolin-2-yl)oxy)ethyl)carbamate as a white amorphous solid (248 mg,  
8 29 %). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.92 (d, *J* = 8.9 Hz, 1H), 7.88 (d, *J* = 1.6 Hz, 1H), 7.74 –  
9 7.66 (m, 2H), 6.94 (d, *J* = 8.8 Hz, 1H), 5.14 (br s, 1H), 4.56 (t, *J* = 5.1 Hz, 2H), 3.61 (br s, 2H),  
10 1.46 (s, 9H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 145.03, 137.93, 132.86, 129.48, 128.93, 117.42,  
11 113.99, 65.52, 40.14, 28.40, (2 carbons missing). HRMS (ESI<sup>+</sup>): calcd for C<sub>16</sub>H<sub>20</sub><sup>79</sup>BrN<sub>2</sub>O<sub>3</sub> (M +  
12 H)<sup>+</sup>, 367.0652; found 367.0649.

13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27 *n*-BuLi (2.12 M in hexanes, 0.350 mL, 0.743 mmol) and *tert*-butyl (2-((6-bromoquinolin-2-  
28 yl)oxy)ethyl)carbamate (0.124 g, 0.338 mmol) in anhydrous THF (3.0 mL) were reacted  
29 according to method F. The reaction was quenched with water and the reaction mixture  
30 concentrated to remove THF. The resulting aqueous solution was washed with ethyl acetate (1x)  
31 (brine was added to help clear the emulsion formed) and then acidified with 2 M HCl to pH 2-3.  
32 The aqueous layer was extracted with dichloromethane (3x) and the combined organic layer  
33 dried over magnesium sulfate to afford 2-(2-((*tert*-butoxycarbonyl)amino)ethoxy)quinoline-6-  
34 carboxylic acid as a white amorphous solid (52 mg, 46 %). <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ  
35 13.06 (br s, 1H), 8.56 (d, *J* = 1.9 Hz, 1H), 8.41 (d, *J* = 8.9 Hz, 1H), 8.13 (dd, *J* = 8.7, 2.0 Hz,  
36 1H), 7.80 (d, *J* = 8.8 Hz, 1H), 7.07 (d, *J* = 8.9 Hz, 1H), 7.04 (t, *J* = 5.7 Hz, 1H), 4.43 (t, *J* = 5.8  
37 Hz, 2H), 3.37 (q, *J* = 5.6 Hz, 2H), 1.37 (s, 9H). HRMS (ESI<sup>+</sup>): calcd for C<sub>17</sub>H<sub>21</sub>N<sub>2</sub>O<sub>5</sub> (M + H)<sup>+</sup>,  
38 333.1445; found 333.1447.

1  
2  
3 2-(2-((*tert*-Butoxycarbonyl)amino)ethoxy)quinoline-6-carboxylic acid (46 mg, 0.138 mmol),  
4 HATU (66 mg, 0.173 mmol) and *N*-(3-aminophenyl)-2,3-dihydrobenzo[*b*][1,4]dioxine-6-  
5 carboxamide (39 mg, 0.138 mmol) in *N,N*-diisopropylethylamine (0.073 mL, 0.415 mmol) and  
6 anhydrous DMF (2 mL) were reacted according to method B. The crude material was purified by  
7 flash column chromatography using a gradient of 1-3 % methanol in dichloromethane to afford  
8 the product as an off-white amorphous solid (77 mg, 56 %). <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ  
9 10.07 (s, 1H), 10.07 (s, 1H), 8.57 (d, *J* = 2.1 Hz, 1H), 8.39 (d, *J* = 8.8 Hz, 1H), 8.22 (dd, *J* = 8.8,  
10 2.1 Hz, 1H), 7.86 (d, *J* = 8.8 Hz, 1H), 7.86 (d, *J* = 2.2 Hz, 1H), 7.58 (dd, *J* = 8.5, 2.2 Hz, 1H),  
11 7.54 (d, *J* = 2.0 Hz, 1H), 7.51 (dd, *J* = 8.4, 2.2 Hz, 1H), 7.24 (d, *J* = 8.5 Hz, 1H), 7.09 (d, *J* = 8.9  
12 Hz, 1H), 7.06 (t, *J* = 5.6 Hz, 1H), 6.98 (d, *J* = 8.4 Hz, 1H), 4.45 (t, *J* = 5.7 Hz, 2H), 4.33 – 4.28  
13 (m, 2H), 3.39 (ap q, *J* = 5.7 Hz, 2H), 2.24 (s, 3H), 1.38 (s, 9H). <sup>13</sup>C NMR (126 MHz, DMSO-*d*<sub>6</sub>)  
14 δ 165.39, 164.81, 163.12, 147.95, 146.80, 143.39, 140.71, 137.76, 136.79, 130.57, 129.23,  
15 128.88, 128.58, 128.15, 127.21, 124.53, 121.66, 119.08, 118.58, 117.30, 117.12, 114.47, 78.21,  
16 65.13, 64.86, 64.48, 39.72, 28.70, 17.95, (2 carbons missing). HRMS (ESI<sup>+</sup>): calcd for  
17 C<sub>33</sub>H<sub>35</sub>N<sub>4</sub>O<sub>7</sub> (M + H)<sup>+</sup>, 599.2500; found 599.2495.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

38 Trifluoroacetic acid (0.75 mL) was added to a solution of *tert*-butyl (2-((6-((5-(2,3-  
39 dihydrobenzo[*b*][1,4]dioxine-6-carboxamido)-2-methylphenyl)carbamoyl)quinolin-2-  
40 yl)oxy)ethyl)carbamate (0.039 g, 0.065 mmol) in anhydrous dichloromethane (0.75 mL) and the  
41 reaction mixture was stirred at room temperature for 75 min, concentrated, added  
42 dichloromethane and concentrated again. Diluted with a small amount of methanol, then a 1:1  
43 mixture of sat. NaHCO<sub>3</sub> (aq.) was slowly added. The resulting precipitate was isolated by  
44 filtration and washed with water. The crude material was purified by flash column  
45 chromatography using 10 % methanol in dichloromethane then a gradient of 5 to 9 % 2 M NH<sub>3</sub>  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 methanol/DCM to afford the title compound (22 mg, 68 %) as an off-white amorphous solid. <sup>1</sup>H  
4 NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 10.08 (s, 2H), 8.57 (d, *J* = 2.0 Hz, 1H), 8.39 (d, *J* = 8.9 Hz, 1H),  
5  
6 8.22 (dd, *J* = 8.7, 2.1 Hz, 1H), 7.89 – 7.84 (m, 2H), 7.58 (dd, *J* = 8.3, 2.2 Hz, 1H), 7.54 (d, *J* =  
7  
8 2.1 Hz, 1H), 7.51 (dd, *J* = 8.5, 2.2 Hz, 1H), 7.24 (d, *J* = 8.4 Hz, 1H), 7.12 (d, *J* = 8.7 Hz, 1H),  
9  
10 6.99 (d, *J* = 8.4 Hz, 1H), 4.42 (t, *J* = 5.8 Hz, 2H), 4.33 – 4.28 (m, 4H), 2.99 (t, *J* = 5.9 Hz, 2H),  
11  
12 2.25 (s, 3H), 2.06 (br s, 2H). <sup>13</sup>C NMR (126 MHz, DMSO-*d*<sub>6</sub>) δ 165.41, 164.81, 163.40, 148.07,  
13  
14 146.81, 143.39, 140.64, 137.76, 136.80, 130.58, 130.48, 129.23, 128.86, 128.58, 128.15, 127.20,  
15  
16 124.48, 121.66, 119.08, 118.58, 117.31, 117.12, 114.51, 68.85, 64.86, 64.49, 41.13, 17.96.  
17  
18 HRMS (ESI<sup>+</sup>): calcd for C<sub>28</sub>H<sub>27</sub>N<sub>4</sub>O<sub>5</sub> (M + H)<sup>+</sup>, 499.1976; found 499.1974.  
19  
20  
21  
22  
23

## 24 ASSOCIATED CONTENT

### 25 26 27 **Supporting Information**

28  
29 The Supporting Information is available free of charge on the ACS Publications website.  
30  
31  
32

33  
34 SMILES molecular formula strings (CSV).  
35  
36

37  
38 Video files of WM266.4 cell migration in the scratch-wound assay (mp4)  
39  
40

41 NMR Spectra of Final Compounds, CDK Inhibition Assay, Cancerxgene Cell Line Profiling,  
42  
43 DiscoverX KinomeScan, Kinase Inhibition Assays, BRAF Inhibitors, Solubilizing Group  
44  
45 Optimization, Mouse Pharmacokinetics, In Vivo Mouse Efficacy Studies, Cerep Diversity  
46  
47 Screen, SILAC Target Identification, Surface Plasmon Resonance (SPR), Pirin Crystallography,  
48  
49 Full Experimental Procedures, (PDF).  
50  
51

### 52 53 **PDB ID Codes**

54  
55  
56  
57  
58  
59  
60

1  
2  
3 Atomic coordinates and structure factors for the crystal structures of pirin with compound **26**  
4  
5 can be accessed using PDB code: 5JCT. Authors will release the atomic coordinates and  
6  
7 experimental data upon article publication.  
8  
9

## 10 11 12 AUTHOR INFORMATION

13  
14  
15  
16 Corresponding Author

17  
18  
19 \*Author to whom correspondence should be addressed.

20  
21  
22 Keith.Jones@icr.ac.uk; Paul.Workman@icr.ac.uk

23  
24  
25  
26 Phone: +44 (0) 20 8722 4334

## 27 28 29 Author Contributions

30  
31 The manuscript was written through contributions of all authors. All authors have given approval  
32  
33 to the final version of the manuscript.  
34  
35

## 36 37 38 ACKNOWLEDGMENT

39  
40 This work was supported by Cancer Research UK grant numbers C309/A8274 and  
41  
42 C309/A11566. We acknowledge CRUK Centre funding and NHS funding to the NIHR  
43  
44 Biomedical Research Centre at The Institute of Cancer Research and the Royal Marsden  
45  
46 Hospital. Professor Paul Workman is a CRUK Life Fellow. We thank Dr Nora Cronin and the  
47  
48 staff of the European Synchrotron Radiation facility for their support during data collection.  
49  
50  
51

## 52 53 54 ABBREVIATIONS

55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

CTB, Cell Titer Blue; ELISA, enzyme-linked immunosorbent assay; HSF1, heat-shock factor protein 1; HSP70, 70 kilodalton heat-shock proteins; SAR, structure activity relationship; HSP72, heat-shock 70 KDa protein 1; HSP90, heat-shock protein 90; 17-AAG, Tanespimycin (17-*N*-allylamino-17-demethoxygeldanamycin); ELISA, enzyme-linked immunosorbent assay; BRAF, B-Raf proto-oncogene, serine/threonine kinase; KIT, tyrosine protein kinase KIT; PDGFRA, platelet-derived growth factor receptor alpha polypeptide; PDGFRB, beta-type platelet-derived growth factor receptor; HTS, high-throughput screen; nM, nanomolar;  $\mu$ M, micromolar; IC<sub>50</sub>, half minimal (50%) inhibitory concentration; GI<sub>50</sub>, concentration for 50% of maximal inhibition of cell proliferation; CDK2, Cyclin-dependent kinase 2; CDK9, Cyclin-dependent kinase 9; SEM, standard error of the mean; K<sub>d</sub>, dissociation constant; HATU, 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate; MLM, mouse liver microsomes; KS, kinetic solubility; HBF, hepatic blood flow; EMT, Epithelial-mesenchymal transition; SPR, surface plasmon resonance; GPCR, G protein-coupled receptors, NF $\kappa$ B, nuclear factor kappa-light-chain-enhancer of activated B cells; EAF2/U19, ELL-associated factor 2; NRF2, nuclear factor erythroid 2 related factor 2; BCL3, B-cell lymphoma 3-encoded protein; NFI/CTF1, Nuclear factor I; p65, nuclear factor NF-kappa-B p65 subunit; EMT, Epithelial–mesenchymal transition; GSK3 $\beta$ , Glycogen synthase kinase 3 beta; PDE6D, Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta; SILAC, Stable isotope labeling by amino acids in cell culture; PK, pharmacokinetics; AUC, area under the curve; AUC<sub>u</sub>, unbound area under the curve; C<sub>av</sub><sup>0-24hrs</sup>, average concentration over a 24 hr period; po, *per os*, oral dose; qd, *quaque die*, once-a-day dose; Cl, clearance; Cl<sub>u</sub>, unbound clearance; V<sub>ss</sub>, volume of distribution at steady-state; V<sub>du</sub>, unbound volume of distribution; %F, percentage oral bioavailability; f<sub>up</sub>, fraction unbound in plasma; f<sub>ub</sub>, fraction unbound in blood;

1  
2  
3  $f_{ua}$ , fraction unbound in the assay; B:P, blood to plasma ratio; CYP450, cytochrome P450; DMF,  
4 dimethylformamide; DCM, dichloromethane; DIPEA, diisopropylethylamine; THF  
5 tetrahydrofuran.  
6  
7  
8  
9

## 10 REFERENCES

11  
12  
13  
14  
15  
16  
17  
18 (1) (a) Holohan, C.; Schaeybroeck, S. V.; Longley, D. B.; Johnston, P. G. Cancer drug  
19 resistance: an evolving paradigm. *Nat. Rev. Cancer* **2013**, *13*, 714-726. (b) Zahreddine, H.;  
20 Borden, K. L. B. Mechanisms and insights into drug resistance in cancer. *Front. Pharmacol.*  
21 **2013**, *4*, 1-8. (c) Garraway, L. A.; Janne, P. A. Circumventing cancer drug resistance in the era of  
22 personalized medicine. *Cancer Discovery* **2012**, *2*, 214-226. (d) Al-Lazikani, B.; Banerji, U.;  
23 Workman, P. Combinatorial drug therapy for cancer in the post-genomic era. *Nat. Biotechnol.*  
24 **2012**, *30*, 679-692.  
25  
26  
27  
28  
29  
30  
31  
32

33  
34  
35 (2) (a) Kinch, M. S. An analysis of FDA-approved drugs for oncology. *Drug Discovery Today*  
36 **2014**, *19*, 1831-1835. (b) Patel, M. N.; Halling-Brown, M. D.; Tym, J. E.; Workman, P.; Al-  
37 Lazikani, B. Objective assessment of cancer genes for drug discovery. *Nat. Rev Drug Discovery*  
38 **2013**, *12*, 35-50.  
39  
40  
41  
42  
43  
44

45 (3) (a) Kotz, J. Phenotypic screening, take two. *SciBX* **2012**, *5*, 1-3. (b) Tang, H.; Duggan, S.;  
46 Richardson, P. L.; Marin, V.; Warder, S. E.; McLoughlin, S. M. Target identification of  
47 compounds from a cell viability phenotypic screen using a bead/lysate-based affinity capture  
48 platform. *J. Biomol. Screening* **2016**, *21*, 201-211.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 (4) (a) Moffat, J. G.; Rudolph, J.; Bailey, D. Phenotypic screening in cancer drug discovery -  
6 past, present and future. *Nat. Rev. Drug Discovery* **2014**, *13*, 588-602. (b) Vincent, F.; Loria, P.;  
7 Pregel, M.; Stanton, R.; Kitching, L.; Nocka, K.; Doyonnas, R.; Steppan, C.; Gilbert, A.;  
8 Schroeter, T.; Peakman, M. Developing predictive assays: the phenotypic screening “rule of 3”.  
9 *Sci. Transl. Med.* **2015**, *7*, 293ps15. (c) Swinney, D. C.; Anthony, J. How were new medicines  
10 discovered? *Nat. Rev. Drug Discovery* **2011**, *11*, 507-519. (d) Cheeseman M. D.; Faisal, A.;  
11 Rayter, S.; Barbeau, O.; Kalusa, A.; Westlake, M.; Burke, R.; Swan, M.; van Montfort, R.;  
12 Linardopoulos, S.; Jones, K. Targeting the PPM1D phenotype; 2,4-bisarylthiazoles cause highly  
13 selective apoptosis in PPM1D amplified cell-lines. *Bioorg. Med. Chem. Lett.* **2014**, *24*, 3469-  
14 3474.

15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30 (5) (a) Zheng, W.; Thorne, N.; McKew, J. C. Phenotypic screens as a renewed approach for  
31 drug discovery. *Drug Discovery Today* **2013**, *18*, 1067-1073. (b) Lee, J. A.; Uhlik, M. T.;  
32 Moxham, C. M. Tomandl, D.; Sall, D. J. Modern phenotypic drug discovery is a viable,  
33 neoclassic pharma strategy. *J. Med. Chem.* **2012**, *55*, 4527-4538. (c) Eder, J.; Sedrani, R.;  
34 Wiesmann, C. The discovery of first-in-class drugs: origins and evolution. *Nat. Rev. Drug*  
35 *Discovery* **2014**, *13*, 577-587.

36  
37  
38  
39  
40  
41  
42  
43  
44  
45 (6) (a) Anighoro, A.; Bajorath, J.; Rastelli, G. Polypharmacology: challenges and opportunities  
46 in drug discovery. *J. Med. Chem.* **2014**, *57*, 7874-7887. (b) Peters, J. Polypharmacology – foe or  
47 friend? *J. Med. Chem.* **2013**, *56*, 8955-8971. (c) Medina-Franco, J. L.; Giulianotti, M. A.;  
48 Welmaker, G. S.; Houghten, R. A. Shifting from the single to the multitarget paradigm in drug  
49 discovery. *Drug Discovery Today* **2013**, *18*, 495-501. (d) Jalencas, X.; Mestres, J. On the origins  
50 of drug polypharmacology. *MedChemComm.* **2013**, *4*, 80-87.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 (7) Swinney, D. C. The value of translational biomarkers to phenotypic assays. *Front.*  
6  
7  
8 *Pharmacol.* **2014**, *5*, 171.

9  
10  
11 (8) Zhanga, Z.; Guana, N.; Li, T.; Mais, D. E.; Wang, M. Quality control of cell-based high-  
12  
13 throughput drug screening. *Acta Pharm. Sin. B* **2012**, *2*, 429-438.

14  
15  
16 (9) (a) Arrowsmith, C. H.; Audia, J. E.; Austin, C.; Baell, J.; Bennett, J.; Blagg J.; Bountra, C.;  
17  
18 Brennan, P. E.; Brown, P. J.; Bunnage, M. E.; Buser-Doepner, C.; Campbell, R. M.; Carter, A.  
19  
20 J.; Cohen, P.; Copeland, R. A.; Cravatt, B.; Dahlin J. L., Dhanak, D.; Edwards, A. M.;  
21  
22 Frederiksen, M.; Frye, S. V.; Gray, N.; Grimshaw, C. E.; Hepworth, D.; Howe, T.; Huber, K. V.;  
23  
24 Jin, J.; Knapp, S.; Kotz, J. D.; Kruger, R. G.; Lowe, D.; Mader, M. M.; Marsden, B.; Mueller-  
25  
26 Fahrnow, A.; Müller, S.; O'Hagan, R. C.; Overington, J. P.; Owen, D. R.; Rosenberg, S. H.;  
27  
28 Roth, B.; Ross, R.; Schapira, M.; Schreiber, S. L.; Shoichet B.; Sundström, M.; Superti-Furga,  
29  
30 G.; Taunton, J.; Toledo-Sherman, L.; Walpole, C.; Walters, M. A.; Willson, T. M.; Workman P.;  
31  
32 Young, R. N.; Zuercher, W. J. The promise and peril of chemical probes. *Nat. Chem. Biol.* **2015**,  
33  
34 *11*, 536-541. (b) Workman, P.; Collins, I. Probing the probes: fitness factors for small molecule  
35  
36 tools. *Chem. Biol.* **2010**, *17*, 561-577. (c) Bunnage, M. E.; Piantnitski Chekler, E. L.; Jones, L. H.  
37  
38 Target validation using chemical probes. *Nat. Chem. Biol.* **2013**, *9*, 195-199.

39  
40  
41 (10) (a) Ziegler, S.; Pries, V.; Hedberg, C.; Waldmann, H. Target identification for small  
42  
43 bioactive molecules: finding the needle in the haystack. *Angew. Chem. Int. Ed.* **2013**, *52*, 2-51.

44  
45  
46 (b) Rix, U.; Superti-Furga, G. Target profiling of small molecules by chemical proteomics. *Nat.*  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
*Chem. Biol.* **2009**, *5*, 616-624.

1  
2  
3  
4  
5 (11) Schirle, M.; Jenkins J. L. Identifying compound efficacy targets in phenotypic drug  
6 discovery. *Drug Discovery Today* **2016**, *21*, 82-89.  
7

8  
9  
10 (12) Hann, M. M.; Keseru, G. M. Finding the sweet spot: the role of nature and nurture in  
11 medicinal chemistry. *Nat. Rev. Drug Discovery* **2012**, *11*, 355-365.  
12  
13

14  
15 (13) (a) Vihervaara, A.; Sistonen, L. HSF1 at a glance. *J. Cell Sci.* **2014**, *127*, 261-266. (b)  
16 Anckar, J.; Sistonen, L. Regulation of HSF1 function in the heat stress response: implications in  
17 aging and disease. *Annu. Rev. Biochem.* **2011**, *80*, 1089-1115. (c) Jiang, S.; Tu, K.; Fu, Q.;  
18 Schmitt, D. C.; Zhou, L.; Lu, N.; Zhao, Y. Multifaceted roles of HSF1 in cancer. *Tumor Biol.*  
19 **2015**, *36*, 4923-4931.  
20  
21  
22  
23  
24  
25  
26  
27

28  
29 (14) (a) Whitesell, L.; Lindquist, S. Inhibiting the transcription factor HSF1 as an anticancer  
30 strategy. *Expert Opin. Ther. Targets* **2009**, *13*, 469-478. (b) Moore, C. L.; Dewal, M. B.;  
31 Nekongo, E. E.; Santiago, S.; Lu, N. B.; Levine, S. S.; Shoulders, M. D. Transportable, chemical  
32 genetic methodology for the small molecule-mediated inhibition of heat shock factor 1. *ACS*  
33 *Chem. Biol.* **2016**, *11*, 200-210. (c) de Billy, E.; Travers, J.; Workman, P. Shock about heat  
34 shock in cancer. *Oncotarget* **2012**, *3*, 741-743.  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 (15) Mendillo, M. L.; Santagata, S.; Koeva, M.; Bell, G. W.; Hu, R.; Tamimi, R. M.; Fraenkel,  
45 E.; Ince, T. A.; Whitesell, L.; Lindquist, S. HSF1 drives a transcriptional program distinct from  
46 heat shock to support highly malignant human cancers. *Cell* **2012**, *150*, 549-562.  
47  
48  
49

50 (16) (a) Santagata, S.; Hu, R.; Lin, N. U. Mendillo, M. L.; Collins, L. C.; Hankinson, S. E.;  
51 Schnitt, S. J.; Whitesell, L.; Tamimi, R. M.; Lindquist, S.; Ince, T. A. High levels of nuclear  
52 heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer. *Proc. Natl. Acad.*  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

---

*Sci. U.S.A.* **2011**, *108*, 18378-18383. (b) Fang, F.; Chang, R.; Yang, L. Heat shock factor 1 promotes invasion and metastasis of hepatocellular carcinoma in vitro and in vivo. *Cancer* **2012**, *118*, 1782-1794. (c) Scott, K. L.; Nogueira, C.; Heffernan, T. P.; Doorn, R. V.; Dhakal, S.; Hanna, J. A.; Min, C.; Jaskelioff, M.; Xiao, Y.; Wu, C-J; Cameron, L. A.; Perry, S. R.; Zeid, R.; Tamar Feinberg, T.; Kim, M.; Woude, G. V.; Granter, S. R.; Bosenberg, M.; Chu, G. C.; DePinho, R. A.; Rimm, D. L.; Chin, L. Pro-invasion metastasis drivers in early stage melanoma are oncogenes. *Cancer Cell* **2011**, *20*, 92-103.

(17) For a discussion of transcription inhibitors in oncology see: (a) Bensaude, O. Inhibiting eukaryotic transcription, which compound to choose? how to evaluate its activity? *Transcr.* **2011**, *2*, 103-108. (b) Stellrecht, C. M.; Chen, L. S. Transcription inhibition as a therapeutic target for cancer. *Cancers* **2011**, *3*, 4170-4190. (c) Kwiatkowski, N.; Zhang, T.; Rahl, P. B.; Abraham, B. J.; Reddy, J.; Ficarro, S. B.; Dastur, A.; Amzallag, A.; Ramaswamy, S.; Tesar, B.; Jenkins, C. E.; Hannett, N. M.; McMillin, D.; Sanda, T.; Sim, T.; Kim, N. D.; Look, T.; Mitsiades, C. S.; Weng, A. P.; Brown, J. R.; Benes, C. H.; Marto, J. A.; Young, R. A.; Gray, N. S. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. *Nature* **2014**, *511*, 616-620. (d) Nguyen, T. K.; Grant, S. Dinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1- and 5-dependent mechanism. *Mol. Cancer Ther.* **2013**, *20*, 662-674. (e) Lam, F.; Abbas, A. Y.; Shao, H.; Teo, T.; Adams, J.; Peng Li, P.; Bradshaw, T. D.; Fischer, P. M.; Walsby, E.; Pepper, C.; Chen, Y.; Ding, J.; Wang, S. Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73. *Oncotarget* **2014**, *5*, 7691-7704. (f) Wang, S.; Griffiths, G.; Midgley, C. A.; Barnett, A. L.; Cooper, M.; Grabarek, J.; Ingram, L.; Jackson, W.; Kontopidis, G.; McClue, S. J.; McInnes, C.; McLachlan, J.; Meades,



1  
2  
3  
4  
5 C.; Mezna, M.; Stuart, I.; Thomas, M. P.; Zheleva, D. I.; Lane, D. P.; Jackson, R. C.; Glover, D.  
6  
7 M.; Blake D. G.; Fischer, P. M. Discovery and characterization of 2-anilino-4-(thiazol-5-  
8  
9 yl)pyrimidine transcriptional CDK inhibitors as anticancer agents. *Chem. Biol.* **2010**, *17*, 1111-  
10  
11 1121. (g) Villicana, C.; Cruz, G.; Zurita, M. The basal transcription machinery as a target for  
12  
13 cancer therapy. *Cancer Cell Int.* **2014**, *14*, 18.  
14  
15

16  
17  
18 (18) Solimini, N. L.; Luo, J.; Elledge, S. J. Non-oncogene addiction and the stress phenotype  
19  
20 of cancer cells. *Cell* **2007**, *130*, 986-988.  
21  
22

23  
24 (19) (a) Zou, J.; Guo, Y.; Guettouche, T.; David F. Smith, D. F.; Voellmy, R. Repression of  
25  
26 heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-  
27  
28 sensitive complex with HSF1. *Cell* **1998**, *94*, 471-480. (b) Doubrovin, M.; Che, J. T.; Serganova,  
29  
30 I.; Moroz, E.; Solit, D. B.; Ageyeva, L.; Kochetkova, T.; Pillarsetti, N.; Finn, R.; Rosen, N.;  
31  
32 Blasberg, R. G. Monitoring the induction of heat shock factor 1/heat shock protein 70 expression  
33  
34 following 17-allylamino- demethoxygeldanamycin treatment by positron emission tomography  
35  
36 and optical reporter gene imaging. *Mol. Imaging* **2012**, *11*, 67-76. (c) Au, Q.; Zhang, Y.; Barber,  
37  
38 J. R.; Chung NG, S.; Zhang, B. Identification of inhibitors of HSF1 functional activity by high-  
39  
40 content target-based screening. *J. Biomol. Screening* **2009**, *14*, 1165-1175.  
41  
42  
43  
44

45  
46 (20) West, J. D.; Wang, Y.; Morano, K. A. Small molecule activators of the heat shock  
47  
48 response: chemical properties, molecular targets, and therapeutic promise. *Chem. Res. Toxicol.*  
49  
50 **2012**, *25*, 2036-2053.  
51  
52

53  
54 (21) (a) Rocaglamide A: Santagata, S.; Mendillo, M. L; Tang, Y.; Subramanian, A.; Perley, C.  
55  
56 C.; Roche, S. P.; Wong, B.; Narayan, R.; Kwon. H.; Koeva, M.; Amon, A.; Golub, T. R.; Porco  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

---

Jr., J. A.; Whitesell, L.; Lindquist, S. Tight coordination of protein translation and HSF1 activation supports the anabolic malignant state. *Science* **2013**, *341*, 1238303. (b) Triptolide: Westerheide, S. D.; Kawahara, T. L. A.; Orton, K.; Morimoto, R. I. Triptolide, an inhibitor of the human heat shock response that enhances stress-induced cell death. *J. Biol. Chem.* **2006**, *281*, 9616-9622. (c) BEZ235 and SNS-032: Acquaviva, J.; He, S.; Sang, J.; Smith, D. L.; Sequeira, M.; Zhang, C.; Bates, R. C.; Proia, D. A. mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis. *Mol. Cancer Res.* **2014**, *12*, 703-713. (d) For Dinaciclib and SNS-032 see reference 28.

(22) The compound library was provided by AstraZeneca, see reference 28.

(23) 17-AAG was purchased from <http://www.invivogen.com/17-aag> (August 31, 2016). For a description of 17-AAG as an HSP90 inhibitor see: Powers, M. V.; Valenti, M.; Miranda, S.; Maloney, A.; Eccles, S. A.; Thomas, G.; Clarke, P. A.; Workman, P. Mode of cell death induced by the HSP90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic BAX. *Oncotarget* **2013**, *4*, 1963-1965.

(24) Jones, K.; Rye, C.; Chessum, N.; Cheeseman, M.; Pasqua, A. E.; Pike, K. G.; Faulder, P. F. Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1. WO 2015/049535 A1, April 9, 2015.

(25)  $pIC_{50} = -\log_{10} IC_{50}$  (M). All results are quoted to 3 significant figures as geometric mean  $\pm$  standard error of the mean (SEM). The geometric mean and the number of repeats are quoted in the parenthesis.

1  
2  
3  
4  
5 (26) Hardcastle, A.; Boxall, K.; Richards, J.; Tomlin, P.; Sharp, S.; Clarke, P.; Workman, P.;  
6  
7  
8 Aherne, W. Solid-phase immunoassays in mechanism-based drug discovery: their application in  
9  
10 the development of inhibitors of the molecular chaperone heat-shock protein 90. *Assay Drug*  
11  
12 *Dev. Technol.* **2005**, *3*, 273-285.

13  
14  
15 (27) Laitem, C.; Zaborowska, J.; Isa, N. F.; Kufs, J.; Dienstbier, M.; Murphy, S. CDK9  
16  
17 inhibitors define elongation checkpoints at both ends of RNA polymerase II-transcribed genes.  
18  
19  
20 *Nat. Struct. Mol. Biol.* **2015**, *22*, 396-405.

21  
22  
23 (28) Rye, C. S.; Chessum, N. E. A.; Lamont, S.; Pike, K. G.; Faulder, P.; Demeritt, J.;  
24  
25  
26 Kemmitt, P.; Tucker, J.; Zani, L.; Cheeseman, M. D.; Isaac, R.; Goodwin, L.; Boros, J.;  
27  
28  
29 Raynaud, F.; Hayes, A.; Henley, A.; de Billy, E.; Lynch, C. J.; Sharp, S. Y.; te Poele, R.; O' Fee,  
30  
31  
32 L.; Foote, K. M.; Green, S.; Workman, P.; Jones, K. Discovery of 4,6-disubstituted pyrimidines  
33  
34 as potent inhibitors of the heat shock factor (HSF1) stress pathway and CDK9. *MedChemComm*  
35  
36 **2016**, *7*, 1580-1586.

37  
38  
39 (29) (a) Guettouche, T.; Boellmann, F.; Lane, W. S.; Voellmy, R. Analysis of phosphorylation  
40  
41 of human heat shock factor 1 in cells experiencing a stress. *BMC Biochem.* **2005**, *6*:4. (b)  
42  
43  
44 Budzynski, M. A.; Puustinen, M. C.; Joutsen, J.; Sistonena, L. Uncoupling stress-inducible  
45  
46 phosphorylation of heat shock factor 1 from its activation. *Mol. Cell. Biol.* **2015**, *35*, 2530-2540.

47  
48  
49 (30) <https://www.discoverx.com/services/drug-discovery-development-services/kinase->  
50  
51  
52 profiling/kinomescan (August 31, 2016).

(31) <http://www.thermofisher.com/uk/en/home/products-and-services/services/custom-services/screening-and-profiling-services/selectscreen-profiling-service.html?icid=fr-dd-1>

(August 31, 2016).

(32) All BRAF inhibitors were purchased from Selleckchem and were used without further purification, <http://www.selleckchem.com> (August 31, 2016). See supporting information for details.

(33) All BRAF inhibitors were screened in the human ovarian carcinoma cell-line SK-OV-3.

(34) Garnett, M. J.; Edelman, E. J.; Heidorn, S. J.; Greenman, C. D.; Dastur, A.; Lau, K. W.; Greninger, P.; Thompson, I. R.; Luo, X.; Soares, J.; Liu, Q.; Iorio, F.; Surdez, D.; Chen, L.; Milano, R. J.; Bignell, G. R.; Tam, A. T.; Davies, H.; Stevenson, J. A.; Barthorpe, S.; Lutz, S. R.; Kogera, F.; Lawrence, K.; McLaren-Douglas, A.; Mitropoulos, X.; Mironenko, T.; Thi, H.; Richardson, L.; Zhou, W.; Jewitt, F.; Zhang, T.; O'Brien, P.; Boisvert, J. L.; Price, S.; Hur, W.; Yang, W.; Deng, X.; Butler, A.; Choi, H. G.; Chang, J.W.; Baselga, J.; Stamenkovic, I.; Engelman, J. A.; Sharma, S.V.; Delattre, O.; Saez-Rodriguez, J.; Gray, N. S.; Settleman, J.; Futreal, P. A.; Haber, D. A.; Stratton, M. R.; Ramaswamy, S.; McDermott, U.; Benes, C. H. Systematic identification of genomic markers of drug sensitivity in cancer cells. *Nature* **2012**, *483*, 570-575.

(35) ATCC: [http://www.lgcstandards-atcc.org/products/all/HTB-77.aspx?geo\\_country=gb](http://www.lgcstandards-atcc.org/products/all/HTB-77.aspx?geo_country=gb) (August 31, 2016). For examples of using the SK-OV-3 cell-line in drug discovery see: (a) Huang, R. Y-J; Kuay, K. T.; Tan, T. Z.; Asad, M.; Tang, H. M.; Ng, A. H. C.; Ye, J.; Chung, V. Y.; Thiery, J. P. Functional relevance of a six mesenchymal gene signature in epithelial-

mesenchymal transition (EMT) reversal by the triple angiokinase inhibitor, nintedanib (BIBF1120). *Oncotarget* **2015**, *6*, 22098-22113. (b) Zhang, Z.; Xie, Z.; Sun, G.; Yang, P.; Li, J.; Yang, H.; Xiao, S.; Liu, Y.; Qiu, H.; Qin, L.; Zhang, C.; Zhang, F.; Shan, B. Reversing drug resistance of cisplatin by HSP90 inhibitors in human ovarian cancer cells. *Int. J. Clin. Exp. Med.* **2015**, *8*, 6687-6701. (c) Wu, W.; Yu, L-H; Ma, B.; Xu, M-J. The inhibitory effect of doxycycline on cisplatin-sensitive and -resistant epithelial ovarian cancer. *PLoS One* **2014**, *9*, e89841. (d) Fekete, M.; Santiskulvong, C.; Eng, C.; Dorigo, O. Effect of PI3K/AKT pathway inhibition-mediated G1 arrest on chemosensitization in ovarian cancer cells. *Anticancer Res.* **2012**, *32*, 445-452. (e) Tan, L.; Wang, J.; Tanizaki, J.; Huang, Z. F.; Aref, A. R.; Rusan, M.; Zhu, S. J.; Zhang, Y. Y.; Ercan, D.; Liao, R. G.; Capelletti, M.; Zhou, W. J.; Hur, W.; Kim, N.; Sim, T.; Gaudet, S.; Barbie, D. A.; Yeh, J. R. J.; Yun, C. H.; Hammerman, P. S.; Mohammadi, M.; Janne, P. A.; Gray, N. S. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. *Proc. Natl. Acad. Sci. U.S.A.* **2014**, *111*, E4869-E4877.

(36) For examples of SK-OV-3 murine xenograft studies see: (a) Shaw, T. J.; Senterman, M. K.; Dawson, K.; Crane, C. A.; Vanderhyden, B. C. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. *Mol. Ther.* **2004**, *10*, 1032-1042. (b) Faratian, D.; Zweemer, A. J. M.; Nagumo, Y.; Sims, A. H.; Muir, M.; Dodds, M.; Mullen, P.; Um, I.; Kay, C.; Hasmann, M.; Harrison, D. J.; Langdon, S. P. Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies. *Clin. Cancer Res.* **2011**, *17*, 4451-4461. (c) Zhang, A. L.; Shen, G. D.; Zhao, T.; Zhang, G. H.; Liu, J.; Song, L. H.; Wei, W.; Bing, L.; Wu, Z. S.; Wu, Q. Augmented inhibition of angiogenesis by combination of HER2 antibody ChA21

1  
2  
3  
4  
5 and trastuzumab in human ovarian carcinoma xenograft. *J. Ovarian Res.* **2010**, *3*, 20. (d) Li, W.;  
6 Ji, Z-L; Zhuo, G-C; Xu, R-J; Wang, J.; Hong, R-U. Effects of a selective cyclooxygenase-1  
7 inhibitor in SKOV-3 ovarian carcinoma xenograft-bearing mice. *Med. Oncol.* **2010**, *27*, 98-104.  
8  
9 (e) Bauerschlag, D. O.; Schem, C.; Tiwari, S.; Egberts, J. H.; Weigel, M. T.; Kalthoff, H.; Jonat,  
10 W.; Maass, N.; Meinhold-Heerlein, I. Sunitinib (SU11248) inhibits growth of human ovarian  
11 cancer in xenografted mice. *Anticancer Res.* **2010**, *30*, 3355-3360.  
12  
13  
14  
15  
16  
17  
18  
19

20  
21 (37) Obach, R. S. Prediction of human clearance of twenty-nine drugs from hepatic  
22 microsomal intrinsic clearance data: an examination of in vitro half-life approach and  
23 nonspecific binding to microsomes. *Drug Metab. Dispos.* **1999**, *27*, 1350-1359.  
24  
25  
26  
27

28  
29 (38) The in-house HPLC method to measure LogD7.4 is based on: Kerns, E. H.; Li Di, L.;  
30 Petuskya, S.; Kleintop, T.; Huryn, D.; McConnell, O.; Carter, G. Pharmaceutical profiling  
31 method for lipophilicity and integrity using liquid chromatography-mass spectrometry. *J.*  
32 *Chromatogr. B: Anal. Technol. Biomed. Life Sci.* **2003**, *791*, 371-388.  
33  
34  
35  
36  
37

38  
39 (39) The free-fraction in the cell assay was measured by dialysis using standard techniques,  
40  $f_{ua}=0.47$  (90%CI=0.54-0.42). Free  $GI_{50}=GI_{50} * f_{ua}$   
41  
42  
43

44 (40) Hepatic blood flow (HBF) in mouse was assumed to be 90 ml/min/Kg. Sanoh, S.;  
45 Horiguchi, A.; Sugihara, K.; Kotake, Y.; Tayama, Y.; Ohshita, H.; Tateno, C.; Horie, T.;  
46 Kitamura, S.; Ohta, S. Prediction of in vivo hepatic clearance and half-life of drug candidates in  
47 human using chimeric mice with humanized liver. *Drug Metab. Dispos.* **2012**, *40*, 322-328.  
48  
49  
50  
51

52  
53 (41) Smith, D. A.; Kerns, E. H. The effect of plasma protein binding on in vivo efficacy:  
54 misconceptions in drug discovery. *Nat. Rev. Drug Discovery* **2010**, *9*, 929-939.  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8

---

(42)  $C_{av}^{0-24hrs} = AUC^{0-24hrs} / 24$

9  
10  
11  
12  
13

(43) Smith, D. A.; Beaumont, K.; Maurer, T. S.; Di, Li. Volume of distribution in drug design. *J. Med. Chem.* **2015**, *58*, 5691-5698.

14  
15  
16

(44) Assumes linear scaling of free exposure ( $AUC_u$ ) between different doses.

17  
18  
19  
20  
21  
22  
23  
24

(45) 2 mice were dosed at 30 mg/Kg po qd for 4 days and were then monitored for the following 3 days. Both mice retained good condition over that period as assessed by %body weight. See supporting information for details.

25  
26  
27  
28  
29  
30

(46) Smith, M. A.; Houghton, P. A proposal regarding reporting of in vitro testing results. *Clin. Cancer Res.* **2013**, *19*, 2828-2833.

31  
32  
33  
34  
35  
36  
37  
38  
39  
40

(47) The Tumor Growth Inhibition is defined as  $\%TGI = (((C_t - C_0) - (T_t - T_0)) / (C_t - C_0)) * 100$ ;  $T_t$  = arithmetic mean volume of treated tumors at time = t;  $T_0$  = arithmetic mean volume of treated tumors at time = 0;  $C_t$  = arithmetic mean volume of control tumors at time = t;  $C_0$  = arithmetic mean volume control tumors at time = 0.

41  
42  
43  
44  
45  
46  
47  
48

(48) The p-value refers to the comparison of untransformed arithmetic means of the treated and control arms using an unpaired Student's t-test with Welch's correction. The value is reported to 2 significant figures.

49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

(49) de Billy, E. Powers, M. V.; Smith, J. R.; Workman, P. Drugging the heat shock factor 1 pathway: exploitation of the critical cancer cell dependence on the guardian of the proteome. *Cell Cycle* **2009**, *8*, 3806-3808.

1  
2  
3  
4  
5 (50) <http://www.cerep.fr/cerep/users/pages/catalog/profiles/DetailProfile.asp?profile=2121>  
6  
7  
8 (August 31, 2016).

9  
10  
11 (51) (a) [https://www.evotec.com/uploads/media\\_library/36/2015-09\\_DDUpservices\\_target\\_identification.pdf](https://www.evotec.com/uploads/media_library/36/2015-09_DDUpservices_target_identification.pdf) (August 31, 2016). (b) Sharma, K.; Weber, C.; Bairlein, M.;  
12  
13 Greff, Z.; Kéri, G.; Cox, J.; Olsen, J. V.; Daub, H. Proteomics strategy for quantitative protein  
14  
15 interaction profiling in cell extracts. *Nat. Methods* **2009**, *6*, 741-744.

16  
17  
18 (52) Cheng, Y.; Prusoff, W. H. Relationship between the inhibition constant ( $K_1$ ) and the  
19  
20 concentration of inhibitor which causes 50 per cent inhibition ( $I_{50}$ ) of an enzymatic reaction.  
21  
22  
23  
24  
25  
26 *Biochem. Pharmacol.* **1973**, *22*, 3099-3108.

27  
28  
29 (53) Trinkle-Mulcahy, L.; Boulon, S.; Lam, Y. W.; Urcia, R.; Boisvert, F-M; Vandermoere, F.;  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
Morrice, N. A.; Swift, S.; Rothbauer, U.; Leonhardt, H.; Lamond, A. Identifying specific protein  
interaction partners using quantitative mass spectrometry and bead proteomes. *J. Cell Biol.* **2008**,  
*183*, 223-239.

(54) In-house data using a biotinylated bisamide derivative in a protein pull-down experiment  
also identified Pirin as a molecular target of the cellularly active bisamide series (data not  
shown).

(55) Wendler, W. M. F.; Kremmer, E.; Forster, R.; Winnacker, E. L. Identification of pirin, a  
novel highly conserved nuclear protein. *J. Biol. Chem.* **1997**, *272*, 8482-8489.



1  
2  
3  
4  
5 (56) Dechend, R.; Hirano, F.; Lehmann, K.; Heissmeyer, V.; Ansieau, S.; Wulczyn, F. G.;  
6  
7 Scheidereit, C.; Leutz, A. The BCL-3 oncoprotein acts as a bridging factor between NF- $\kappa$ B/REL  
8 and nuclear co-regulators. *Oncogene* **1999**, *18*, 3316-3323.  
9  
10

11  
12  
13 (57) Liu, F.; Rehmania, I.; Esakia, S.; Fua, R.; Chena, L.; Serranoa, V.; Liu, A. Pirin is an iron-  
14 dependent redox regulator of NF- $\kappa$ B. *Proc. Nat. Acad. Sci. U.S.A.* **2013**, *110*, 9722-9727.  
15  
16

17  
18 (58) (a) Brzoska, K.; Stepkowski, T. M.; Kruszewski, M. Basal PIR expression in HeLa Cells  
19 is driven by NRF2 via evolutionary conserved antioxidant response element. *Mol. Cell. Biochem.*  
20 **2014**, *389*, 99-111. (b) Gelbman, B. D.; Heguy, A.; O'Connor, T. P.; Zabner, J.; Crystal, R. G.  
21 Upregulation of pirin expression by chronic cigarette smoking is associated with bronchial  
22 epithelial cell apoptosis. *Respir. Res.* **2007**, *8*, 10.  
23  
24  
25  
26  
27  
28  
29

30  
31 (59) Qiao, Z.; Wang, D.; Hahn, J.; Ai, J.; Wang, Z. Pirin down-regulates the EAF2/U19 protein  
32 and alleviates its growth inhibition in prostate cancer cells. *Prostate* **2014**, *74*, 113-120.  
33  
34  
35

36  
37 (60) Licciulli, S.; Luise, C.; Scafetta, G.; Capra, M.; Giardina, G.; Nuciforo, P.; Bosari, S.;  
38 Viale, G.; Mazzarol, G.; Tonelli, C.; Lanfrancone, L.; Alcalay, M. Pirin inhibits cellular  
39 senescence in melanocytic cells. *Am. J. Pathol.* **2011**, *178*, 2397-2406.  
40  
41  
42  
43  
44

45 (61) Miyazaki, I.; Simizu, S.; Okumura, H.; Takagi, S.; Osada, H. A small-molecule inhibitor  
46 shows that pirin regulates migration of melanoma cells. *Nat. Chem. Biol.* **2010**, *6*, 667-673.  
47  
48  
49

50 (62) Yamaoka, H.; Sumiyoshi, H.; Higashi, K.; Nakao, S.; Minakawa, K.; Sumida, K.; Saito,  
51 K.; Ikoma, N.; Mabuchi, T.; Ozawa, A.; Inagaki, Y. A novel small compound accelerates dermal  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 wound healing by modifying infiltration, proliferation and migration of distinct cellular  
6 components in mice. *J. Dermatol. Sci.* **2014**, *74*, 204-213.

7  
8  
9  
10  
11 (63) (a) Komai, K.; Niwa, Y.; Sasazawa, Y.; Simizu, S. Pirin regulates epithelial to  
12 mesenchymal transition independently of BCL3-SLUG signaling. *FEBS Lett.* **2015**, *589*, 738-  
13 743. (b) Marcucci, F.; Stassi, G.; De Maria, R. Epithelial–mesenchymal transition: a new target  
14 in anticancer drug discovery. *Nat. Rev. Drug Discovery* **2016**, *15*, 311-325.

15  
16  
17  
18  
19  
20  
21 (64) In-house studies using siRNA to inhibit pirin synthesis in SK-OV-3 cells demonstrated  
22 only limited effects on proliferation. Further studies are ongoing.

23  
24  
25  
26  
27 (65) TPh A was purchased from Sigma-Aldrich:  
28 <http://www.sigmaaldrich.com/catalog/product/sigma/t6205?lang=en&region=GB> (August 31,  
29 2016).  
30  
31  
32

33  
34  
35 (66) (a) Dunwell, J. M.; Culham, A.; Carter, C. E.; Sosa-Aguirre, C. R.; Goodenough, P. W.  
36 Evolution of functional diversity in the cupin superfamily. *Trends Biochem. Sci.* **2001**, *26*, 740-  
37 746. (b) Dunwell, J. M.; Purvis, A.; Khuri, S. Cupins: the most functionally diverse protein  
38 superfamily? *Phytochem.* **2004**, *65*, 7-17.

39  
40  
41  
42  
43  
44  
45 (67) (a) Khuri, S.; Bakker, F. T.; Dunwell, J. M. Phylogeny, function, and evolution of the  
46 cupins, a structurally conserved, functionally diverse superfamily of proteins. *Mol. Biol. Evol.*  
47 **2001**, *18*, 593-605. (b) Uberto, R.; Moomaw, E. W. Protein similarity networks reveal  
48 relationships among sequence, structure, and function within the cupin superfamily. *PLoS One*  
49 **2013**, *8*, e74477.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 (68) PDB:1J1L: Pang, H.; Bartlam, M.; Zeng, Q.; Miyatake, H.; Hisano, T.; Miki, K.; Wong,  
6 L. L.; Gao, G. F.; Rao, Z. Crystal structure of human p130Cas an iron-binding nuclear protein and  
7 transcription cofactor. *J. Biol. Chem.* **2004**, *279*, 1491-1498. For other examples of p130Cas crystal  
8 structures see: PDB:3ACL, reference 61; PDB: 3ACL, 4ERO, 4EWA, 4EWD, 4EWE, 4GUL,  
9 4HLT, reference 57.

10  
11  
12  
13  
14  
15  
16  
17  
18 (69) Lindsley, C. W. 2013 Philip S. Portoghese Medicinal Chemistry Lectureship: Drug  
19 Discovery Targeting Allosteric Sites. *J. Med. Chem.* **2014**, *57*, 7485-7498.

20  
21  
22  
23  
24 (70) Dosa, P. I.; Amin, E. A. Tactical approaches to interconverting GPCR agonists and  
25 antagonists. *J. Med. Chem.* **2016**, *59*, 810-840.

26  
27  
28  
29 (71) Blomen, V. A.; Májek, P.; Jae, L. T.; Bigenzahn, J. W.; Nieuwenhuis, J.; Staring, J.;  
30 Sacco, R.; van Diemen, F. R.; Olk, N.; Stukalov, A.; Marceau, C.; Janssen, H.; Carette, J. E.;  
31 Bennett, K. L.; Colinge, J.; Superti-Furga, G.; Brummelkamp, T. R. Gene essentiality and  
32 synthetic lethality in haploid human cells. *Science* **2015**, *350*, 1092-1096.

33  
34  
35  
36  
37 (72) Wang, T.; Birsoy, K.; Hughes, N. W.; Krupczak, K. M.; Post, Y.; Wei, J. J.; Lander, E. S.;  
38 Sabatini, D. M. Identification and characterization of essential genes in the human genome.  
39 *Science* **2015**, *350*, 1096-1101.


40  
41  
42  
43  
44 (73) (a) Staben, S. T.; Feng, J. A.; Lyle, K.; Belvin, M.; Boggs, J.; Burch, J. D.; Chua, C.; Cui,  
45 H.; DiPasquale, A. G.; Friedman, L. S.; Heise, C.; Koeppen, H.; Kotey, A.; Mintzer, R.; Oh, A.;  
46 Roberts, D. A.; Rouge, L.; Rudolph, J.; Tam, C.; Wang, W.; Xiao, Y.; Young, A.; Zhang, Y.;  
47 Hoeflich, K. P. Back pocket flexibility provides group II p21-activated kinase (PAK) selectivity  
48 for type I/II kinase inhibitors. *J. Med. Chem.* **2014**, *57*, 1033-1045. (b) Lefranc, F.; Dewelle, J.;  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 Pottier, L.; Mathieu, V.; Spiegl-Kreinecker, S.; Sauvage, S.; El Yazidi, M.; Dehoux, M.; Berger,  
6 W.; Quaquebeke, E.; Kiss, R. Structure–activity relationship analysis of novel derivatives of  
7 narciclasine (an amaryllidaceae isocarbostryl derivative) as potential anticancer agents. *J. Med.*  
8 *Chem.* **2009**, *52*, 1100-1114. (c) Singh, J. P.; Tamang, S.; Rajamohanan, P. R.; Jima, N. C.;  
9 Chakraborty, G.; Kundu, G. C.; Gaikwad, S. M.; Khan, M. I. Isolation, structure, and functional  
10 elucidation of a modified pentapeptide, Cysteine protease inhibitor (CPI-2081) from  
11 streptomyces species 2081 that exhibit inhibitory effect on cancer cell migration. *J. Med. Chem.*  
12 **2010**, *53*, 5121-5128. (d) Nagababu, P.; Barui, A. K. Thulasiram, B.; Devi, C. S.; Satyanarayana,  
13 S.; Patra, C. R.; Sreedhar, B. Antiangiogenic activity of mononuclear copper(II) polypyridyl  
14 complexes for the treatment of cancers. *J. Med. Chem.* **2015**, *58*, 5226-5241. (e) Amin, H.; Wani,  
15 N. A.; Farooq, S.; Nayak, D.; Chakraborty, S.; Shankar, S.; ur Rasool, R.; Koul, S.; Goswami,  
16 A.; Rai, R. Inhibition of invasion in pancreatic cancer cells by conjugate of EPA with  $\beta$ 3,3-Pip-  
17 OH via PI3K/Akt/NF-kB pathway. *ACS Med. Chem. Lett.* **2015**, *6*, 1071-1074.

18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37 (74) In-house PAINS filter protocol: Biovia Pipeline Pilot Version 9.5

38  
39  
40 (75) Lagerlund, O.; Larhed, M. Microwave-promoted aminocarbonylations of aryl chlorides  
41 using  $\text{Mo}(\text{CO})_6$  as a solid carbon monoxide source. *J. Comb. Chem.* **2006**, *8*, 4-6.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Table of Contents graphic






Figure 1. Inhibitors of HSF1-mediated transcriptional activity

144x68mm (300 x 300 DPI)




Figure 2. HSF1 pathway inhibitor, bisamide 1 (CCT245232)

69x30mm (300 x 300 DPI)




Figure 3. Efficacy of bisamide 26 against SK-OV-3 human ovarian carcinoma xenograft model. Blue: vehicle control n=8, Red: 26 at 20 mg/Kg po qd n=8, (Vehicle=10% DMSO, 90% of a 25% (2-hydroxypropyl)- $\beta$ -cyclodextrin in 50 mM citrate buffer pH 5). Error bars: arithmetic mean $\pm$ SEM. Dosing breaks were carried out on days 5-12, 14, 16, 18, 20, 22, 24, 26, 29, 31.

192x131mm (300 x 300 DPI)






Figure 4. Tool compounds for target identification. All quoted cellular activities are in the SK- OV-3 cell line, the numbers of repeats are in parentheses

205x78mm (300 x 300 DPI)




Figure 5. Representative SPR sensorgram and binding isotherm of bisamide 26 bound to recombinant pirin. The dotted-line represents the time-point the equilibrium response was measured. The binding isotherm was fitted to a one-site specific binding model using Graphpad Prism 6.

195x134mm (300 x 300 DPI)




Figure 5. Representative SPR sensorgram and binding isotherm of bisamide 26 bound to recombinant pirin. The dotted-line represents the time-point the equilibrium response was measured. The binding isotherm was fitted to a one-site specific binding model using Graphpad Prism 6

281x189mm (300 x 300 DPI)




Figure 6. X-ray crystal structure of bisamide 26. PDB 5JCT, Pymol image of pirin (light blue cartoon representation) in complex with bisamide 26 (cyan stick representation), 2 Fo-Fc map contoured at 1.0  $\sigma$  (blue mesh) and Pymol image of pirin (magenta, blue stick representation) in complex with bisamide 26 (cyan stick representation), distances shown are in Ångstroms, 2 Fo-Fc map contoured at 1.0  $\sigma$  (blue mesh). Crystals belonged to the space group P212121 and diffracted to resolution of 1.73 Å.

254x190mm (300 x 300 DPI)






Figure 6. X-ray crystal structure of bisamide 26. PDB 5JCT, Pymol image of pirin (light blue cartoon representation) in complex with bisamide 26 (cyan stick representation), 2 Fo-Fc map contoured at 1.0  $\sigma$  (blue mesh) and Pymol image of pirin (magenta, blue stick representation) in complex with bisamide 26 (cyan stick representation), distances shown are in Ångstroms, 2 Fo-Fc map contoured at 1.0  $\sigma$  (blue mesh). Crystals belonged to the space group P212121 and diffracted to resolution of 1.73 Å.

254x190mm (300 x 300 DPI)



32 Figure 7. The anti-migratory activity of chemical probe bisamide 26. A: wound healing images of WM266.4  
33 cells, after 30 h the wound has almost completely healed in the control in contrast to 100 nM 26. B:  
34 quantification of the relative wound density reveals the maximum anti- migratory activity is achieved at 100  
35 nM 26.

36 254x190mm (96 x 96 DPI)



Scheme 1. Synthesis of the benzodioxane bisamide replacements.

Reagents and conditions: (i) O  
105x61mm (300 x 300 DPI)





Figure 7. The anti-migratory activity of chemical probe bisamide 26. A: wound healing images of WM266.4 cells, after 30 h the wound has almost completely healed in the control in contrast to 100 nM 26. B: quantification of the relative wound density reveals the maximum anti-migratory activity is achieved at 100 nM 26.


212x197mm (300 x 300 DPI)






Scheme 2. Synthesis of solubilizing group analogues

Reagents and conditions: (i) O  
110x80mm (300 x 300 DPI)



32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 4. Molecular targets from the pull-down assay using the bisamide probes in SK-OV-3 cell lysate  
A: SK-OV-3 cell lysate protein  
106x81mm (300 x 300 DPI)



33 Table 4. Molecular targets from the pull-down assay using the bisamide probes in SK-OV-3 cell lysate  
34 A: SK-OV-3 cell lysate protein  
35 105x81mm (300 x 300 DPI)

36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Table of Contents Graphic

20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60